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Abstract 
 
 
Milk from dairy cows is an important human food. It contains the protein beta-
lactoglobulin (BLG) which is not present in human milk and thought to be a major 
allergen in the milk of cows. RNA interference (RNAi), mediated by sequence-
specific micro RNAs (miRNAs), provides a new molecular tool to reduce the 
levels of undesirable proteins.  
In this study, I have screened ten miRNAs targeting the BLG mRNA for their 
potential to knockdown BLG expression using a cell-based in vitro assay. I 
identified four miRNAs which showed substantial bovine BLG (bBLG) (78-97%) 
and ovine BLG (oBLG) (33-94%) knockdown activity in vitro. Tandem miRNA 
constructs with combinations of these four single miRNAs did not result in 
significantly increased knockdown efficiency compared to the respective single 
miRNA constructs in the in vitro assay (P>0.05). Because targeting of two 
different regions has the potential for greater knockdown efficiency in vivo, I 
chose a tandem construct which achieved in vitro up to 99% bBLG knockdown as 
compared to 92% and 74% of bBLG knockdown by the single miRNAs. The 
tandem construct also showed 90% of oBLG knockdown in comparison to 92% 
and 69% of oBLG knockdown by the single miRNAs in the in vitro assay which 
made it an ideal candidate for the subsequent evaluation in transgenic (Tg) mice. 
For the in vivo studies, the cytomegalovirus (CMV) promoter of the selected 
miRNA constructs was replaced with the promoter of the mouse milk protein gene 
for whey acid protein (WAP) which directs the expression of the BLG-specific 
miRNAs to the lactating mammary gland. The Tg mouse lines generated with the 
tissue-specific tandem construct and the single miRNAs used for the tandem 
miRNA construct were then crossed with an oBLG or bBLG expressing Tg mouse 
line to generate double transgenic (miRNA-BLG) mice for assessing BLG 
knockdown in vivo. Analysis of the milk proteins demonstrated that the tandem 
miRNA reduced the levels of oBLG and bBLG in milk from the miRNA-BLG 
mice up to 96% and 46%, respectively. This study validates the mammary gland 
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specific expression of miRNAs as a promising approach to knockdown allergenic 
proteins in milk. 
Keywords: BLG, miRNA, RNAi, Transgenic mouse, Gene knockdown. 
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1.1 Allergy 
Allergy is a misguided hypersensitivity reaction to foreign substances by specific 
immunologic mechanisms. Hypersensitivities have been divided into four types 
based on the mechanisms involved and time taken for the reaction as described by 
Gell and Coombs (1). These types are type I- immediate (anaphylactic) 
hypersensitivity, type II- antibody-mediated cytotoxic (cytolytic) hypersensitivity, 
type III- immune complex-mediated hypersensitivity and type IV- cellular-
immune (delayed) hypersensitivity. Among the four types of hypersensitivity 
reactions, type I is the best understood. In this type of allergy, after ingestion, 
inhalation or injection, the body produces specific IgE antibodies within minutes 
or hours and releases histamine (2). The symptoms of this type of reaction may 
involve skin (eczema), eyes (red eyes), nasopharynx (rhinitis) and 
bronchopulmonary tissues (asthma) (3). Depending on the severity of the reaction, 
it may cause a range of symptoms from minor inconvenience to death.  
1.2 Food allergy and allergens 
In the past few decades, food allergy (FA) has become a very severe health 
problem and there has been a significant increase in the prevalence of FA in 
infancy and childhood. It has been reported that 25% of adults believe they or 
their children suffer from FA, however, only approximately 5–8% of children and 
1–2% of adults suffer from true FA (4) (5). Over 90% of food allergies in 
childhood are caused by eight foods: cow's milk, hen's egg, soy, peanuts, tree 
nuts, wheat, fish and shellfish (6). When allergic individuals consume above-
mentioned foods, their immune system becomes stimulated by the specific protein 
in food and as a consequence specific IgE antibodies are produced. The IgE 
antibodies react with the allergen that results in the release of histamine and 
causes the above-mentioned symptoms.  
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1.2.1 Cow milk allergy (CMA) 
Milk is the sole nutrition for young in mammals and contains all the essential 
nutrients for mammalian growth. In the early years of the last century cow‟s milk 
was reported as a cause of diarrhoea and other unexplained problems in infants 
(7). By the middle of the last century, CMA became known as a cause of child 
disease due to the decline in breast feeding and increased use of cow milk as 
infant nutrition in the developed world (7). Although cow‟s milk is a good food 
for the young and it has developed into an important human food source, there are 
at least 18 protein components that may cause allergic reactions in the body (8). 
Cow milk protein allergy (CMPA) is an immunologically mediated adverse 
reaction in human due to immune system responding against the foreign milk 
protein by creating specific antibodies- called immunoglobulin E (IgE) (9). The 
free-floating IgE molecules specific to the antigen first attach to the cell surface 
receptors on mast cells and trigger the release of histamine (10), which results in 
symptoms ranging from mild to moderate to severe such as, irritability, vomiting, 
wheezing, swelling, hives, other itchy bumps on the skin, and bloody diarrhoea 
(11). Though most children experience allergenic reactions, for the majority the 
symptoms remain rather minor. However, symptoms can be severe and 12% of 
patients who are allergenic to cow milk may have a very serious life-threatening 
allergic reaction known as anaphylaxis (12). This severe allergic reaction causes 
swelling of mouth, throat and lungs that results in difficulty in breathing and even 
it is severe enough to cause death (13). Most of the children develop symptoms 
before one month of age and allergic symptoms can be seen in the following 
organ systems: gastrointestinal (50–60%), skin (50–60%) and respiratory tract 
(20–30%) (14). The symptoms of allergic reactions may vary between individuals 
and an individual can be allergic to more than one milk protein (15) (16). Usually 
CMA develops in the first year of infancy (17) and 1.9% to 7.5% of infants suffer 
from CMA (17) (18). It has been reported that 87% of affected children recover 
from CMA by the age of three (19). In adults, CMA is rare, only a few case 
studies reported cow milk proteins as the potential source of allergenic reactions 
(20) (21). The digestive tract of infants is not fully developed and lacks defense 
factors (22). So, immune system exerts allergic reactions when milk proteins pass 
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through their gut (23) (24). The milk is compromised of two main protein 
fractions, whey and casein, and an individual may be allergenic to either or both. 
The caseins account for 80% of total milk protein and they can be the major 
allergenic component of cow‟s milk to a small fraction of population (25). The 
non-casein fraction or whey, accounts for 20% of total milk protein and mainly 
consists of α-lactalbumin and BLG. The antigenicity of BLG was studied in mice 
and rabbits immunized with bBLG and dominant antigenic regions were 
recognized by IgG antibodies against BLG in both animals (26). 
1.2.1.1 BLG 
BLG is the major whey protein of cow‟s milk at about 2-3 g/l (27) and is also 
present in the milk of many other mammalian species, such as, goat, sheep, pig, 
horse, cat and dog (28). However, the milk of rodents and humans does not 
contain BLG (28).  
1.2.1.1.1 Allergenic properties of BLG 
Like most of the milk proteins, BLG is produced in mammary gland epithelial 
cells, under the stimulation of prolactin hormone (29). BLG remains stable in the 
acidic environment of the stomach and reaches the small intestine mostly 
unchanged (30) (31). BLG-associated allergic reactions are caused by the 
presence of specific amino acid sequences (epitopes) of BLG which are 
recognized by antibodies. Epitopes are amino acid sequences of 8–16 amino acids 
on the protein surface and act as a potentially allergenic material. At least six 
epitopes have been found on BLG that are recognized by human IgE from 
children with CMA (32). The allergenicity of BLG belongs to the type I 
hypersensitivity. So, when milk is ingested by an infant, BLG resists enzymatic 
digestion by pepsin in the stomach, allowing it to pass intact through the gut 
epithelial cells into the blood circulation. The immune system triggers white blood 
cells to produce BLG-specific allergy antibodies (IgE) and leads to allergy 
symptoms (33).  
1.2.1.1.2 Biological role of BLG 
Every year 300 journal articles are published on BLG (28) but the exact 
physiological function of this whey protein has not been reported (27). BLG 
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belongs to the lipocalin family of proteins which are generally transporters of 
small hydrophobic molecules (34). It has been reported that BLG is associated 
with the transportation of bromododecanoic acid (35), palmitic acid (36) and 
retinol (27). It has also been linked to hypocholesterolemia (37) and has been 
ascribed antioxidant properties (38). In the neonatal calf, intestine BLG–retinol 
complexes have been identified (39) and thus BLG may be involved in 
transportation and uptake of intact protein directly (40) or indirectly (41). In 
addition, BLG has also been identified to be an extracellular counterpart of the 
intracellular fatty acid binding proteins in cow‟s milk (42). It has been reported 
that BLG enhances the activity of pre-gastric lipase (42).  
1.3 Current strategies to reduce BLG in milk 
Cow‟s milk has become an essential source of food in humans but it contains 
BLG, a powerful inducer of allergy in early infancy. As a consequence, in the 
recent years hypoallergenic formulas based on whey protein hydrolysates have 
been developed to meet the requirements of high risk infants and children. Infant 
formula companies have produced hypoallergenic formula milk for babies to 
minimize BLG-related effects. In New Zealand, Nutramigen was the extensively 
hydrolysed formula (EHF) available that has been replaced by the whey 
hydrosylate, Pepti-Junior. Nestle has developed an infant formula called NAN HA 
1, which is a 100% partially hydrolysed whey protein. Another formula is 
available in the market known as Neocate which is a synthetic 100% free amino 
acid-based hypoallergenic formula and is manufactured in a milk protein free 
environment. It is recommended for infants who are allergic to extensively 
hydrolysed formula milk (43). The above-mentioned formula milk products are 
produced by the dairy industries using mainly enzymatic hydrolysis (44). Though 
enzymatic hydrolysis has become a widely used method of milk processing, it 
never became popular due to the fact it involves the cleavage of the peptide bond 
between two amino acid residues that results in breakdown of the intact allergen 
into smaller peptides. The enzymes used in the hydrolysis step should be specific 
otherwise one can end up with residual antigenicity by the highest molecular 
weight peptides (45). Moreover, the degree of enzymatic hydrolysis determines 
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the breakdown of protein bonds. It has been reported that free (non-protein bound) 
amino acids such as glutamic acid, aspartic acid and cysteine may act as 
excitotoxins and can effectively damage brain and nervous system (46). In 
addition, enzymatic hydrolysis causes unpalatable taste in milk due to the 
exposure of hydrophobic amino acids such as, serine or glutamate (47) (48). 
Moreover, the processing technique is very expensive. 
Milk components have been targeted for the modification of its nutritional source 
in order to improve its nutritional value. Two strategies could be used as an 
alternative tool of expensive post-harvest milk processing to reduce or prevent 
production of BLG by a more direct approach, RNAi or total deletion of the BLG 
gene using homologous recombination (HR) (49). It has been reported in mice 
that complete deletion of another whey protein, α-lactoglobulin, an essential 
protein component of lactose synthetase resulted in lactose-free milk (50). Lactose 
controls milk volumes and its absence in milk affects the osmolarity of milk. As a 
consequence, milk became highly viscous and pups were unable to suck milk 
from the mammary gland (50). Due to this technical difficulties knockout of BLG 
in farm animals has not yet been reported yet. Moreover, the efficiency of HR 
remains very low in farm animals due to low HR in primary somatic cells (49). In 
comparison to the knockout approach, RNAi could be a straightforward approach 
to unravel the role of BLG and reduce the allergenicity of cow's milk (51). 
Moreover, RNAi could allow fine-tuning of BLG expression in particular if some 
BLG is required for normal milk physiology.  
1.4 RNAi 
1.4.1 Introduction 
RNAi is a phenomenon of mRNA degradation in which short doubled-stranded 
RNA (dsRNA) is the initiating factor for post-transcriptional gene silencing 
(PTGS) (52). RNAi plays a vital role in triggering a cascade of events that lead to 
the degradation or blocking of the corresponding mRNA in a sequence-specific 
manner (53) and subsequently to a reduction of the level of the corresponding 
protein (54). RNAi is a conserved biological response to double-stranded RNA 
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that mediates resistance to both endogenous parasites and exogenous pathogenic 
nucleic acids (55). In addition, RNAi has also emerged as an important regulator 
for the expression of endogenous transcripts (54). The power and utility of RNAi 
and its recent advances has driven its incredibly rapid adaption as a tool for the 
stable silencing of genes in a variety of different animal species including 
mammals.  
RNA-induced gene silencing was first observed in 1990 when scientists 
encountered an unexpected suppression of endogenous chalcone synthase (CHS) 
gene (a pigment producing gene) after introduction of a chimeric CHS gene under 
the control of a strong promoter into petunia genotypes (56). This phenomenon 
was initially known as co-suppression where the transgene silenced its expression 
as well as the expression of the endogenous gene (57). In this reversible co-
suppression mechanism RNA polymerase uses sense transcript as a template to 
produce the dsRNA and triggers RNA silencing. As a result, instead of expected 
deep purple colour flowers, the flowers became multi-coloured or completely 
white (56). The co-suppression occurs at the post-transcriptional level and it was 
defined as PTGS later on (57). The phenomenon of RNAi became clear in 1998 
when Fire, Mello and co-workers published their work on C. elegans, used as a 
model animal to study the mechanism of RNAi triggered by dsRNA (52). They 
injected specific dsRNA molecules or only the sense or antisense RNA strand into 
C. elegans and reported that gene silencing was more effective by dsRNA than 
sense and antisense strand separately (52). DsRNA-based RNAi was also shown 
in Drosophila and it was reported that dsRNA can silence target gene in the 
microinjected Drosophila embryos (58). Researchers tested specific dsRNAs as a 
tool to target vertebrate genes using zebrafish and mouse as model animals. It was 
shown that the silencing efficiency of dsRNA was less efficient than in worms 
and flies (59). Moreover, dsRNA induced off-target effects in zebrafish, 
seemingly severely limiting the use of RNAi in the organism (60). Thus, although 
the use of dsRNA was so successful in worms and flies, it did not seem to work in 
mammals. As we now know, the reason for the initial failure of the dsRNA-based 
RNAi in mammals is that long dsRNA molecules elicit an immune response by 
inducing interferone-linked pathways (61). Long sequences of dsRNA molecules 
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induce the activation of protein kinase R (PKR), a cellular dsRNA-dependent 
protein kinase that can be activated either by viral dsRNA intermediates or by the 
synthetic polyribonucleotide duplexes and can potentially cause non-specific 
RNA knockdown and ultimately inhibits protein synthesis (62). After the initial 
disappointment further research showed that small 21 nt long dsRNA molecules 
(siRNA) can overcome the problem with the unwanted immune responses and 
cytotoxicity seen for long dsRNAs and work effectively in mammalian cells (63). 
Soon after this report siRNAs became a popular tool and were successfully used 
against infectious diseases such as HIV and hepatitis C virus (HCV). It has been 
reported that synthetic siRNA can specifically inhibit the replication of HIV-I rev 
transcript in human cells (64) and in vivo blocking of HCV gene expression in 
human liver cells (65). The siRNA approach has shown to be a valid strategy but 
some specific limitations became apparent such as, the undesired knockdown of 
non-target transcripts, poor delivery to cells, degradation within a few days and 
high cost of synthetic siRNAs (66). To resolve these limitations, several groups 
developed U6 or H1 PolIII promoter-based expression constructs to produce short 
double-stranded RNA hairpin molecules (shRNA) effective in eliciting gene 
silencing in mammalian cells (67) (68). Most polIII-based promoters are quite 
strong and give robust silencing in cell culture systems. However, PolIII 
promoters are constitutively active and do not allow for restricted expression in a 
tissue-specific manner. The resulting high level of shRNA expression increases 
the chances of non-specific gene knockdown and that elicits off-target effects 
such as interferon response and cytotoxicity (69). These drawbacks of shRNAs 
have led researchers to improve the design and optimize existing RNAi triggers, 
in particular miRNA (70). In 1993, Ambros, Ruvkun and co-workers showed that 
a short non-coding RNA (later called miRNA) lin-4, a 22 nt long RNA sequence 
was partially complementary to multiple sequences in the 3‟ UTR of the lin-14 
mRNA in C. elegans. Base paring of the shorter lin-4 transcript with the lin-14 
mRNA transcript knocked down the expression of the gene during development 
(71). A later study in 2000 reported a second miRNA (let-7) that appeared to 
repress the expression of lin-41, lin-14, lin-28, lin-42, and daf-12 during 
developmental stage transitions in C. elegans (72).  
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The majorities of the identified endogenous miRNAs are located within the 
introns of known protein coding genes and regulate endogenous gene function. 
The primary transcripts of miRNAs give rise to several different mature miRNAs 
as clusters (73). Generally miRNAs are thought to be involved only in knockdown 
and/or degradation of target protein coding genes, but recent reports suggested 
that miRNAs have functions other than knocking down gene expression and 
blocking protein translation. Vasudevan et al., demonstrated that in human cells 
(G0-stage), miRNA-369-3p can activate the expression of the tumor necrosis 
factor-α mRNA through binding to an AU-rich element at the 3‟ UTR on cell 
cycle arrest (74). MiRNAs can also bind to the promoter regions of certain genes 
and up-regulate gene expression (75). In 2002, it was reported that natural and 
artificially designed miRNAs can inhibit target mRNA in human cells (76). 
Typically miRNAs are on average 22 nt in length. miRNAs are generally 
transcribed by RNA polymerase II (77) (78) and result in the degradation or 
repression of translation of the target mRNA in plants and animals. Recently polII 
promoter-based miRNA expression vectors have emerged such as- 
pCDNA6.2GW/EmGFP-miR, Invitrogen. The design of the target specific 
miRNAs is modeled on the structure of an endogenously expressed miRNA. The 
miRNAs expressed by the polII promoter get processed by the cell machineries 
into siRNAs and enter the RNAi pathway for gene silencing. A particularly 
attractive feature of miRNAs is their potential for tissue-specific or conditional 
expression in vivo and polycistronic strategies (allowing delivery of multiple 
siRNA sequences) (79) (80). The following Table 1-1 summarizes major 
discoveries in RNAi field.  
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Table 1-1: Milestone discoveries in the field of RNAi. 
Year Milestone 
discovery 
Approach Achievement Mammalian Reference 
1990 Co-suppression 
of the target 
gene  
Introduction 
of chimeric 
CHS gene 
Inhibition of 
CHS gene 
expression 
Petunia (56) 
1993 Non-coding 
RNA-mediated 
knockdown of 
specific mRNA 
Identification 
of endogenous 
lin-4 miRNA 
Knockdown of 
Lin-14 gene 
C. elegans (71) 
1998 dsRNA as 
potent and 
specific cause of 
RNAi identified 
Injection of 
dsRNA  
Suppression 
endogenous 
target gene 
C. elegans (52) 
2001 siRNA duplexes 
provide a new 
tool for studying 
gene function 
Transfection 
of siRNA 
Knockdown of 
endogenous and 
heterologous 
genes 
Mammalian 
cells 
(63) 
2002 shRNA-based 
knockdown of 
gene 
Transfection 
of shRNA 
Knockdown of 
firefly luciferase 
gene 
Mammalian 
cells 
(67) 
2002 Artificial and 
natural miRNAs 
can induce the 
RNAi pathway 
Transfection 
of miRNA 
Sequence 
specific 
suppression of a 
gene 
Human cells (76) 
 
1.4.2 General mechanism of RNAi 
RNAi is triggered by dsRNAs in the form of invading RNA viruses or artificial 
dsRNA molecules. Invading dsRNA molecules (more than 30 bp) are produced by 
viral replication. The dsRNAs homologous to the target mRNA are converted into 
21-23 nt siRNA duplexes by a RNase III enzyme called dicer in the cytoplasm 
(81) and these siRNA duplexes are assembled into a multi-protein RNA-induced 
silencing complex (RISC) in the cytoplasm. Functional RISC has helicase, 
exonuclease and endonuclease activities, and also comprises homology searching 
domains (82). Within RISC, the siRNA molecule becomes separated and the 
“sense” strand is degraded. RISC uses the unwound antisense strand as a guide 
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strand to base-pair with the target mRNA to disrupt the function of the specific 
gene (63). To protect from the invading virus dsRNAs, host organisms utilize the 
RNAi pathway to destroy cognate RNAs. On the other hand, miRNAs can be 
produced from intergenic regions of genome that regulates endogenous gene 
expression or artificially introduced molecules such as- shRNA or miRNA 
(sh/miRNA). The hairpin RNAs are first transcribed in the cell nucleus as a long 
primary transcripts that posses a 5‟ cap and a poly-A tail (83) (84). The 
transcribed primary transcript is cleaved in the nucleus by drosha enzyme and 
produces a 70 nt hairpin transcript (pre-miRNA) (85) (86). The pre-sh/miRNA 
transcripts are transported to the cytoplasm by exportin 5 through nuclear pores. 
In the cytoplasm, the pre-miRNA transcripts are cleaved by dicer enzyme and the 
small ds-transcripts are loaded into RISC complex (81). Hairpin-based RNAi 
pathway mediates either cleavage or translation termination. A perfect match of 
mRNA and antisense strand in RISC induces cleavage of target mRNA (most 
plant miRNAs) (87) (Figure 1-1). In animals, most of the identified miRNAs have 
partial homology to the target gene encoded protein and causes translational 
repression. However, miRNAs can also cleave the target mRNA. It has been 
reported by Yekta et al., 2004 that miRNA-196 had exact complementarity to 
HOXB8 gene can potentially cleave the message found in mouse embryos (88). 
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Figure 1-1: RNAi pathways. 
Hairpin-based RNAi pathway: Long dsRNA molecules are cleaved by drosha to 
produce shRNA/miRNA. Hairpin RNA molecules are then transported to the cell 
cytoplasm and again processed into siRNA molecules by dicer. The siRNA molecules are 
then incorporated into a RISC. The duplex RNA is unwound leaving the anti-sense strand 
to guide RISC to complementary mRNA for subsequent translational inhibition. 
RNAi pathway: Long dsRNA molecules are cleaved to produce siRNA molecules by 
dicer. The siRNA molecules are then binds with RISC. The duplex RNA is unwound 
leaving the anti-sense strand to guide RISC to complementary mRNA for subsequent 
mRNA degradation. 
1.4.3 Recent progress of RNAi in animals 
1.4.3.1 Delivery of RNAi molecules: from cells to animals 
In the last decade, RNAi has become widely used as a powerful experimental tool 
and promising biotherapeutic in the field of functional genomics. The 
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development in the field of RNAi began with the identification of dsRNA in 
plants and lower organisms targeting specific gene expression. Later on two other 
small RNAi molecules (synthetic siRNAs and plasmid vector-based shRNAs) 
were used in mammalian cells to understand gene function. In order to introduce 
RNAi molecules into cells, several delivery methods such as, retroviral, lentiviral 
and adenoviral vector systems have been developed to allow efficient and cell 
type-independent stable RNAi (89). Retroviral vectors are very efficient tools 
derived from the murine stem cell virus or Moloney murine leukaemia virus and 
allow stable gene transduction only in dividing cells without transferring any viral 
gene (90). However, gene transduction by retroviral vectors does not work in non-
dividing cells. The major limitation of using retroviral-based gene therapy is the 
possible transfer of replication competent virus to the patients (91). To address 
this problem of retroviral vectors, human immunodeficiency virus (HIV)-1-based 
lentiviral vectors were developed and shown to be efficient to infect both dividing 
and non-dividing post-mitotic cells, such as, neurons (92). From a biosafety point 
of view, lentiviruses are acceptable because they are not infectious to human. 
Adeno-associated virus (AAV) is a small virus and an excellent tool which infects 
humans and some other primates. It can infect both dividing and non-dividing 
cells (93) and becomes an attractive tool for gene therapy as this virus has not 
been reported to cause any disease in human and animals (94). Adenoviral vectors 
based on AAV have been reported as safer than the other two vectors because 
adenoviral DNA does not integrate into the genome and remains as an episome in 
the nucleus. Later on, further improvement on RNAi research was achieved to 
regulate RNAi externally using conditional RNAi systems. Conditional RNAi-
mediated gene knockdown was shown in mice using Cre/loxP for tissue specific 
control of shRNA expression (95) (96). This procedure of gene expression 
regulation usually involves the removal of a genetic element that either limits or 
promotes shRNA expression using the Cre recombinase. Thus it permits to 
investigate the effect of a gene of interest. Flippase recombination enzyme (FLP)-
flippase recognition target (FRT) is another analogous site-specific recombination 
technique to Cre/loxP that has been applied by Premsrirut et al., (97). FLP/FRT 
involves site-specific recombination between FRT sites mediated by Flp 
recombinase. Premsrirut, et al., (97) developed a miRNA-30-based shRNA vector 
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system where shRNA was embedded in the 3′ UTR of a GFP transcript 
downstream of the inducible TRE-CMV promoter. This vector system showed 
efficient gene silencing in ES cells and embryonic and adult mouse tissues. These 
discoveries led to the rapid application of RNAi tools not only limited to cell 
culture or certain laboratory animals but also make it feasible to apply them in 
livestock and potentially in drug discoveries. RNAi has helped to better 
understand gene function in a wide range of organisms. In C. elegans and 
drosophila (Drosophila melanogaster), gene manipulation was performed by 
soaking the animals in a solution containing siRNAs or by adding bacteria 
expressing siRNAs to the diet (98) (99). RNAi technology has been successfully 
applied in drosophila to identify the genes with essential functions in biochemical 
signalling cascades, embryonic development, and other basic cellular processes 
(100). The whole genome sequencing projects reveals the opportunities to 
research on novel genes predicted by genome annotation. The biological functions 
of genes become elucidated using knock-out or knock-down of target genes. In 
the past, zebrafish (Danio rerio) has become a vertebrate model organism to study 
gene function on embryonic development (101). Soon after the dsRNA-based 
RNAi study reported in C. elegans by Fire et al., (52), RNAi became an effective 
approach in other eukaryotes, including zebrafish. Microinjection of dsRNAs 
targeting different genes essential for embryonic development showed specific 
embryonic defects in embryos (20–30%) (59). Later on, another study showed 
that a plasmid vector-based dsRNA can potentially knockdown GFP protein 
(>95%) co-injected in zebrafish embryos (101). The RNAi research in zebrafish 
was moved forward using siRNA instead of dsRNA because injection of dsRNA 
has been reported to trigger non-specific effects and toxicity to embryos (102). 
Liu W-Y et al., (103) reported that siRNA designed against zebrafish no tail gene 
by in vitro transcription can cause specific developmental defects similar to the 
known no tail mutant. Since these studies, RNAi has become a useful tool for 
quick and cheap gene knockdown in animals. The delivery of RNAi constructs 
into model mammalian organism has been achieved by pronucleus injection of 
mouse zygotes (104) or by introducing shRNAs or siRNAs into adult mice using 
hydrodynamic injection via tail vein (105) (106) (107).  
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1.4.3.2 The use of RNAi for the study of disease-associated genes in 
livestock 
Livestock improvements by genetic selection have resulted in considerable 
progress in livestock production systems worldwide. However, in order to ensure 
the increasing demands of our expanding population, the use of this strategy is 
limited as the genetic capabilities and location of the animals are different. Thus 
the application of RNAi has been evolved to be an attractive method to improve 
livestock production through disease resistance, production efficiency and 
nutritional value (108). Livestock production and animal welfare are adversely 
affected by diseases and they have a great impact on the socio-economic status of 
farmers and our health. Most of the livestock diseases are caused by viruses, 
prions, bacteria or parasites. Majority of the bacterial and parasitic diseases can be 
prevented by proper vaccination and deworming measures. But until today 
vaccination has remained inefficient to treat viral diseases because viruses use 
host cell machineries for its replication and thus it becomes difficult to find targets 
for the drug without interfering with host cells. However, there are a few antiviral 
drugs with specific antiviral activity on stable viruses but the use of such drugs is 
limited to those who have already been infected. As a consequence, to control 
viral diseases, keeping animals in isolation, immunization, vaccination or even 
killing of infected animals have become routine measures for disease control in 
livestock. Though using vaccines has been successful in controlling diseases of 
infected animal population, it has limitation as it has to be delivered by 
individually injecting each infected animals. Moreover, vaccines are shown to be 
expensive. Thus, there is a demand for developing new techniques to protect 
animals from surrounding diseases that have a major impact on our economy and 
health. Soon after its discovery, RNAi was applied to tackle or at least limit virus 
shedding and thereby reducing disease spread and the numbers of animals 
slaughtered despite using the aforesaid measures. RNAi technology has become a 
new therapeutic tool to study viral cycle and fight against all types of viruses 
(plus-strand, negative-strand, single stranded and double stranded DNA/RNA) 
(109). A few examples of economically important viral diseases in livestock such 
as, foot-and-mouth disease (FMD), bovine viral diarrhoea virus (BVDV), avian 
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influenza virus (AIV), swine flu (swine influenza), Newcastle disease (ND) and 
prion disease have been chosen to describe the effectiveness of RNAi to control 
these diseases. 
1.4.3.2.1 FMD  
FMD is a highly contagious viral disease in livestock, in particular cattle, sheep, 
goat, deer and pig and globally it has got the first and foremost priority (110). It is 
spread by the pathogen, foot-and-mouth disease virus (FMDV) found in infected 
animals‟ saliva, milk and dung. The virus can be picked up by the animal or from 
the direct contact of other infected animals. Moreover, human can be infected by 
this virus from infected animals. Currently, FMD vaccines based on inactivated 
virus are available but still carry the risk of incomplete inactivation because 
complete protection cannot be induced until day seven (111). Thus, development 
of an alternative strategy became important to resolve the outbreak of FMD. 
RNAi has been pursued to test its feasibility controlling FMD outbreaks using 
siRNA to decrease replication of the virus in BHK-21 cells (112). Kahana et al., 
(112) designed three siRNAs from highly conserved 3B and 3D polymerase gene 
of FMDV serotype O1 involved in the virus replication. The mixture of siRNAs 
showed over 90% inhibition of virus replication. Since this result was obtained in 
cell culture, RNAi has also become a potential tool against FMDV in animal 
systems. However, the major limitation of this technique is the delivery of the 
siRNA to the target tissue of an adult organism (113). To deliver RNAi molecules 
more efficiently in tissues or whole organisms, Chen et al., (114) carried out a 
study using a plasmid vector-based shRNA targeting 1D and 3D regions of 
FMDV also involved in virus replication. They designed one specific shRNA for 
each of the FMDV 1D and 3D regions and tested the effectiveness of the shRNA 
against the virus replication in swine kidney cells (IBRS-2). They demonstrated 
complete knockdown of FMDV replication in IBRS-2 delivered by recombinant 
replication-defective human adenovirus type 5 (rAd5). They also tested these 
FMDV-specific rAd5 constructs in guinea pig by intramuscular injection with 
FMDV HKN/2002. Three out of five guinea pigs did not show any clinical signs 
such as vesicles on foot and mouth or high fever. Other animals developed few 
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smaller vesicles but recovered quickly afterwards. A mixture of rAd5 constructs 
was injected in guinea pig but did not show significant antiviral effect.  
1.4.3.2.2 BVD 
Bovine viral diarrhoea (BVD) is another viral disease in ruminants, including 
cattle and sheep, affecting herds worldwide and causing significant economic 
impacts. Many production losses from BVDV occur and as a consequence of 
persistent infections, milk production and conception rate become low and the 
animals become susceptible to respiratory disorders and other diseases (115). The 
BVD virus transmits vertically (before birth) that leads to congenital infections of 
the fetus and causes abortion or stillbirth. It can also transmit to other healthy 
animals after birth of the animal. Traditionally, infected cattle are separated or 
discarded from the other healthy animals to reduce chances of spreading of the 
virus. Calves are fed high quality colostrum to increase the antibody titer to fight 
against infections. Final strategy is to use vaccines of BVDV to treat infected 
animals. Despite the use of one or a combination of these methods, BVDV 
remains the most prevalent infectious agent in cattle herds all over the world 
(116). The effect of the disease can cause huge economic losses and that is why 
the application of RNAi therapeutics has become so important for this disease. It 
has been reported by Lambeth et al., (116) that siRNA and shRNA can efficiently 
inhibit the replication of BVDV in Madin-Darby bovine kidney (MDBK) cells. 
They designed seven siRNAs to inhibit BVDV replication by targeting coding 
regions (C, NS4B and NS5A proteins) of the BVDV genome required for BVDV 
replication. The siRNAs were first transfected into MDBK cells and three of 
seven siRNAs showed significant suppression of BVDV antigen production 
(P<0.05). To compare siRNAs and shRNAs against inhibition of BVDV antigen 
production, they constructed DNA-based shRNA expression vectors using the 
most effective siRNA sequences. The efficiency of shRNAs was very low 
compared to siRNAs and the best siRNA showed >90% inhibition of BVDV 
antigen, only 50% by the shRNA.  
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1.4.3.2.3 AIV 
Highly pathogenic AIV was one of the first viral diseases described in poultry. 
H5N1 is a subtype of the influenza A virus also known as "bird flu", which can 
cause illness in humans and many other animal species. The bird flu virus has 
already killed millions of birds and forced farmers to dispose hundreds of millions 
of poultry to stop its proliferation. When H5N1 strain infects humans, it replicates 
in the lower part of the respiratory tract and ultimately it causes viral pneumonia 
(117). Vaccines of either killed virus or recombinant surface glycoproteins have 
been using to prevent the pandemics of the virus. But the use of these vaccines is 
limited due to the continual mutation of H5N1, rendering the vaccines ineffective 
against any new virus subtype. So, effective and relatively inexpensive RNAi 
technique has become a potential anti-influenza therapeutics alternative to the 
classical vaccinations. Zhang et al., (118) showed siRNA-mediated knockdown of 
avian influenza virus subtype H5N1 both in vitro and in vivo. They targeted 
Polymerase A (PA) gene conserved among different avian influenza virus 
subtypes and strains, including H5N1. PA protein is the part of the influenza virus 
RNA polymerase complex which is the crucial component in the viral RNA 
transcription and replication. For in vitro studies they designed three siRNAs 
specific to the N-terminal region of the PA gene and transfected into Madin Darby 
canine kidney (MDCK) cell lines infected with the virus. Analysis of the 
transfected MDCK cells showed a 5-78-fold reduction of virus titers by the 
siRNAs. The most effective siRNA construct was injected with the virus into 
mouse. After one day of injection the mouse was sacrificed and the lung 
homogenates showed significant reduction of virus replication by the siRNA.  
1.4.3.2.4 Swine flu 
Another type A influenza virus known as swine flu virus is a threat to swine 
industry. Swine flu is a respiratory disease in pig and it is contagious transmitting 
from pig to human. Several subtypes of influenza virus A have identified in pigs 
such as, H1NI, H1N2, H3N2 and H3N1. H1N1 is the most common version and 
its outbreaks have caused significant monetary damage in the swine industry 
world wide. Swine flu has similar symptoms to other influenza such as fever, 
coughing, nasal secretion, headache, vomiting and diarrhoea. The most recent 
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strain (H1N1) of swine flu virus was found in Mexico in 2009 and it caused 
277,607 cases of viral infection including 3205 deaths (as of September 2009) 
reported by the World Health Organization (WHO) (119). The virus had been 
found in most of the countries in that year. Commercially available vaccines for 
swine flu showed limited effect in pigs challenged with the virus (120). For 
human, four antiviral drugs (oseltamivir, zanamivir, amantadine and rimantadine) 
are available on the market and they show limited protection against the virus 
with side effects. The side effects are similar to the other seasonal vaccines, 
including a mild fever, headache and fatigue. The 2009 swine flu outbreak drew 
attention to researchers to find an alternative treatment than vaccination as viruses 
have high mutation rate that makes vaccines ineffective. RNAi-based silencing of 
swine flu virus has recently been started since its outbreak in 2009. Last year it 
was reported that the novel H1N1 virus replication can be inhibited using 
synthetic RNAi molecules in vitro (119). They tested 35 synthetic siRNAs 
specific to the conserved regions of the H1N1 virus mRNA in A549 cells and ten 
of them showed over 90% inhibition of the virus replication in cells.  
1.4.3.2.5 ND 
ND is another infectious viral disease of birds caused by the Newcastle disease 
virus. It affects the respiratory, nervous and digestive systems of the bird. ND 
does not pose hazard to human health like avian influenza virus, but it causes 
substantial economic losses in the poultry industry worldwide. Yin et al., (121) 
targeted Newcastle disease viral matrix protein gene using specific shRNA in cell 
cultures. In vitro studies showed that DNA vector-based shRNA could efficiently 
block the replication of the virus.  
1.4.3.2.6 Prion disease 
Another important target of RNAi is prion (PrP) disease. Prions (PrPs) are 
infectious agents that contain malformed proteins. Prions are responsible for the 
transmission of spongiform encephalopathies in cattle (also known as mad cow 
disease) which can be potentially transmitted to humans. Introduction of a prion 
into a healthy organism induces the pre-existing properly-folded proteins to 
convert into misfolded proteins. As a consequence, highly stable misfolded 
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protein accumulates in infected tissue, causing tissue damage and cell death (122). 
When prions infect central nervous system, they accumulate in infected tissues 
within the central nervous system and form plaques known as amyloid which 
disrupt normal tissue structure. Symptoms of such neurodegenerative disease 
include convulsion, dementia and behavioral changes leading to brain dysfunction 
and death. In 2006, RNAi-based knockdown of PrP in goat and cattle was 
reported (123). Golding et al., transfected human embryonic kidney (HEK)-293T 
cells with PrP mRNA specific shRNAs and firefly luciferase-PrP expression 
plasmid. Some of the shRNAs showed high PrP mRNA knockdown up to 86% in 
cell cultures and similar results were revealed in a Tg fetus (123).  
1.4.3.3 The use of RNAi for the study of genes associated with 
livestock improvement 
1.4.3.3.1 Myostatin 
In order to meet the extra demand for the increasing population, it is important to 
improve livestock production efficiency and food value of daily consumable food 
such as cow milk. Production efficiency of animals can be increased by silencing 
endogenous gene expression, such as the myostatin gene using RNAi. Myostatin 
is known as growth differentiation factor 8 which inhibits muscle differentiation 
and growth. Primarily it is secreted from the skeletal muscle cells and acts on 
skeletal tissues. Animals that produce less myostatin have larger skeletal muscles. 
In order to increase meat production, scientists have targeted myostatin gene using 
RNAi to control its expression. The gene encoding myostatin was discovered in 
1997 by McPherron et al.,(124). They also generated myostatin knockout mice 
which showed remarkable increase in skeletal muscle mass compared to wild type 
mice. Soon after this report, research on myostatin became attractive to scientists. 
In some cattle breeds such as Belgian Blue and Piedmontese, these animals have 
mutations in their myostatin gene and absence of the functional gene helps in 
growth and proliferation of muscle cells (125). In vitro studies on myostatin 
expression showed that over expression of this growth factor decreases muscle 
mass and fiber size in Tg mice (126). After the discovery of RNAi in 1998, it has 
become a prime tool to prevent the expression of myostatin gene. Magee et al., 
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(127) showed that plasmid vector-based shRNA silenced mouse myostatin gene 
expression in cell culture. They also demonstrated in vivo suppression of the gene 
and consequently skeletal muscle mass increase was seen in rat after 
intramuscular electroporation of the effective shRNA. Another study was reported 
by Kinouchi et al., (128), they showed the possible use of siRNA as a novel 
therapeutic strategy to silence the expression of myostatin gene expression in 
mice. They delivered myostatin-specific siRNA into normal or diseased mice 
through nanoparticle formation of chemically unmodified siRNAs with 
atelocollagen (ATCOL). Within few weeks of time they observed a remarkable 
increase in skeletal muscle mass in mice. After these successes RNAi has been 
applied to inhibit caprine myostatin gene. Four shRNAs were designed based on 
the bovine and caprine myostatin gene and caprine fibroblast cells were 
transfected with plasmid vector containing myostatin-specific shRNAs. All of the 
tested shRNAs showed 22-92% knockdown of the gene (129).  
1.4.3.3.2 Porcine BLG 
Very recently, a paper has been published on knockdown of porcine BLG using 
various RNAi molecules (shRNAs and artificial miRNAs) using an in vitro 
system (130). They compared six shRNAs driven by U6 promoter and the 
expression of the two miRNAs was driven by CMV promoter against the 
expression of porcine BLG gene. Transient transfection of HEK293 revealed that 
four shRNAs were efficient to knockdown BLG in the range of 22-74%. MiRNAs 
were also shown to be effective to knockdown the gene up to 60%. 
1.4.3.4 The use of RNAi-based therapeutics for clinical applications 
Since its discovery, RNAi has become a versatile tool to understand and control 
gene function. Researchers have worked on RNAi over a decade to understand its 
mechanism and its role on gene function. Expression of gene of interest has been 
studied by using different RNAi molecules both in cell cultures and in animals. In 
addition, the use of RNAi technology has moved to pre-clinical studies due to 
advancement made in understanding cellular pathways during states of 
pathogenesis, gene delivery systems and availability of a wide range of in vivo 
models. From the in vitro and in vivo studies, RNAi has raised a lot of interest in 
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developing RNAi-based therapeutics for clinical applications. In order to develop 
RNAi-based therapeutics, RNAi sequences are first designed and tested against 
targets in the cell cultures and selected RNAi sequences are then applied to animal 
models with diseases of interest. Well-performing RNAi sequences may finally be 
considered for the advance stages of clinical trials. Since the discovery of RNAi, 
many rapid advances have been achieved but using RNAi as therapeutics is still in 
its infancy. Currently, few clinical trials are in progress targeting several genes 
that if knocked down might be expected to improve human health. The most 
advanced clinical trials are in the treatment of age-related macular degeneration 
(AMD) which is the common cause of blindness. The genes for vascular 
endothelial growth factor (VEGF) and the VEGF receptor (VEGFR) were targeted 
by injecting siRNA into the macula of the eye in order to stop excessive 
vascularization of the eyes which leads to blindness in preclinical models (131). 
This research led the therapeutic to test in human clinical trials. Acuity 
Pharmaceuticals carried out first clinical trials for the treatment of AMD, of which 
phase I and II were reported with a lack of adverse systemic effects (132). This 
drug had gone into phase III trials carried out by Opko Health, but unfortunately 
phase III trials were terminated because it was found that siRNAs could block 
angiogenesis and activate an immune receptor called toll-like receptor 3 (TLR3) 
in mouse models of AMD regardless of its sequence (133). Though the 
effectiveness of RNAi has become questionable after AMD clinical trials, 
however, some RNAi-based clinic trials that have been published show promising 
results for other therapeutic target, such as respiratory syncytial virus (RSV) 
nucelocapsid (N) protein. RSV is a very common virus that causes cold-like 
symptoms in adults and older healthy children. It can be severe in young babies 
producing about 10-fold higher mortality rates than influenza in United States 
(134). Alnylam Pharmaceuticals Inc., Cambridge, MA, USA has made a major 
advancement for targeting RSV N gene (135). The ALN-RSV01 therapeutics in 
phase II and it is considered as the most advanced program in the global RNAi 
pipeline (136). They have used an unmodified siRNA formulated in saline which 
is administered daily via a nasal spray to patients two days before and three days 
after inoculation with RSV and which has resulted in 38% decrease in the RSV 
infected patients (137).  
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1.5 Rationale and Objectives of the Study 
Cow milk is a common food for both infants and adults. Cow milk allergy (CMA) 
is more prevalent in infants as milk is their primary source of nutrition and it is 
uncommon in adults and older children. Cow milk evolved as an optimal food for 
calves, but human milk and nutritional requirements of human are different. So, 
milk from dairy ruminants has become the subject of intense investigations to 
improve or modify its quality (138). The composition of milk can be altered either 
by nutritional management (139) or by alteration of genetic potential of the dairy 
cows (140). Nutritional management includes feeding of balanced ration to the 
dairy cows to help to express their genetic potential and for milk production, and 
milk protein and milk fat composition. Genetic improvement in the dairy cows 
can be made by selection and breeding of cows with superior genetic merits. 
Although more efforts have gone into these traditional methods, changes in the 
milk composition are slow (141) and not too much change has been achieved 
especially for the traits that are low heritable and difficult to measure by their 
breeding value (142). Recent advancements in genomic research including whole 
genome sequencing and high throughput single nucleotide polymorphism (SNP) 
genotyping has opened the door to identify new genetic variants for milk quality 
improvement (142). Moreover, identification of SNPs can also play an important 
role in crop and livestock improvement through breeding programmes. The use of 
Tg technologies has sparked in livestock improvement. Such improvements could 
include the modification of the major milk proteins (caseins) to improve the 
nutritive value of cheese, reducing lactose content in milk to reduce intestinal 
disorders, production of milk with the over expression of the human form of the 
antimicrobial protein lyzozyme and human lactoferrin to increase protection 
against gastro-intestinal infections and removing undesirable, potentially allergic 
components (e.g., BLG) to create „hypoallergic‟ milk (51). Reducing the level of 
those proteins causing allergies could make milk amenable for individuals 
currently experiencing milk allergies. The most common product of the dairy 
industry is whole milk and fat-reduced milk, both of which are not modified to 
mimic human milk. Moreover, infant formula manufacturers are also producing 
hypoallergenic or hydrolyzed milk, where milk proteins are broken down into 
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smaller peptides so they are less allergenic than whole proteins. But as a 
consequence, the taste of milk becomes bitter and almost unpalatable (143).  
 
A number of molecular genetic techniques have been developed to study gene 
expression and its physiological function. The techniques include gene knockout, 
and most recently RNAi (144). The gene knockout is a technique in which an 
endogenous gene of an organism is deleted or mutated to make the gene 
inoperative. The absence or mutation of the gene can be crucial for the expression 
of other genes and thus limits the use of this technique (145). Since the discovery 
of endogenous antiviral defense mechanism mediated by siRNA molecules in 
plants and animals, RNAi has become an effective alternative tool for gene 
silencing applications. While RNAi was first demonstrated in nematodes with the 
introduction of exogenous long dsRNA molecules (52), it soon became clear that 
RNAi is a conserved strategy utilized by the most eukaryotes to fight viral 
infections and fine tune the regulation of genes (54).  
 
So, the main aim of this doctoral thesis was to demonstrate the feasibility of 
reducing the level of BLG in milk by mammary gland-specific expression of 
miRNAs using a mouse model. The detailed objectives are shown below: 
 
- Evaluation of in vitro knockdown efficiency of BLG-specific miRNAs 
targeting bBLG and oBLG expression. 
- Generation of Tg mouse lines for the mammary gland -specific expression 
of functional BLG–specific miRNAs. 
- Generation of Tg mouse lines expressing bBLG in their milk. 
- Generation of miRNA-BLG mouse lines expressing bBLG or oBLG and 
BLG specific miRNAs. 
- Evaluation of the miRNA mediated knockdown potential in vivo. 
1.6 Thesis Layout 
The thesis contains six chapters and appendices summarized as follows: 
Chapter One: This chapter provides a literature review addressing the effects of 
cow milk allergy (CMA) on infant health. This chapter particularly emphasizes on 
BLG and reviews its allergenic and biological properties and current strategies to 
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handle this milk allergen as decribed in the literature. This chapter introduces 
RNAi in more detail and presents recent use of this technology to improve 
livestock production and health or to stop replication of life threatening viruses. 
This chapter concludes with an outline of five research objectives to conduct this 
research. 
Chapter Two: The general materials and methodologies used to perform this 
study are written in details in this chapter. This chapter also includes 
methodologies specificly used for chapter three, four and five. 
Chapter Three: This chapter covers results on transfection efficiency 
optimization of COS7 cells. It also investigates the effect of single and tandem 
miRNA constructs against BLG expression in vitro. The chapter ends with a 
discussion on comparing the obtained results with the published datas. 
Chapter Four: This chapter includes results on generation of miRNA, bBLG and 
miRNA-o/bBLG mice and characterization of the Tg mice. Finally, a discussion is 
added at the end of this chapter to compare the results obtained with the published 
information on Tg mouse production. 
Chapter Five: This chapter presents knockdown activity of single and tandem 
miRNA constructs against bBLG and oBLG expression in mice. A discussion is 
added which covers the comparision of BLG knockdown ability by single and 
tandem miRNA constructs using coomassie staining and western blot analysis. It 
also includes a comparison of BLG knockdown efficiency by the single and 
tandem miRNA constructs in vitro and in vivo. 
Chapter Six: This chapter presents a general discussion of the thesis with 
recommendations for future research.  
Appendices: Appendices include results obtained from miRNA constructs 
screening, generation of BLG constructs, generation of tissue-specific miRNA 
constructs and preparation of tissue specific miRNA and bBLG constructs for 
pronuclear microinjection. Appendices also include gene sequencing results of 
miRNA, WAP promoter and BLG gene. 
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Chapter Two: Materials and 
Methods 
 
2.1 General Materials and Methods 
2.1.1 General Materials 
2.1.1.1 General chemicals and reagents 
Name Source 
Avertin Sigma (Germany) 
Bovine serum albumin (BSA) Sigma (Germany) 
Bromophenol blue sodium salt Sigma (Germany) 
Chloroform BDH (UK) 
Coomassie Brilliant Blue R-250 crystals Bio Rad (USA) 
Diethyl pyrocarbonate (DEPC) Sigma (Germany) 
Dimethyl sulfoxide (DMSO) Sigma (Germany) 
Dithiothreitol (DTT) (1 M) Invitrogen (USA) 
Dulbeccos Modified Eagles Medium 
(DMEM) 
Invitrogen (USA) 
Ethanol (EtOH) Fisher Scientific (UK) 
Ethidium bromide (EB) (10 mg/ml) Invitrogen (USA) 
Ethylenediaminetetraacetic acid (EDTA) BDH (UK) 
Fetal calf serum (FCS) Gibco (USA) 
Formaldehyde J T Baker (USA) 
Formamide Fisher Scientific (UK) 
Glacial acetic acid J T Baker (USA) 
Glycerol J T Baker (USA) 
N-2-ethane-sulphonic acid (HEPES) Invitrogen (USA) 
Human chorionic gonadotropin (hCG) Intervet (UK) 
Hydrochloric acid (HCl) J T Baker (USA) 
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Isopropanol Biolab (AU) 
Magnesium chloride (MgCl2) J T Baker (USA) 
Methanol Fisher Scientific (UK) 
3-(N-morpholino)-propane sulfonic acid 
(MOPS) 
Sigma (USA) 
OptiMEM Invitrogen (USA) 
Oxytocin Sigma (USA) 
Penicillin Sigma (USA) 
Phenylmethylsulfonyl fluoride (PMSF) Sigma (USA) 
Phosphate buffered saline (PBS) Oxoid (UK) 
Ponceau Sigma (USA) 
Pregnant mare serum gonadotropin (PMSG) Intervet (UK) 
Proteinase Inhibitors cocktail Sigma (USA) 
RNA sample buffer Invitrogen (USA) 
RNase AWAY Thermo Fisher Scientific Inc 
(USA) 
See blue plus 2 pre-stained marker Invitrogen (USA) 
Sodium bicarbonate (NaHCO3) Sigma (USA) 
Sodium chloride (NaCl) Sigma (USA) 
Sodium dedecyl sulphate (SDS) Sigma (USA) 
Sodium hydroxide (NaOH) BDH (UK) 
Streptomycin Sigma (USA) 
N, N, N‟, N‟- Tetraethylethylenediamine 
(TEMED) 
Sigma (USA) 
Tris-base J T Baker (USA) 
Triton-X 100 Sigma (USA) 
TRIzol Invitrogen (USA) 
Trypan blue Sigma (USA) 
Trypsin/EDTA Invitrogen (USA) 
Tween 20 Bio Rad (USA) 
Whatman 3 MM Paper Whatman (USA) 
Biomax XAR film Kodak (USA) 
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Xylene cyanol Biolab (AU) 
2.1.1.2 General biological materials 
2.1.1.2.1 Molecular biology  
Name Source 
Bacto-agar BDH (UK) 
Bacto-tryptone Difco Microbiology (USA) 
Takara DNA ligation mighty mix Takara (Japan) 
Ultra pure agarose Axygen (Spain) 
Yeast extract Sigma (USA) 
1 kb
+
 DNA ladder Invitrogen (USA) 
2.1.1.2.2 PCR reagents 
Name Source 
Deoxyribonucleotide triphosphate (dNTP) Roche (USA) 
PCR reaction buffer (10 x) Roche (USA) 
Taq DNA polymerase Roche (USA) 
Expand High Fidelity PCR System Roche (USA) 
All stock solutions were stored at -20 °C. 
2.1.1.2.3 Enzymes 
Proteinase K Invitrogen (USA) 
Restriction endonucleases- following restriction enzymes were purchased from 
various commercial sources  
Table 2-1: A list of restriction enzymes used in this experiment. 
Restriction enzyme Recognition sequence Source 
BamHI G/GATCC Roche (USA) 
BglI GCCNNNN/NGGC Roche (USA) 
BglII A/GATCT Roche (USA) 
DraI TTT/AAA Roche (USA) 
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EcoRV GAT/ATC Roche (USA) 
FspI TGC/GCA Roche (USA) 
HindIII A/AGCTT Roche (USA) 
NotI GC/GGCCGC Roche (USA) 
MScI TGG/CCA Roche (USA) 
SacII CCGC/GG Roche (USA) 
SalI G/TCGAC Roche (USA) 
Shrimp alkaline phosphatase 
(SAP) (1 U/µl) 
 Promega (USA) 
SpeI A/CTAGT Roche (USA) 
XhoI C/TCGAG Roche (USA) 
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2.1.1.3 Oligonucleotides 
All used oligonucleotides were obtained from Invitrogen and are indicated in Table 2-2 and Table 2-3. 
Table 2-2: RNAi-specific oligonucleotides.  
Name Number Position Sequence 5´-3´ Application 
miRNA 1 GL 705 
 
GL 706 
BLG mRNA exon 1 TGCTGATATCCAGGCCCTTCATGGTCGTTTTGGCCACTGACTGACGACCATGAGGCCTGGATAT 
CCTGATATCCAGGCCTCATGGTCGTCAGTCAGTGGCCAAAACGACCATGAAGGGCCTGGATATC 
BLG mRNA 
knockdown 
miRNA 2 GL 707 
GL 708 
BLG mRNA exon 2 TGCTGTTCTGCAGCAGGATCTCCAGGGTTTTGGCCACTGACTGACCCTGGAGACTGCTGCAGAA 
CCTGTTCTGCAGCAGTCTCCAGGGTCAGTCAGTGGCCAAAACCCTGGAGATCCTGCTGCAGAAC 
BLG mRNA 
knockdown 
miRNA 3 GL 709 
GL 710 
BLG mRNA exon 2 TGCTGAGCTCCTCCACATACACTCTCGTTTTGGCCACTGACTGACGAGAGTGTGTGGAGGAGCT 
CCTGAGCTCCTCCACACACTCTCGTCAGTCAGTGGCCAAAACGAGAGTGTATGTGGAGGAGCTC 
BLG mRNA 
knockdown 
miRNA 4 GL 711 
GL 712 
BLG mRNA exon 4 TGCTGTTTGTAGTCGGTGTCCAGCACGTTTTGGCCACTGACTGACGTGCTGGACCGACTACAAA 
CCTGTTTGTAGTCGGTCCAGCACGTCAGTCAGTGGCCAAAACGTGCTGGACACCGACTACAAAC 
BLG mRNA 
knockdown 
miRNA 5 GL 713 
GL 714 
BLG mRNA exon 5 and 
6 
TGCTGAGATGTGGCACTGCTCCTCCAGTTTTGGCCACTGACTGACTGGAGGAGGTGCCACATCT 
CCTGAGATGTGGCACCTCCTCCAGTCAGTCAGTGGCCAAAACTGGAGGAGCAGTGCCACATCTC 
BLG mRNA 
knockdown 
miRNA 6 GL 715 
GL 716 
BLG mRNA exon 3 TGCTGCTTCTGAGCACACTCACCGTTGTTTTGGCCACTGACTGACAACGGTGAGTGCTCAGAAG 
CCTGCTTCTGAGCACTCACCGTTGTCAGTCAGTGGCCAAAACAACGGTGAGTGTGCTCAGAAGC 
BLG mRNA 
knockdown 
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miRNA 7 GL 717 
GL 718 
BLG mRNA exon 3 TGCTGATCTTGAACACCGCAGGGATCGTTTTGGCCACTGACTGACGATCCCTGGTGTTCAAGAT 
CCTGATCTTGAACACCAGGGATCGTCAGTCAGTGGCCAAAACGATCCCTGCGGTGTTCAAGATC 
BLG mRNA 
knockdown 
miRNA 8 GL 719 
GL 720 
BLG mRNA exon 3 and 
4 
TGCTGTTCAAGGCATCGATCTTGAACGTTTTGGCCACTGACTGACGTTCAAGAGATGCCTTGAA 
CCTGTTCAAGGCATCTCTTGAACGTCAGTCAGTGGCCAAAACGTTCAAGATCGATGCCTTGAAC 
BLG mRNA 
knockdown 
miRNA 9 GL 721 
GL 722 
BLG mRNA exon 4 TGCTGCCAGCACAAGGACTTTGTTCTGTTTTGGCCACTGACTGACAGAACAAACCTTGTGCTGG 
CCTGCCAGCACAAGGTTTGTTCTGTCAGTCAGTGGCCAAAACAGAACAAAGTCCTTGTGCTGGC 
BLG mRNA 
knockdown 
miRNA 
10 
GL 723 
GL 724 
BLG mRNA exon 4 TGCTGTTTGCTCGGGCTCAGCACTGTGTTTTGGCCACTGACTGACACAGTGCTGCCCGAGCAAA 
CCTGTTTGCTCGGGCAGCACTGTGTCAGTCAGTGGCCAAAACACAGTGCTGAGCCCGAGCAAAC 
BLG mRNA 
knockdown 
*bBLG and oBLG mRNA sequence accession numbers are NM_173929 and NM_001009366, respectively. 
 
Table 2-3: Oligonucleotides used for PCR for direct cloning and genotyping. 
Name Number Sequence 5´-3´ Application 
oBLG_F GL 356 TGGGCCTCAGAGACCAAGAG Internal control for genotyping 
oBLG_R GL 357 AACTGTGTCCCACTAACCCC Internal control for genotyping 
miRNA_F GL 725 TCCCAAGCTGGCTAGTTAAG miRNA forward sequencing primer 
miRNA_R GL 726 CTCTAGATCAACCACTTTGT miRNA reverse sequencing primer 
oBLG_F GL 727 ATGAAGTGCCTCCTGCTTGCC oBLG cDNA forward sequencing primer 
oBLG_R GL 728 CTAGACGTGGCACTGCCCCTC oBLG cDNA reverse sequencing primer 
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M13_R GL 729 CAGGAAACAGCTATGAC Sequencing 
pGTC451_F GL 730 GATCTCGAGCTCAAGCTTCCT 
             XhoI 
PCR cloning for generation of pGL 449 
pGTC451_R GL 731 GTTCTCGAGTCACCTAGATGTGGCACTGCT 
            XhoI 
PCR cloning for generation of pGL 449 
pGTC451_F GL 732 AGCATGGAGTCTTGGACATT PCR for genotyping bBLG mice 
pGTC451_R GL 733 CTCCTCCACATACACTCTCAG PCR for genotyping bBLG mice 
WAP-MBP_F GL 734 GTTTACTAGTGCAATTCTTTCACTG 
              SpeI 
PCR cloning for generation of pGL 298 
WAP-MBP_R GL 735 GTTTGATATCGCAAGTGACTGATGG 
            EcoRV 
PCR cloning for generation of pGL 298 
pGEM-T_WAP_1F GL 736 GCAATTCTTTCACTGCTAAA Sequencing of WAP promoter 
pGEM-T_WAP_1R GL 737 GCTGATAGTGAGATTCTGCTG Sequencing of WAP promoter 
pGEM-T_WAP_2F GL 738 TAGAGTTTCAAGAGGCTGA Sequencing of WAP promoter 
pGEM-T_WAP_2R GL 739 CCAGAGCTCTGTTCTCTCTA Sequencing of WAP promoter 
pGEM-T_WAP_3F GL 740 CACACTGTGCTCATCACTTTG Sequencing of WAP promoter 
pGEM-T_WAP_3R GL 741 CTCTTGCTTGTCCTCTGAGC Sequencing of WAP promoter 
pGEM-T_WAP_4F GL 742 CTGGAATAGACGAATGTAGA Sequencing of WAP promoter 
pGEM-T_WAP_4R GL 743 TGCTCCATGTAGAGAGTGTC Sequencing of WAP promoter 
pGEM-T_WAP_5F GL 744 CAGCAGGACATCTCTTCCTGC Sequencing of WAP promoter 
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pGEM-T_WAP_5R GL 745 TATCGCAAGTGACTGATGGC Sequencing of WAP promoter 
miRNA_F GL 746 GAGGTAGTGAGTCGACCAGTG PCR for genotyping miRNA mice 
miRNA_R GL 747 AGTGCGGCCAGATCTGGG PCR for genotyping miRNA mice 
*Underlined sequence represents additional restriction enzyme site 
2.1.1.4 Expression vectors 
 
Table 2-4: Plasmid DNA expression vectors. 
 
Plasmid Index number Functional sequence Reference or Source 
pBS SK pGL 40  Stratagene (USA) 
pGFP-BLG pGL 152 CMV promoter driven bBLG cassette Ben Wilson (AgResearch, Ruakura, Hamilton, NZ) 
pcDNA5/FRT pGL 164 CMV promoter driven expression construct Invitrogen
 
(USA) 
pEGFP-C1 pGL 195 CMV promoter driven GFP expression vector Clontech (USA) 
pEPI WAP-MBP pGL 263 WAP promoter driven MBP cassette Stefan Wagner (AgResearch, Ruakura, Hamilton, NZ) 
pcDNA™6.2-GW/EmGFP 
miRNA (linearize) 
pGL 273 CMV miRNA expression vector containing an 
GFP expression cassette 
Invitrogen (USA) 
pGFP-miRNA 1 pGL 274 GFP CMV miRNA expression vector miRNA oligos GL 705 and GL 706 were annealed and 
ligated into pGL 273 vector 
pGFP-miRNA 2 pGL 275 GFP CMV miRNA expression vector miRNA oligos GL 707 and GL 708 were annealed and 
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ligated into pGL 273 vector 
pGFP-miRNA 3 pGL 276 GFP CMV miRNA expression vector miRNA oligos GL 709 and GL 710 were annealed and 
ligated into pGL 273 vector 
pGFP-miRNA 4 pGL 277 GFP CMV miRNA expression vector miRNA oligos GL 711 and GL 712 were annealed and 
ligated into pGL 273 vector 
pGFP-miRNA 5 pGL 278 GFP CMV miRNA expression vector miRNA oligos GL 713 and GL 714 were annealed and 
ligated into pGL 273 vector 
pGFP-miRNA 6 pGL 279 GFP CMV miRNA expression vector miRNA oligos GL 715 and GL 716 were annealed and 
ligated into pGL 273 vector 
pGFP-miRNA 7 pGL 280 GFP CMV miRNA expression vector miRNA oligos GL 717 and GL 718 were annealed and 
ligated into pGL 273 vector 
pGFP-miRNA 8 pGL 281 GFP CMV miRNA expression vector miRNA oligos GL 719 and GL 720 were annealed and 
ligated into pGL 273 vector 
pGFP-miRNA 9 pGL 282 GFP CMV miRNA expression vector miRNA oligos GL 721 and GL 722 were annealed and 
ligated into pGL 273 vector 
pGFP-miRNA 10 pGL 283 GFP CMV miRNA expression vector miRNA oligos GL 723 and GL 724 were annealed and 
ligated into pGL 273 vector. 
pGFP-miRNA 11 pGL 285 GFP CMV tandem miRNA expression vector Tandem construct contains miRNA 2 and miRNA 3. 
pGFP-miRNA 12 pGL 286 GFP CMV tandem miRNA expression vector Tandem construct contains miRNA 2 and miRNA 6. 
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pGFP-miRNA 13 pGL 287 GFP CMV tandem miRNA expression vector Tandem construct contains miRNA 3 and miRNA 6. 
pGFP-miRNA 14 pGL 288 GFP CMV tandem miRNA expression vector Tandem construct contains miRNA 2 and miRNA 4. 
pGFP-miRNA 15 pGL 289 GFP CMV tandem miRNA expression vector Tandem construct contains miRNA 6 and miRNA 4. 
pGFP-miRNA 16 pGL 290 GFP CMV tandem miRNA expression vector Tandem construct contains miRNA 3 and miRNA 4. 
pcDNA™6.2-GW/miRNA-neg 
control 
pGL 291 CMV miRNA expression vector containing an 
GFP expression cassette and a scramble miRNA 
Invitrogen (USA) 
pGTC 451 pGL 293 Goat beta casein promoter, 2 x chicken insulator 
and beta casein flanking sequences 
GTC (USA) 
pcDNA5/FRT-bBLG pGL 297 CMV promoter driven bBLG cassette  
WAP-miRNA 6-4 pGL 298 Mammary tissue specific WAP promoter driven 
miRNA 6-4 cassette 
 
WAP-miRNA 4 pGL 446 Mammary tissue specific WAP promoter driven 
miRNA 4 cassette 
 
WAP-miRNA 6 pGL 447 Mammary tissue specific WAP promoter driven 
miRNA 6 cassette 
 
pcDNA5/FRT-oBLG pGL 448 CMV promoter driven oBLG cassette  
pGTC451-bBLG pGL 449 Goat beta-casein promoter driven bBLG cassette  
TOPO-TA  For T/A nucleotide cloning of PCR insert Invitrogen (USA) 
pGEM-T Easy  For T/A nucleotide cloning of PCR insert Promega (USA) 
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2.1.1.5 Kits 
Kit Source 
BCA protein assay kit Thermo Fisher Scientific Inc 
(USA) 
Calibrite 
TM
 3 BD Biosciences (USA) 
MinElute PCR Purification Kit Qiagen (Germany) 
pGEM-T Easy cloning kit Promega (USA) 
QIAGEN Plasmid kit (mini) Qiagen (Germany) 
QIAGEN Plasmid kit (maxi) Qiagen (Germany) 
Super Script® III First Strand Synthesis 
System 
Invitrogen (USA) 
TOPO TA Cloning kit Invitrogen Invitrogen (USA) 
Wizard
®
 SV gel and PCR clean-up system Promega (USA) 
2.1.1.6 Bacterial cell culture materials 
All media and glassware were sterilized by autoclaving at 121°C for 30 minutes. 
2.1.1.6.1 Bacterial strains 
Strain Genotype Source 
MAX Efficiency 
DH5α cells 
F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 
recA1 endA1 hsdR17 (rK–, mK+) phoA 
supE44 λ– thi-1 gyrA96 relA1 
Invitrogen 
(USA) 
One Shot TOP10-
cells 
F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(ara leu) 7697 galU galK rpsL (StrR) 
endA1 nupG 
Invitrogen 
(USA) 
Top 10F E. coli F´{lacIq, Tn10(TetR)}c mcrA Δ(mrr-
hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(ara leu) 7697 galU galK 
rpsL (StrR) endA1 nupG 
Invitrogen 
(USA) 
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2.1.1.6.2 Lauria-Bertani (LB) medium 
LB broth for bacteria culture contained 1% (w/v) bacto-tryptone, 0.5% (w/v) yeast 
extract and 1% NaCl. The powder was suspended in MilliQ H2O and sterilized by 
autoclaving. Culture plates for bacteria colony selection contained 1.5% (w/v) 
bacto-agar. 
2.1.1.6.3 SOC medium 
SOC medium contained 20 g bacto tryptone, 5 g bacto yeast extract, 2 ml of 5 M 
NaCl, 2.5 ml of 1 M KCl, 10 ml of 1 M MgCl2, 10 ml of 1 M MgSO4, 20 ml of 1 
M glucose in 1 litre (L) of MilliQ H2O. The solution was sterilized by autoclaving 
and kept at room temperature. 
2.1.1.6.4 SOB medium 
SOB medium contained 20 g bacto tryptone, 5 g bacto yeast extract and 0.5 g 
NaCl in 950 ml of MilliQ H2O. 
2.1.1.7 Mammalian cell culture 
2.1.1.7.1 Cells 
The African green monkey kidney fibroblast-like cell line COS7 was obtained 
from the American Type Culture Collection (ATCC ® CCL-70). Cells were 
aliquoted into cryogenic storage vials with 10% of DMSO and stored into liquid 
nitrogen (see Section 2.1.2.15.3).  
2.1.1.7.2 Cell culture medium 
The base cell culture medium was purchased from Gibco (USA) and 15.6 g of the 
powder was dissolved in 850 ml of MilliQ H2O with 1.2 g of NaHCO3. The pH 
was adjusted to 7.2 and made up to 1000 ml. The medium was sterilized by 
filtration through a 0.20 µm disposable filter. The medium was kept at 4°C for up 
to one month.  
2.1.1.8 Antibodies used for western blot assay 
Unconjugated rabbit anti-bBLG antibody was purchased from Bethyl 
Laboratories, USA (1 mg/ml). Anti-GFP rabbit antibody (2 mg/ml) was obtained 
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from Invitrogen. Horseradish Peroxidase (HRP) conjugated goat anti-rabbit 
antibody (1 mg/ml) was supplied by Sigma (USA). 
2.1.1.9 Buffers and stock solutions 
All solutions were made up using deionised MilliQ H2O from a water purification 
system (Millipore). 
2.1.1.9.1 General buffers and stock solutions 
EDTA (0.5 M) 14.6 g EDTA in 100 ml ddH2O, pH 8.0. 
PBS (10 x) 80 g of NaCl, 2.0 g KCL, 11.5 g of Na2HPO4 and 2.0 g 
of NaH2PO4 in 1 L of MilliQ H2O, pH 7.2. The solution 
was sterilized by autoclaving and stored at room 
temperature. 
PBS (1 x) Stock solution (10 x) was diluted 10-fold in MilliQ 
H2O. 
PBST 0.05% tween 20 in 1 x PBS, pH 7.2. 
Tris base (1 M) 121.1 g of tris base in 1 L of MilliQ H2O, pH 7.5. 
Trypan blue solution 0.5 g of trypan blue and 0.8 g in 100 ml MilliQ H2O. 
The stock solution was sterilized by filtration through a 
0.20 µm disposable filter. The solution was kept at 4°C.  
2.1.1.9.2 Antibiotic solutions for cell cultures 
Ampicillin (50 mg/ml) 0.5 g of ampicillin in 10 ml of MilliQ H2O. The 
solution was sterilized by filtration through a 0.20 
µm disposable filter and was stored at -20°C. 
Kanamycin (25 mg/ml) 0.25 g of kanamycin sulphate in 10 ml of MilliQ 
H2O. The solution was sterilized by filtration 
through a 0.20 µm disposable filter and was 
stored at -20°C. 
Streptomycin (50 mg/ml) 0.5 g of streptomycin in 10 ml of MilliQ H2O. 
The solution was sterilized by filtration through a 
0.20 µm disposable filter and was kept at -20°C. 
Spectinomycin (20 mg/ml) 0.2 g of spectinomycin in 10 ml MilliQ H2O. The 
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solution was sterilized by filtration through a 0.20 
µm disposable filter was kept at -20°C. 
X-gal (20 mg/ml) 0.2 g of X-gal (5-bromo-4-chloro-3-indolyl b-D-
galactopyranoside) in 10 ml of DMF 
(dimethylformamide). The stock solution was 
stored protected from light at -20°C.  
2.1.1.9.3 Buffers and stock solutions for molecular biology 
Cell lysis buffer 20 mM Tris-HCL (pH 7.5), 5 mM EDTA, 
1% triton X and 1 mM PMSF. PMSF was 
added fresh to the buffers immediately prior 
to use. 
DEPC-H2O 100 μl DEPC to 100 ml ddH2O. Mixed well 
and let set at room temperature for 1 hour. 
The solution was sterilized by autoclaving 
and stored at room temperature.  
DNA loading buffer (10 x) 0.25% (w/v) bromophenol blue and 0.25% 
(w/v) xylene cyanol in 30% (v/v) glycerol in 
MilliQ H2O. 
Glycerol (25%) 25 ml of glycerol in 100 ml of MilliQ H2O. 
The solution was sterilized by autoclaving 
and stored at room temperature. 
Inoue transformation buffer 55 mM MnCl2.4H2O, 15 mM CaCl2.2H2O, 
250 mM KCL and PIPES (0.5 M, pH 6.7). 
Lysis buffer for mouse tails 100 mM Tris (pH 8), 5 mM EDTA, 0.1% 
SDS and 200 mM NaCl 
Microinjection buffer 
 
10 mM Tris-HCl, 0.1 mM EDTA and 100 
mM NaCl. 
10 x MOPS buffer 0.2 M MOPS, 0.05 M sodium acetate, 0.001 
M EDTA, pH 7.0. The solution was 
sterilized by filtration through a 0.20 µm 
disposable filter and was stored at room 
temperature. 
Chapter Two: Materials and Methods 
 
39 
 
TAE (20 x) 96 g of tris base, 22.84 ml of glacial acetic 
acid and 100 ml of 0.5 M EDTA in 1 L of 
MilliQ H2O. The buffer was kept at room 
temperature. 
TE buffer 1 ml of 1 M tris-HCl (pH 8.0) and 0.2 ml of 
0.5 M EDTA in 100 ml of MilliQ H2O.  
2.1.1.10 Reagents for transfection analysis 
Name Source 
FuGENE 6 Roche (USA) 
Lipofectamine 2000 Invitrogen (USA) 
Lipofectamine LTX plus Invitrogen (USA) 
2.1.1.11 Buffers and reagents for western blot assay 
2.1.1.12 Coomassie blue stain solutions 
Name Source 
Antibody incubation solution 0.1% BSA (w/v) and 0.05% (v/v) tween 
Blocking buffer 1.0% (w/v) PVP, 0.1% BSA (w/v) and 
0.05% (v/v) tween 
Bis-Tris pre-cast polyacrylamide 
gel 
Invitrogen (USA) 
ECL detection reagent A GE Healthcare (UK) 
ECL detection reagent B GE Healthcare (UK) 
SDS-PAGE sample buffer (4 x) Invitrogen (USA) 
SDS-PAGE running buffer (20 x) Invitrogen (USA) 
Destaining solution 50% (v/v) methanol in MilliQ H2O with 10% (v/v) 
acetic acid. 
Gel fixing solution 50% (v/v) ethanol in MilliQ H2O with 10% (v/v) acetic 
acid. 
Gel washing solution 50% (v/v) methanol in MilliQ H2O with 10% (v/v) 
acetic acid. 
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2.1.1.13 Equipment  
2.1.1.13.1 Specific equipment and instruments 
Name Source 
Autoclave Tuttnauer autoclave (USA) 
Bacteria incubator Sanyo (USA) 
Bacteria shaker Infos HT (Switzerland) 
Bench centrifuge Eppendorf (Germany) 
Cell culture incubator Thermo Forma (USA) 
Cell culture microscope Nikon TMS (Japan) 
Cell culture hood Gelman Sciences (USA) 
Computer HP (USA) 
Cryofreezing block Nalgene™, Nunc International (USA)  
Deep freezer (-80°C) Thermo Fisher Scientific Inc (USA) 
Developing cassettes Kodak (USA) 
Developing machine All-Pro Imazing Corp (USA) 
Electrophoresis power supply E-C Apparatus Corporation (USA) 
Electrophoresis unit Horizon
TM
 (USA) 
Becton Dickinson FACS sorter BD Biosciences (USA) 
Gel Doc 1000 Bio Rad (USA) 
Heating block Eppendorf (Germany) 
Hemocytometer Improved Neubauer; Weber, (UK) 
iBlot® dry blotting unit Invitrogen (USA) 
Ice machine A best kitchen (USA) 
Liquid nitrogen tank Chart MVE Biological Systems 
(USA) 
Millipore H2O-prduction unit Milli-Q 
plus 
Bio Lab (AU) 
Staining solution 0.1% (w/v) of coomassie blue R 350, 20% (v/v) 
methanol and 10% (v/v) acetic acid in MilliQ H2O. The 
stain solution was filtered through a 0.20 µm disposable 
filter to remove any insoluble material. 
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Microwave oven Sharp (China) 
NanoDrop spectrophotometers Thermo Fisher Scientific Inc (USA) 
Olympus BX50 microscope Olympus (Japan) 
pH meter Mettler Toledo (USA) 
PCR Bio Rad (USA) 
Pipettes (p-20, p-200, p-1000) Biohit group (Finland) 
Scale Sartorius (Germany) 
Spectrophotometer Eppendorf (Germany) 
Sonicator (Thyristor Regler TR50) IKA (USA) 
Sorvall refrigerated centrifuge International MI-SS, Inc (USA) 
Vortex Chiltern Scientific (Australia) 
Water bath (37°C, 42°C and 65°C) Grant Instruments ltd (UK) 
2.1.1.13.2 Culture vessels 
2.1.1.13.2.1 Plastic ware 
Disposable non-treated and sterile cell culture dishes (10 cm), multi-well plates 
(6-well, 12-well and 24-well) and cryogenic vials were purchased from Nalge 
Nunc International (Denmark). Sterile plastic centrifuge tubes (15 ml and 50 ml) 
were purchased from Becton Dickinson lab ware (USA). Single-use disposable 
sterile pipettes (1 ml, 2 ml, 5 ml, 10 ml and 25 ml) were obtained from Bio Lab 
(AU). Disposable filter tips with different sizes (10 µl, 20 µl, 200 µl and 1,000 µl) 
were purchased from Molecular Bio products (USA). Micro centrifuge tubes (1.5 
ml and 2.0 ml) were obtained from Bio Lab (AU). PCR-reaction tubes were 
purchased from Axygen Scientific Inc (USA). 
2.1.1.13.2.2 Glassware  
Storage bottle with different sizes (100 ml, 250 ml, 500 ml and 1000 ml), 
volumetric flasks (100 ml, 250 ml, 500 ml, and 1,000 ml), beakers (50 ml, 100 ml, 
250 ml, and 400 ml), and measuring cylinder (50 ml, 100 ml, 250 ml and 500 ml) 
were purchased from Schott Duran (Germany) and Pasteur pipettes were 
purchased from Poulten & Graf Ltd (UK). All glassware used in this research 
were washed with detergent, rinsed in water and sterilized by autoclaving at 
121°C for 30 minutes. 
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2.1.1.13.2.3 Other Consumables 
Biomax XAR film was purchased from Kodak (USA). iBlot® transfer stack 
consumables were obtained from Invitrogen (USA).  
2.1.1.14 Software 
Name Source 
BLOCK-iT™ RNAi Designer tool Invitrogen (USA) 
CellQuest Pro BD Biosciences (USA) 
Chromas Lite version 2.01 Technelysium pty ltd (Australia) 
Microsoft Excel 2007 Microsoft (USA) 
Quantity One software Bio Rad (USA) 
Vector NTI Advance™ 11 Invitrogen (USA) 
2.1.1.15 Animals and Animal Ethics Approval 
Pathogen-free mouse colonies were raised in pathogen-free conditions at the SAC, 
AgResearch, Ruakura, Hamilton, New Zealand. For microinjection and generation 
of the Tg mouse lines, the FVB and C57BL/6 mice strains were used. 
Homozygous oBLG expressing mice were kindly provided by Dr. Bruce 
Whitelaw (Roslin Institute, UK). The study protocol 764 has been approved by 
the University of Waikato research and ethics committee on December, 2008. 
2.1.2 General methods 
2.1.2.1 Generation of chemically competent cells  
Competent cells of E. coli DH5α were prepared by a method described previously 
(146). In brief, a single colony of E. coli was cultured overnight at 37 C with 
moderate shaking (230 rpm) in 5 ml of LB medium. The bacterial culture was 
inoculated into a 1 L flask containing 250 ml SOB and incubated at 37
o
C with 
shaking. The culture was monitored every 45 minutes until the optical density 
(OD) reached 0.55 at 600 nm. The cells were harvested by centrifuging at 4,500 
rpm (Sorvall GSA rotor) in a 50 ml falcon tube for 10 minutes at 4
o
C. The 
supernatant was discarded and the cell pellet was resuspended in 80 ml of ice-cold 
Inoue transformation buffer. The cell suspension was centrifuged at 4,500 rpm 
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(Sorvall GSA rotor) for 10 minutes at 4
o
C to remove traces of SOB medium. The 
resulting cell pellet was resuspended gently in 20 ml of ice-cold Inoue 
transformation buffer and 1.5 ml of DMSO was added into the bacterial 
suspension which was incubated on ice for 10 minutes. The bacterial suspension 
was aliquoted into chilled, sterile microfuge tubes and snap-frozen by immersing 
into liquid nitrogen. The ampoules of competent cells were stored at -80
o
C for 
future use. The transformation efficiency of the bacteria was measured by 
transforming a circular plasmid DNA (pGL 40) (see Section 2.1.2.12) and the 
bacterial preparation producing ~0.8x10
7
 colony forming units (CFU) per µg of 
plasmid DNA. 
2.1.2.2 Isolation of nucleic acids 
2.1.2.2.1 Small-scale preparations of plasmid DNA by miniprep 
Small-scale plasmid DNA isolation was done using the QIAprep Spin Miniprep 
Kit according to the manufacturer‟s instructions. In brief, the bacterial cultures 
were pelleted by low speed centrifugation at 6,000 rpm for 5 minutes on a bench-
top microfuge (Eppendorf). Harvested bacterial cells were resuspended in 250 μl 
P1 buffer and transferred to a microcentrifuge tube. The cells were lysed by 
adding 250 μl of P2 buffer and mixed thoroughly by inverting the tube 4–6 times. 
350 μl of N3 buffer was then added and mixed immediately as above to neutralize 
the reaction and centrifuged for 10 minutes at 13,000 rpm (~17,900 x g) in a 
table-top microcentrifuge. The supernatant was retained by decanting into the 
QIAprep spin column and centrifuged at 13,000 rpm for 60 seconds. The flow-
through was discarded and the QIAprep spin column was washed by adding 0.5 
ml of PB buffer followed by centrifuging for 60 seconds. Again the flow-through 
was discarded and the QIAprep spin column was washed by adding 0.75 ml PE 
buffer and centrifuged for 60 seconds. The QIAprep column was placed in a clean 
1.5 ml microcentrifuge tube and DNA was eluted in 50 μl EB buffer. 
2.1.2.2.2 Large-scale preparations of plasmid DNA by maxiprep 
Large-scale plasmid DNA isolation was done using the QIAprep Spin Maxiprep 
Kit in accordance to the manufacturer‟s instructions. In brief, a single colony was 
cultured over night in 500 ml of LB containing the appropriate antibiotic at 37 C 
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with shaking (225 rpm). The bacterial cells were harvested by centrifugation at 
6,000 rpm for 15 minutes at 4 C (Sorvall GSA rotor). All traces of supernatant 
were removed and the pellet was completely resuspended in 10 ml P1 buffer. The 
cells were lysed by adding 10 ml of P2 buffer and mixed thoroughly by inverting 
the tube 4–6 times and incubated at room temperature for 5 minutes. The reaction 
was neutralized by adding 10 ml of chilled P3 buffer followed by inverting 4-6 
times and centrifuged at 18,000 rpm (Sorvall SS 34 rotor) for 30 minutes at 4 C 
(in Beckman 40 ml polypropylene tubes). The supernatant was poured into a clean 
centrifuge tube and re-centrifuged at 18,000 rpm (Sorvall SS 34 rotor) for 15 
minutes at 4 C. The Qiagen tip was equilibrated by applying 10 ml QBT buffer 
and by gravity flow. The supernatant was poured into the column and allowed to 
enter the resin by gravity flow. The tip was washed twice with 15 ml QC buffer 
and DNA was eluted with 5 ml EB buffer in a 40 ml polypropylene centrifuge 
tube. The eluted DNA was precipitated by adding 10.5 ml propan-2-ol at room 
temperature. The DNA was collected by centrifugation at 18,000 rpm (Sorvall SS 
34 rotor) for 30 minutes at 4 C. The DNA pellet was washed with 5 ml ice-cold 
70% ethanol and centrifuged at 18,000 rpm (Sorvall SS 34 rotor) for 10 minutes at 
4 C. Finally, the pellet was air dried at room temperature for 10 minutes and 
dissolved in 100 µl TE buffer. 
2.1.2.2.3 Isolation of genomic DNA (gDNA) 
For the genotyping of Tg mice gDNA was obtained from 4 mm of mouse tail 
biopsies. They were digested with 99 µl of tail digestion buffer with 1 µl of 
proteinase K (20 mg/ml). The digestion was carried out for 2 hours at 55 ºC and 
1,200 rpm on a thermo mixer for complete disruption of the tail. The lysate was 
centrifuged at 13,000 rpm for 1 minute to spin down the unwanted debris. The 
supernatant was transferred to a fresh microfuge tube and the enzyme was 
inactivated by heating at 65ºC for 15 minutes. Finally, the gDNA was diluted in 
TE buffer (1:20,000 with TE buffer). 
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2.1.2.2.4 Isolation and purification of total RNA 
2.1.2.2.4.1 Handling of RNA 
As ribonucleases (RNases) are very stable and active enzymes, special care was 
taken to isolate total RNA from mouse tissue. RNA isolation place benches were 
treated with RNase AWAY. All solutions were made in DEPC treated MilliQ 
H2O. Sterile, disposable polypropylene tubes and filter pipette tips were used for 
RNA isolation. Electrophoresis tanks, glassware, spatulas, stirring bars, mortar 
and pestle were treated with DEPC-treated water to eliminate RNases. 
2.1.2.2.4.2 Isolation of RNA from mouse mammary tissue 
Total RNA from mammary tissue was carried out in order to isolate mRNA. A 
mRNA is the transcript of a gene and is a source to synthesize cDNA for research 
purpose. So, in order to synthesize oBLG cDNA (variant B), total RNA from Tg 
oBLG mouse mammary tissue was isolated using TRIzol reagent in accordance to 
the manufacturer‟s instruction. In brief, tissue samples were homogenized in 
liquid nitrogen using a pestle and mortar. 1 ml of TRIzol was added per 50-100 
mg of homogenized tissue in a pre-chilled 2 ml nuclease free microfuge tube and 
incubated for 5 minutes at room temperature. Chloroform was added (0.2 ml/tube) 
and mixed by inverting tube for 4-6 times. The solution was incubated for 5 
minutes at room temperature. The sample was centrifuged at 12,000 x g for 15 
minutes at 4°C. The upper aqueous phase was transferred to a fresh microfuge 
tube. RNA was precipitated by adding 0.5 ml of propan-2-ol and incubated for 5 
minutes at room temperature. RNA was pelleted by centrifuging at 12,000 x g for 
10 minutes at 4°C. The pellet was washed once with 75% ice-cold ethanol and 
centrifuged at 7,500 x g for 5 minutes at 4°C. The pellet was air dried for 10 
minutes at room temperature and dissolved in 100 µl DEPC water. 
2.1.2.3 Quantification of nucleic acid 
The concentration of plasmid DNA and total RNA was measured using 
spectrophotometry (Nanodrop). Before nucleic acid measurements the machine 
was calibrated with water followed by blanked it with solutions used to re-
suspend DNA or RNA. The concentration of the nucleic acid sample was 
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measured in ng/μl. The purity of DNA and RNA was determined by dividing the 
readings of the absorbance at 260 nm and 280 nm. A good quality nucleic acid of 
1.7–2.0 at A260/A280 absorbance ratio was considered for further experiments. 
2.1.2.4 Restriction digestion of DNA 
To ensure that the clones contained the target insert, plasmid DNA of the clones 
were restriction digested. DNA to be digested was diluted in 1 x restriction 
digestion buffer provided by the suppliers. Endonucleases of 3-5 units were used 
per μg of DNA. The mixture was mixed by tapping the tube with fingers and 
briefly centrifuged to remove air bubbles. The reaction was incubated at 37°C for 
2 h. The reaction was incubated at 65°C for 15 minutes to de-activate the 
restriction enzymes. 
2.1.2.5 Detection of DNA on agarose gel electrophoresis 
An agarose gel was used to separate DNA fragments. The separation of DNA 
fragments depends on the size of molecules as small fragments run faster than 
larger fragments on gel metrix. To separate smaller DNA fragments (<200 bp) 2% 
agarose gel was used. To separate larger DNA fragments (>200 bp) 0.8% agarose 
gel was used.The gel was prepared by adding 0.8 g of ultra pure agarose powder 
in 100 ml of 1 x TAE running buffer and heated in a microwave oven until 
completely melted. 10 μl of SYBR Safe (10,000 x) (Molecular probes, invitrogen) 
was added to the gel to visualize DNA bands under UV light. The gel was poured 
into a casting tray containing a sample comb and allowed to solidify at room 
temperature. A molecular weight ladder of 1 kb
+
 (Invitrogen) was added in an 
adjacent well in order to determine size of the sample DNA bands. Samples 
containing 6 x DNA loading dye were pipetted into gel wells and run in an 
electrophoresis tank (Invitrogen) at a constant voltage of 100 volts. The gel was 
run until the bromophenol blue dye had run to the 2/3 of the length of the gel. The 
stained DNA was visualized by an ultraviolet transmitter at 350 nm. The image 
was captured using a camera and analysed using Quantity One software (Bio 
Rad). 
Chapter Two: Materials and Methods 
 
47 
 
2.1.2.6 Purification of DNA from agarose gel 
After electrophoresis, the stained gel was visualized on a UV light box (a trans-
illuminator). The desired DNA band was excised using a scalpel blade from the 
agarose gel under the UV transilluminator with a short period of exposure. The 
DNA fragments were purified from the agarose gel using the Wizard
®
 SV Gel and 
PCR Clean-Up System (Promega). In brief, the weight of the individual gel slice 
was determined and three volumes of membrane binding solution were used 
followed by incubation of 65°C for 10 minutes to solubilise the agarose. The 
DNA/gel solution was loaded onto a SV minicolumn. The mixture was 
centrifuged at 13,000 rpm for 1 minute. The flow through was discarded and the 
DNA was washed with membrane wash solution to remove residual salts. The 
column was placed into a sterile 1.5 microfuge tube and the DNA was eluted from 
the column using elution EB buffer. 
2.1.2.7 Dephosphorylation of vectors 
Vectors with compatible ends after restriction digest require dephosphorylating in 
order to prevent re-ligation of the vector to itself. Alkaline phosphatase catalyses 
the removal of 5' phosphate groups from DNA. In order to prevent the re-ligation 
of vectors, the 5‟ phosphate group of the vector was removed using SAP prior to 
ligation. The digested DNA was dephosphorylated using 10 units of SAP per µg 
of vector with 10 x dephosporylation buffer to prevent DNA ligase from re-
circularizing of the vector. The mixture was incubated for 15 minutes at 37°C. 
The SAP was inactivated by incubating at 65°C for 15 minutes.  
2.1.2.8 Polymerase chain reaction (PCR) 
PCR allows amplification of a particular DNA sequence in a cyclic manner. PCR 
amplification consists of three steps: Step 1, denaturation of double strand DNA, 
step 2, primers annealing and step 3, synthesis of new DNA strands (extension). A 
standard PCR was set up for a final volume of 50 μl. 
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A PCR reaction mix included: 
38 μl MilliQ H2O, 5 μl 10 x PCR buffer (MgCl2), 0.5 μl dNTP mix (10 mM each 
dNTP), 0.5 μl sense/forward primer (100 μM), 0.5 μl anti-sense/reverse primer 
(100 μM), 5 μl template and 1 μl Taq polymerase (5 U). 
The PCR cycling condition was: 
95 °C     4:00                                  (minute:second) 
95 °C     0:30 
Tm*       0:30     x 35 
72 °C 0:30** 
72 °C 7:00 
*Tm determined by gradient PCR 
** Primer extension time dependent of the insert size, as a rule 1 kb = 1 minute 
2.1.2.8.1 Primer design for PCR 
The PCR primers were designed to amplify the gene of interest. All primers used 
in this study were designed using Vector NTI (Invitrogen, USA) and the software 
generated primer sequences were further analysed by Geneious Pro (Version 4.8) 
(BioMatters Ltd, NZ) to check for secondary structure in the primer sequence. 
The primers were designed for PCR following with particular specifications. The 
product length was a minimum of 150 bp to maximum 650 bp, optimum 
temperature (Tm) of 50-60 °C, primer length of 20-21 nucleotides, 40-50 % GC, 
avoid complementarity of primes to prevent formation of primer dimmers and 
avoid GC clamps in sequence. Primers were supplied by Invitrogen (USA) and 
the lyophilized primers were diluted in 1 x TE buffer adjusted to the final 
concentration of 100 μM. Although primers were designed according to the rules 
of primer design, it is sometimes hard to find perfect primer pair for PCR. So, a 
gradient PCR was run to determine the annealing temperature in order to amplify 
single product followed by running the products on agarose gel. 
2.1.2.9 Synthesis of first-strand cDNA 
The synthesis of cDNA involves making copies of DNA from specific mRNA. 
The reverse transcriptase enzyme uses the oligo dT primer that binds with the 
polyA tail of the mRNA (3‟) to start DNA synthesis. For the first strand cDNA 
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synthesis, the SuperScript III First-Strand Synthesis System (Invitrogen) was used 
according to the manufacturer‟s instructions. In brief, 5 µg of total RNA was 
taken in a 0.5 ml nuclease free microfuge tube. 1 µl of oligo dT (50 μM), 1 μl of 
dNTP mix (10 mM) and DEPC-dH2O to a final volume of 10 µl were added into 
the tube. The mixture was incubated at 65°C for 5 minutes and kept on ice for 1 
minute. A cDNA synthesis master mix was prepared by adding each component 
in the indicated following order. The master mix was added to the RNA/primer 
mixture and incubated at 50°C for 50 minutes in a thermo mixer. The reaction was 
terminated by incubating at 85°C for 5 minutes and chilled on ice. Finally, 1 μl of 
RNase H was added to each tube and incubated for 20 minutes at 37°C to degrade 
RNA in RNA:DNA hybrids. The first strand cDNA synthesis reaction was 
immediately used for PCR amplification. 
Component Amount 
10 x RT buffer 2 μl 
1 M DTT 2 μl 
25 mM MgCl2 4 μl 
RNaseOUT (40 U/μl) 1 μl 
SuperScript III RT (200 U/μl) 1 μl 
2.1.2.10 Ligation of DNA fragments 
Takara DNA ligation mighty mix was used to ligate the DNA fragments. The 
digested plasmid vector DNA was combined with the insert DNA fragment with a 
molar ratio of 1:3. An equal volume of ligation mix was mixed with the DNA 
mixture and mixed thoroughly. The ligation reaction mix was incubated at 16°C 
for 30 minutes.  
2.1.2.11 Sub-cloning of the PCR product 
Sub-cloning of DNA is the transfer of the DNA fragment from one plasmid of 
interest to another. The TOPO TA (Invitrogen)/pGEM-T Easy (Promega) cloning 
utilizes the enzyme, DNA topoisomerase I to integrate a PCR product. PCR 
products were sub-cloned into shuttle vectors before being cloned into appropriate 
expression vectors. The TOPO vector/pGEM-T vector is a convenient system to 
sub-clone PCR products. A PCR product generated using Taq polymerase 
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contains compatible 3‟ A hanging ends. Annealing of the insert and TOPO vector 
was done in accordance with the manufacturer‟s instructions. 4 µl of PCR product 
was mixed with 1 µl of salt solution and 1 µl of TOPO vector. The mixture was 
incubated at room temperature for 30 minutes. The cloning reaction was 
transformed into competent cells (see Section 2.1.2.12).  
2.1.2.12 Transformation of E. coli competent cells  
E. coli competent cells were thawed on ice and the ligation reaction was added 
into 100 μl of competent cells. The ligation reaction was incubated on ice for 30 
minutes with competent cells. The DNA and cell mixture was heat shocked at 
42°C for 30 seconds and immediately returned to ice and kept on ice for 3 
minutes. A fresh aliquot of 250 μl of SOC medium was added to the 
transformants and incubated at 37°C with shaking at 250 rpm for 1 hour. The cells 
were plated on LB agar plates containing an appropriate concentration of specific 
antibiotic and incubated over night at 37°C with shaking at 250 rpm. 
2.1.2.13 DNA sequencing 
2.1.2.13.1 Sequencing 
Plasmid DNA was send to Massey University for sequencing to confirm that there 
was no introduced point mutation in the DNA sequence and the ligation sites are 
correct. The sequencing reaction was set up in a final volume of 15 μl, with 300 
ng of DNA template and 3.2 pmol of forward and/or reverse sequencing primer.  
2.1.2.13.2 Sequence analysis 
The sequencing results obtained from Massey University were interpreted by 
using sequence analysis software Vector NTI (Invitrogen). Any mismatches in the 
sequenced DNA sequence can be checked by looking at the chromatogram using 
Chromas Lite (technelysium, Au) software. 
2.1.2.14 Glycerol stock 
Bacterial culture of the recombinant positive clone was preserved as a 25% 
glycerol stock by adding 500 μl of an overnight culture to 500 μl of 50% glycerol 
Chapter Two: Materials and Methods 
 
51 
 
in a 2 ml screw top tube. The glycerol stock tube was frozen down at -80
o
C until 
required.  
2.1.2.15 Mammalian cell culture 
The culture of COS7 cells was carried out in a sterile laminar flow hood 
(Westinghouse Pty Ltd, NSW, Australia). To keep the hood sterile it was 
routinely wiped with 70% ethanol before and after use. Everything used for cell 
culture was also wiped with 70% ethanol. Cells were cultured at 37°C and 5% 
CO2 in a water jacket incubator (Forma Scientific). 
2.1.2.15.1 Cell culture 
COS7 cells were seeded into 10 cm
2
 sterile culture plate. When cells were grown 
to log phase, cells were washed gently with sterile PBS to remove dead cells. 
Cells were trypsinized with pre-warmed (37°C) trypsin-EDTA at 37°C for 5 
minutes. The trypsin was deacitivated by adding 5 ml of fresh medium and 
trypsinized cells were pelleted by centrifuging at 1,000 rpm for 3 minutes. The 
supernatant was removed by aspiration and 5 ml of pre-warmed culture medium 
was added to the cell pellet. The cell clumps were broken by pipetting up and 
down and again pelleted by centrifugation at 1,000 rpm for 3 minutes. The 
supernatant containing the residues of trypsin was discarded and 1 ml of fresh pre-
warmed medium was added to resuspend the cell pellet. 
2.1.2.15.2 Viable cell count 
The viability of cells was determined by using trypan blue dye. It stains the dead 
cells by taking up the dye through the damaged cell membrane. In living cells, the 
cell membrane extrudes the dye because it acts as a selective barrier to foreign 
compounds to cross cell membrane. Cell suspension of 20 µl was taken into a 1.5 
ml of microfuge tube and an equal volume of trypan blue solution was mixed with 
the cell suspension by inverting the tube 4-6 times. The number of stained cells 
was counted using a Neubauer hemocytometer using a 20 x inverted phase 
contrast Olympus CK2 microscope. The cell number was determined by counting 
four corners of 4 x 4 squares of the hemocytometer. The following formula was 
used to calculate the number of viable cells: 
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2.1.2.15.3 Cryo-preservation of mammalian cells 
When the cells were in excess they were frozen down in the liquid nitrogen for 
future use. Cultured cells were centrifused at 1,000 rpm and the cells were re-
suspended in 1 ml of fresh culture medium. 1 ml of freezing media was added to 
the cell suspension, which contained 500 μl FCS, 300 μl of DMEM-F12 culture 
medium and 200 μl DMSO. The cells were then divided into two storage cryo 
vials and put them into a “Mr Frosty” (Nalgene™ Cryo 1°C Freezing container) 
that contains isopropanol and placed in a -80°C freezer. The slow freezing of the 
cells prevents cells from damage from ice crystals. On the following day, the cryo 
vials were transferred to a liquid nitrogen tank for long term storage. 
2.1.2.15.4 Recovery of cells from liquid nitrogen storage 
Stocks of surplus cells were kept in cryovials from liquid nitrogen (-196°C) was 
removed and immediately placed in a 37°C water bath. The thawed cell culture 
was pipetted out into a sterile 15 ml tube containing 5 ml of fresh medium. The 
cells were centrifuged at 1,000 rpm for 3 minutes and the supernatant was 
discarded by aspiration. The cell pellet was re-suspended in pre-warmed fresh 
medium and precipitated the cell pellet by centrifugation to remove any residues 
of DMSO. The cell pellet was re-suspended with fresh medium and transferred to 
a tissue culture flask. 
2.1.2.16 Protein analysis by western blot assay 
2.1.2.16.1 Preparation of cell lysate 
After 48 hours of transfection, cells were washed gently with sterile PBS to 
remove dead cells. Cells were trypsinized using trypsin-EDTA (100 µl/well) and 
pelleted at 1,000 rpm for 3 minutes. The cell pellet was washed with 0.5 ml of 
culture medium to get rid of trypsin residues and centrifuged at 1,000 rpm for 3 
minutes. The lysis buffer with protease inhibitor cocktail (1 µl/million of cell) was 
added to the cell pellet. Sample tubes were vortexed before sonication and bursts 
Cell number (cells/ml) =   X 2  
   Total cell counts                
4 x 10
-4
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for two 15 seconds at maximum output power on ice using a Misonix Sonicator 
(U.S.A). Cell lysates was cleared by centrifugation at 13,000 rcf at 4ºC for 15 
minutes. The supernatant was removed and analysed for protein content using the 
BCA (bicinchoninic acid) assay.  
2.1.2.16.2 Quantification of protein 
The protein concentration of the lysates was measured by BCA protein assay kit 
in accordance to the manufacturer‟s guide lines. In brief, a working solution was 
prepared by mixing 50 parts of reagent A with 1 part reagent B. Protein (albumin) 
standards (A-H) were made following the manufacturer‟s guidelines. Sample 
lysate was mixed with the working solution at 1:20 and incubated in a water bath 
at 37ºC for 30 minutes. Finally, the protein concentration of the samples was 
measured using the Nanodrop spectrophotometer at 562 nm.  
2.1.2.16.3 SDS polyacrylamide gel electrophoresis (PAGE) 
The SDS-PAGE was run using a NOVEX gel apparatus. Protein samples were 
mixed with 4 x SDS sample loading buffer with 50 mM DTT and boiled at 95°C 
for 5 minutes before loading. The 10% Bis-Tris pre-cast polyacrylamide gel was 
assembled into the gel tank and 1 x MES running buffer was poured into the tank 
up to the top of the gel (~800 ml) and the comb of the gel was removed carefully. 
The boiled samples were cooled to room temperature and loaded onto the gel with 
a pre-stained marker. Electrophoresis was carried out at constant voltage (120 V) 
until the bromophenol blue dye reached to the bottom of the resolving gel. The gel 
cassette was opened using a spatula to expose the gel. The top and bottom 
electrode areas of the gel were trimmed off by spatula. The gel was ready for 
staining with coomassie stain or western blot procedure. 
2.1.2.16.4 Transfer of protein 
Proteins from gel were transferred to transfer membrane using iBlot gel transfer 
device (Invitrogen, USA). Once the gel was cut out of the cassette, it was placed 
on the transfer membrane of the anode stack. The gel was then topped with a pre-
soaked (MilliQ H2O) filter paper and air bubbles were removed using the blotting 
roller. The cathode stack was topped over the pre-soaked filter paper followed by 
removing air bubbles using the blotting roller. Finally, a disposable sponge was 
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placed with the metal contact of the lid. The transfer was performed in 7 minutes. 
After transfer the membrane was stained with Ponceau for 5 minutes to check 
efficiency of proteins from gel to membrane followed by destaining with MQ 
H2O. The transfer membrane contained the proteins of interest was ready for the 
western blot procedure. 
2.1.2.16.5 Blocking and immune-staining of the blot 
The membrane was blocked with blocking buffer (see Section 2.1.1.11) for 2 
hours at room temperature on a rocker. Following this, the membrane was 
incubated with primary antibody (rabbit anti-bBLG, 1:10,000 dilution) or anti 
rabbit GFP (1:2,000 dilution) in antibody incubation solution against BLG or GFP 
protein for overnight at room temperature. The membrane was washed three times 
with an interval of 10 minutes between each wash. The membrane was then 
incubated with the secondary antibody (goat anti rabbit-HRP conjugated, 1:20,000 
dilutions in antibody incubation solution) for 2 hours at room temperature. 
Finally, three washes of 10 minutes with PBS were done before chemiluminescent 
detection was made.  
2.1.2.16.6 Detection of protein 
Detection was made in dark room using enzyme linked chemiluminescence (ECL) 
detection reagents (A and B) from Amersham (UK). The secondary antibody used 
was horse radish peroxidase conjugated and it catalyses the break down of 
luminol in presence of a substrate (alkaline phosphatase) which produces 
detectable signals (Figure 2-1). ECL reagent A was mixed with ECL reagent B in 
1:1 ratio to give sufficient solution to cover the membrane and incubated for 1 
minute at room temperature. After the incubation, the excess ECL mixture was 
aspirated and the membrane was wrapped in plastic and exposed to an X-ray film 
(KOdak) in a dark room. After developing the film it was scanned and bands on 
the film were quantified by Quantity One software (Bio Rad). 
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Figure 2-1: Binding of Primary and Secondary HRP Antibody and ECL detection. 
2.1.2.17 Statistical analysis 
All data were plotted graphically as mean vertical bars representing standard error 
(S.E.) A Student's t test was used to assess differences between two experimental 
repeats. A probability (P) value of <0.05 was taken as an appropriate level of 
significance. Statistical analysis was done in Excel. 
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2.2 Methods Relating to Chapter Three: In 
Vitro Validation of miRNA Constructs 
2.2.1 Generation of miRNA expression constructs 
2.2.1.1 Selection of miRNA sequences for targeting BLG gene 
MiRNA duplexes were designed targeting bBLG gene (accession no: 
NM_172929, variant B) using BLOCK-iT™ RNAi designer tool (Invitrogen, 
USA). The BLOCK-iT™ RNAi designer tool utilizes proprietary algorithm to 
design miRNA sequences. The BLG gene has 7 exons and spans 500 bp. The 
mRNA sequence of bBLG was retrieved from the NCBI database and 10 BLG 
specific synthetic miRNA oligonucleotides containing different target sequences 
were designed (Table 2-2).  
2.2.1.2 Generation of single miRNA expression constructs 
Both lyophilized single stranded sense and anti-sense miRNA oligos were diluted 
in TE buffer to a final concentration of 200 µM. Each of the above oligos was 
mixed to the final concentration of 50 µM. The following annealing procedure 
(Table 2-5) was set up at room temperature in a 0.5 ml sterile micro centrifuge 
tube. 
Table 2-5: Generation of miRNA duplexes. 
Reagent Amount 
Top strand DNA oligo (200 μM) 5 µl 
Bottom strand DNA oligo (200 μM) 5 µl 
10 x Oligo Annealing Buffer 2 µl 
DNase/RNase-Free Water 8 µl 
Total volume 20 µl 
 
The annealing reaction was incubated at 95°C for 4 minutes and allowed to cool 
down to room temperature for 5-10 minutes. The reaction was centrifuged briefly 
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for 5 seconds and mixed gently. The ds oligo mixture was diluted 100-fold into 
DNase/RNase-free water (1 µl of 50 µM ds oligo into 99 µl of DNase/RNase-free 
water) to obtain the final concentration of 500 nM and vortexed gently to mix. 
The 500 nM of ds oligo was diluted 50-fold into oligo annealing buffer to get a 
final concentration of 10 nM (1 µl of 500 nM ds oligo into 5 µl of 10 x oligo 
annealing buffer and 44 µl of DNase/RNase-free water). The pGL 273 expression 
vector was used to clone and express the ds oligo duplexes under the 
transcriptional control of CMV promoter. This expression vector leads to a 
bicistronic expression of GFP with the miRNA (Figure 2-2). For cloning of the ds 
oligo duplexes into the linearized pGL 273 expression vector a 20 µl ligation 
reaction was set up at room temperature using the following reagents listed in 
Table 2-6. The ligation reaction was mixed well by pipetting up and down and 
incubated for 5 minutes at room temperature. The ligated product was transformed 
to One Shot® TOP 10F competent cells and selected by spectinomycin (50 μg/ml) 
resistance (see Section 2.1.2.12). Few colonies from each plate were picked and 
cultured overnight in LB medium containing 50 μg/ml spectinomycin at 37°C 
with shaking at 250 rpm. 
Table 2-6: A list of reagents to clone ds oligo into the expression vector. 
Reagent Sample Negative control 
5 x ligation buffer 4 μl 4 μl 
pGL 273 (5 ng/μl) 2 μl 2 μl 
miRNA-ds oligo (10 nM) 4 μl - 
DNase/RNase-Free Water 9 μl 13 μl 
T4 DNA Ligase (1 U/μl) 1 μl 1 μl 
Total volume 20 μl 20 μl 
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Figure 2-2: A schematic representation of cloning of miRNA duplex into pGL 273. 
A. miRNA top strand oligonucleotide: the left 5 nt cloning overhang (capitals, 
underlined) is followed by a 21 nt antisense target sequence (lower case, xx marked in 
green colour) and a 19 nt loop (capitals) and the sense target sequence (lower case, xx 
marked in red colour). B. represents reverse complement strand of top strand oligo. C. 
Cloning of the annealed top and bottom strand oligonucleotides into pGL 273 results in 
CMV-GFP-miRNA knockdown vector. The human cytomegalovirus (CMV) promoter is 
highlighted in green color drives the transcription of GFP and miRNA. The total size of 
the generated vector is 5759 bp. EmGFP, Enhanced green fluorescent protein; TK pA, 
TK polyadenylation signal; F1 origin, F1 single strand DNA origin; SV40 early promoter 
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and origin, SV40 early promoter and origin of replication; EM7 promoter, synthetic 
prokaryotic promoter; Blasticidin, Blasticidin resistance gene, SV40 pA, SV40 
polyadenylation signal; pUC origin, pUC plasmid replication origin and Spectinomycin, 
Spectinomycin resistance gene. 
2.2.1.3 Identification of single miRNA inserts  
Screening of single miRNA inserts was done by the plasmid DNA preparation 
(see Section 2.1.2.2.1) and quantification of DNA (see Section 2.1.2.3) followed 
by restriction enzyme digest of the plasmid DNA (see Section 2.1.2.4). The 
miRNA inserts have a unique MscI restriction site and to check the presence of 
the miRNA inserts, miRNA constructs were digested with MscI restriction 
enzyme and visualized by gel electrophoresis (see Section 2.1.2.5). Positive 
clones which were correctly ligated should give rise to bands of 1.4 kb and 4.3 kb. 
As shown in Appendix 1, all clones (lane 1-10) did give this expected pattern of 
bands. Finally, the constructed expression vectors were checked by DNA 
sequencing (see Section 2.1.2.13) using oligonucleotides GL 725 and GL 726 
(Table 2-3). The outcome of the sequencing result was compared with the original 
sequence using Vector NTI Advance™ 11 Invitrogen (USA) and Chromas Lite 
version 2.01 Technelysium pty ltd (Australia). The DNA sequencing results 
showed that the miRNA inserts remained unchanged (see Appendix 19). The 
miRNA expression vector with miRNA inserts were labelled as pGL 274-283 
(miRNA 1-10) for future use (Table 2-4).  
2.2.1.4 Generation of multiple miRNA expression constructs 
To increase the efficiency of single miRNA to down regulate BLG or to see the 
effect of combination of miRNAs on ΒLG expression, the single miRNAs that 
showed consistent knockdown were chained up based on the provider‟s 
(Invitrogen, USA) cloning strategy (see Appendix 2). In order to generate tandem 
miRNA constructs, the insert fragment of pre-miRNA expression cassette 1 and 
the vector backbone of pre-miRNA expression cassette 2 were cut from the 
expression vector using restriction enzymes, SalI and BglII, and SalI and BamHI, 
respectively (see Section 2.1.2.4). The digests were run on agarose gel (see 
Section 2.1.2.5) and DNA fragments (insert and vector backbone) were isolated 
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by gel purification (see Section 2.1.2.6) (see Appendix 2). The insert and the 
linearized miRNA expression vector were ligated using Takara DNA ligation 
mighty mix at 16°C for 30 minutes (see Section 2.1.2.10). The ligation products 
were then transformed into E.Coli cells (see Section 2.1.2.12) and plated on 
spectinomycin selection agar plates. Few positive colonies after overnight 
incubation at 37°C were selected for plasmid DNA preparation (see Section 
2.1.2.2.1). The plasmid DNA was verified by restriction enzyme digestion of SalI 
and XhoI and the digests were run on agarose gel (see Section 2.1.2.5) followed 
by the gel excision of the DNA fragments before exposure to UV light. The 
plasmid with the insert had the higher molecular weight (300 bp) than the plasmid 
without insert (160 bp) after restriction enzyme digestion (see Appendix 3). 
Finally, the miRNA expression vectors with two different miRNA inserts were 
labelled as pGL 285 (miRNA 2-3), pGL 286 (miRNA 2-6), pGL 287 (miRNA 3-
6), pGL 288 (miRNA 2-4), pGL 289 (miRNA 6-4) and pGL 290 (miRNA 3-4) 
(Table 2-4) for future use. The recombinant positive clones of tandem constructs 
were set up a large-scale culture and purify the recombinant plasmid using a 
Plasmid maxiprep kit (see Section 2.1.2.2.2).The clone was preserved as a 25% 
glycerol stock at −80 °C (see Section 2.1.2.14). 
2.2.2 Generation of BLG expression constructs 
2.2.2.1 Construction of a bBLG expression construct 
To facilitate bBLG knockdown in vitro, a bBLG expression construct was 
generated using pGL 164 expression vector. The vector expresses the gene under 
the transcriptional control of CMV promoter. The expression vector was opened 
up by digesting with HindIII and BamHI restriction enzymes. A bBLG cDNA 
construct (variant A) previous constructed by Ben Wilson (AgResearch, Ruakura, 
New Zealand) was used for this study (see Appendix 4). The bBLG cDNA was 
also cut out from an expression construct (pGL 152) using HindIII and BamHI 
restriction digests (see Section 2.1.2.4) (see Appendix 4). Three individual 
putative clones were picked and cultured overnight at 37°C for small scale 
plasmid preparation (see Section 2.1.2.2.1). The ligation was examined by BglII 
and XhoI restriction digestion. As shown in Appendix 5, all three clones displayed 
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the expected 4.0 kb and 1.64 kb fragments for a correctly integrated bBLG cDNA 
insert. The clone containing the bBLG insert was labelled as pGL 297 for further 
use (Table 2-4). 
2.2.2.2 Construction of an oBLG expression construct 
2.2.2.2.1 Sub-cloning of oBLG cDNA into a shuttle vector 
To facilitate oBLG knockdown in vitro, an oBLG expression construct was 
generated using pGL 164 expression vector. Total RNA was isolated from 
lactating mammary tissues of an oBLG expressing mouse (see Section 2.1.2.2.4). 
OBLG first-strand cDNA was synthesized as described in Section 2.1.2.9. The 
first-strand cDNA molecules were PCR amplified (see Section 2.1.2.8) using 
oligos GL 727 and GL 728 (Table 2-3) amplifying the coding sequence of oBLG. 
A proof reading polymerase was used to reduce mismatch incorporation of a base 
by regular Taq polymerase. A single band corresponding to the desired PCR 
product was initially sub-cloned into TOPO vector (see Section 2.1.2.11). The 
clone containing the oBLG cDNA insert was identified by BglI restriction enzyme 
digests (see Appendix 6). Since the oBLG cDNA was generated by PCR, it was 
necessary to confirm the integration of the insert by nucleotide sequencing. The 
plasmid DNA containing oBLG cDNA was prepared for sequencing (se Section 
2.1.2.13.1) and sent to Massey University, Palmerston North, New Zealand for 
sequencing using oligos GL 727 and GL 728 (Table 2-3). The sequencing result 
was aligned with the original sequence of oBLG cDNA using Vector NTI 
Advance™ 11 Invitrogen (USA) and Chromas Lite version 2.01 Technelysium 
pty ltd (Australia). The DNA sequencing results revealed that the oBLG cDNA 
insert remained unchanged (see Appendix 21). The TOPO vector with oBLG 
cDNA insert was used for construction of oBLG expression vector.  
2.2.2.2.2 Cloning of oBLG gene into an expression vector 
To test the ability of oBLG cDNA to express at the protein level, an oBLG 
expression construct was generated using pGL 164 expression vector for 
knockdown analysis of oBLG in vitro. The expression vector was linearized by 
digesting with HindIII and NotI restriction enzymes (see Section 2.1.2.4). The 
oBLG cDNA was also excised from TOPO-oBLG construct using the same 
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restriction enzymes (see Section 2.1.2.4). The digests were run on agarose gel (see 
Section 2.1.2.5). The oBLG cDNA fragment was excised from the gel before 
imaging to avoid introducing any mutation by the UV radiation and both vector 
and the insert were purified from gel (see Section 2.1.2.6) (see Appendix 7). The 
insert was directly cloned into the open expression vector (see Section 2.1.2.10) 
and the ligation was examined by HindIII and NotI restriction digestion. All 
clones showed the expected 5.0 kb vector backbone and 650 bp fragments for a 
correctly integrated oBLG insert (see Appendix 8). The clone containing the 
oBLG insert was labelled as pGL 448 for further use (Table 2-4). 
2.2.2.3 In vitro expression of BLG 
To test the ability of the pGL 297 and pGL 448 to express BLG at the protein 
level in eukaryotic cells, a transfection assay was performed (see Section 2.2.3). 
After 48 hours of transfection, cells were analysed by western blot analysis (see 
Section 2.2.4). Western blot analysis of the transfected cell pool showed high 
bBLG and oBLG expression (see Appendix 9). 
2.2.3 Transfection of mammalian cells  
2.2.3.1 Lipid-based transfection of COS7 cells 
For transfection of cells, 2x10
5 
cells were cultured in 24-well tissue culture plate 
containing 0.5 ml of fresh medium containing 10% FBS. Cells were cultured at 
37°C in a CO2 incubator 12-16 hours prior to transfection (approx. 70-80% 
confluence). In order to express miRNAs transiently in cells, transfection 
efficiency of cells was optimized using three different transfection reagents, 
Lipofectamine 2000, Lipofectamine LTX and FuGENE 6. In this optimization 
experiment, a GFP expression construct, pEGFP-C1 (Clonetech) (pGL 195) 
plasmid DNA was used. Cells were transfected at a range of concentrations 
between 1.0-6.0 μl of transfection reagent with a fixed amount of 1 μg of DNA 
(condition 1, 1 μl of reagent per μg of DNA; condition 2, 2.5 μl of reagent per μg 
of DNA and condition 3, 5 μl of reagent per μg of DNA for the Lipofectamine 
2000 and Lipofectamine LTX transfection reagents and for the FuGENE 6 
reagent, condition 1, 2 μl of reagent per μg of DNA; condition 2, 3 μl of reagent 
Chapter Two: Materials and Methods 
 
63 
 
per μg of DNA and condition 3, 6 μl of reagent per μg of DNA). Except 
Lipofectamine 2000, Lipofectamine LTX and Plus reagent (0.5 μl) were directly 
added to the DNA and FuGENE 6 reagent was also added to the DNA and mixed 
gently. Initially, the transfection reagent was diluted in 50 µL of Opti-MEM 
medium and incubated for 5 minutes at room temperature. The diluted DNA was 
dripped into lipid mix, mixed gently and incubated at room temperature for 20 
minutes. Meanwhile, cell wells were gently washed with fresh medium to remove 
dead cells and 0.5 ml of fresh serum free medium was replaced into each well. 
After the incubation, the DNA and lipid mix was added to the cell well, mixed 
gently by rocking the plate back and forth and allowed to grow for 48 hours at 
37°C in a CO2 incubator. After 4-6 hours of transfection, the medium was 
replaced with fresh medium with 10% FBS and Penicillin-Streptomycin liquid 
(100 x).  
2.2.3.2 Post-transfection glycerol shock 
To increase transfection efficiency of COS7 cells, cells were subjected to shock 
using 10% glycerol. After 20 minutes of transfection period fresh medium was 
replaced in the cell wells. Glycerol was added in the medium and mixed by gentle 
swirling followed by 3 minutes of incubation period at room temperature. Cells 
were washed gently with 1 x PBS to get rid of residues of glycerol. 
2.2.3.3 FACS analysis of transfected cells 
After 48 hours of transfection, medium was changed and cells were washed with 
PBS to remove dead cells floating on the surface. The remaining cells were 
harvested by trypsinization and pelleted by centrifugation at 1,000 rpm for 5 
minutes. The supernatant was removed by aspiration and the cell pellet was 
washed with PBS to remove residues of trypsin. Finally, cells were spun down by 
centrifugation and the pellet was re-suspended with 1 ml of PBS containing 1% 
FBS. Cells were analyzed on a FACScan™ (Beckton Dickinson, San Jose, CA, 
USA), with an Argon laser (488 nm) was used. Everytime before using the 
machine it was calibrated with CaliBRITE™3 beads (BD Biosciences). The 
calibration helps better separation for forward scatter (FSC), side scatter (SSC), 
FL1-FL3 channels. The instrument setting was adjusted for COS7 cells. The FSC 
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and SSC were adjusted to fit maximum events inside the line of FSC/SSC dotplot. 
In each measurement a total of 10,000 events were acquired and acquired data 
was analysed using Cell Quest Pro software (BD). 
2.2.4 In vitro knockdown analysis by western blot 
For in vitro analysis of BLG knockdown, COS7 cells were co-transfected with 
plasmid DNA containing single miRNA or double miRNA or negative miRNA 
control and BLG gene (see Section 2.2.3) (Table 2-4). Transfected cells were 
prepared for western blot analysis as mentioned in Section 2.1.2.18.1. Cell lysate 
containing 15 μg of total protein was subjected to SDS-PAGE along with 
Benchmark
TM
 pre-stained protein ladder (Invitrogen, USA) (see Section 
2.1.2.18.3). A transfer sandwich was set up and placed on the iBlot gel transfer 
device (Invitrogen, USA). Protein transfer was conducted in 7 minutes and 
efficiency of transfer was checked by Ponceau staining (see Section 2.1.2.18.4). 
The membrane was then blocked with blocking buffer for 2 hours at room 
temperature. A rabbit anti-bBLG, (1:10,000 dilution) or anti rabbit GFP (1:2,000 
dilution) in antibody incubation solution against BLG or GFP protein was added 
to the membrane for overnight incubation at room temperature. A goat anti-rabbit 
HRP conjugate antibody diluted 1:20,000 in antibody incubation solution was 
added to the membrane and incubated at room temperature for 2 hours (see 
Section 2.1.2.18.5). The membrane was treated with enzyme linked 
chemiluminescence (ECL) detection reagents (A and B) from Amersham (UK) 
and finally, proteins on the membrane were visualised using an X-ray film 
(KOdak) in a dark room (see Section 2.1.2.18.6). 
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2.3 Methods Relating to Chapter Four: 
Generation of Transgenic Mice 
2.3.1 Generation of Tg mouse 
2.3.1.1 Generation of tissue specific bBLG construct  
The tissue specific milk expression vector, pGL 293 contains a unique XhoI 
restriction site to clone the gene of interest. The bBLG cDNA of pGL 152 vector 
was amplified by PCR with primers GL 730 and GL 731 containing XhoI 
recognition site (Table 2-3) using expand long PCR system (Roche, USA), which 
contains a thermostable DNA polymerase containing proofreading activity (see 
Section 2.1.2.8). The PCR product was initially sub-cloned into pGEM-T easy 
vector (see Section 2.1.2.11). The clone containing the bBLG cDNA was 
identified by XhoI restriction enzyme digest and analysed by agarose gel 
electrophoresis (see Section 2.1.2.5) (see Appendix 10). One clone was sent to 
Massey University, Palmerston North, New Zealand sequencing service for 
sequencing of bBLG (see Section 2.1.2.13) using ologos GL 732 and GL 733 
(Table 2-3) to check inclusion of any point mutations introduced by PCR. The 
sequencing results were aligned with parental sequence and no point mutation was 
found in the clone sequence (Appendix 20). The bBLG cDNA with XhoI hanging 
ends was cloned into pGL 293 previously opened with XhoI restriction enzyme 
(see Section 2.1.2.4 and 2.1.2.10). Transformants containing pGL 293 vector with 
bBLG insert were identified by digesting with XhoI restriction enzyme and all 
four clones showed the presence of the bBLG insert (see Section 2.1.2.4) (see 
Appendix 11). In order to check the orientation of the bBLG insert, the positive 
clones were further digested with an enzyme set of KpnI and SacI (see Section 
2.1.2.4). Two of the clones (clone 3 and 4) showed the expected size of bands on 
gel electrophoresis (see Appendix 12). The clone containing the bBLG insert was 
labelled as pGL 449 for further use (Table 2-4).  
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2.3.1.2 Generation of tissue specific miRNA construct 
2.3.1.2.1 Sub-cloning of WAP promoter into a shuttle vector 
The WAP promoter of the pGL 263 construct was PCR amplified with oligos GL 
734 and GL 735 (Table 2-3) using a proof reading polymerase to reduce 
mismatch-incorporation of a base by regular Taq polymerase (see Section 
2.1.2.8). A single band corresponding to the desired PCR product was initially 
sub-cloned into pGEM-T vector (see Section 2.1.2.11). The clone containing the 
WAP insert was identified by SpeI and EcoRV restriction digest (see Section 
2.1.2.4). The restriction digests, as analysed by agarose gel electrophoresis 
revealed that all five clones showed the expected banding pattern on gel (see 
Appendix 13). One of the clones was send to Massey University for sequencing 
using five different pairs of oligos (GL 736-745) to confirm that there is no 
introduced point mutation in the WAP sequence (see Section 2.1.2.13.1). The 
sequencing results obtained from Massey University were interpreted by using 
sequence analysis software Vector NTI (Invitrogen) and chromas Lite 
(technelysium, Au) analysis. The sequence analysis showed that there was no 
introduced point mutation in the clone (Appendix 22). 
2.3.1.2.2 Generation of tissue specific miRNA constructs 
The tandem miRNA construct (pGL 289) was digested with SpeI and DraI 
restriction enzymes to excise the CMV promoter and the GFP gene. The WAP 
promoter was also excised from pGEM-pWAP construct using SpeI and EcoRV 
restriction digests (see Section 2.1.2.4). The ligation products were transformed 
into E.Coli (Stbl2) cells (see Section 2.1.2.12). The ligation was examined by SpeI 
and SacII restriction digestion. As shown in Appendix 14, clone 1 and 2 showed 
the expected 4 kb and 2.8 kb fragments. The tandem miRNA construct with the 
WAP promoter was labelled as pGL 298 for further use (Table 2-4). To compare 
the knockdown efficiency of single miRNA constructs (pGL 277 and pGL 279) in 
vivo, mammary tissue specific single miRNA constructs were generated. To 
generate tissue specific single miRNA constructs, pGL 277, pGL 279 and pGL 
289 were digested with BamHI and SacII restriction enzymes (see Section 
2.1.2.4). The digests were run on agarose gel (see Section 2.1.2.5) and both vector 
Chapter Two: Materials and Methods 
 
67 
 
backbone of pGL 289 construct and the inserts (miRNA 4 and miRNA 6) were 
excised from the gel before imaging and DNA was purified from gel (see Section 
2.1.2.6) (see Appendix 15). The inserts were directly cloned into the linearized 
pGL 289, using Takara DNA ligation mighty mix at 16°C for 30 minutes (see 
Section 2.1.2.10). The ligation products were transformed into MAX Efficiency 
DH5α cells (see Section 2.1.2.12). Four putative colonies for each of miRNA 4 
and miRNA 6 constructs were picked and cultured overnight at 32°C for small 
scale plasmid preparation (see Section 2.1.2.2.1). The ligation was examined by 
BamHI and SacII restriction digestion (see Section 2.1.2.4). As shown in 
Appendix 16, the expected 215 bp fragment was seen for clones 3 and 4 of 
miRNA 4 and clones 2, 3 and 4 of miRNA 6. The miRNA constructs containing 
miRNA 4 and miRNA 6 with the mammary tissue specific WAP promoter were 
labelled as pGL 446 and pGL 447, respectively (Table 2-4). 
2.3.1.3 Preparation of DNA constructs for microinjection 
To generate Tg bBLG mice, the plasmid DNA of pGL 449 was digested with NotI 
restriction enzyme (see Section 2.1.2.4). The NotI restriction enzyme cut two 
different positions within the construct and excised a 16.3 kb fragment. The 
resulting fragment contained chicken ß-globin insulator, goat ß-casein promoter, 
bBLG coding sequence and ß-casein flanking sequence (see Appendix 17). To 
generate mice carrying the tandem miRNAs (miRNA 4 and 6), the plasmid DNA 
harbouring miRNAs was digested with SpeI and KspI restriction enzymes (see 
Section 2.1.2.4). The restriction digest separated WAP promoter with miRNAs 
fragment that lacks the pA signal and the vector backbone. In order to include the 
pA signal, the tandem construct (pGL 298) and the other two single miRNA 
constructs (pGL 446 and pGL 447) were digested with SpeI and FspI restriction 
enzymes (see Section 2.1.2.4). The restriction enzymes excised fragments of 3.70 
kb and 3.2 kb of the pGL 298 and 3.7 kb and 3.0 kb fragments of the pGL 446 and 
pGL 447. The resulting 3.2 kb/3.0 kb fragment contains the WAP promoter, 
miRNA 6-4/miRNA 4/miRNA 6 and the SV40 polyA tail. Another plasmid (pBS 
2 x insulator) was digested with NotI and XhoI restriction enzymes to obtain the 
2.4 kb fragment of chicken ß-globin insulator (see Section 2.1.2.4) (see Appendix 
18). The band of interest was cut out using a clean scalpel blade and the gel slice 
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transferred into a DNase-free Eppendorf tube. The DNA was purified from the gel 
using the Qiagen MinElute PCR Purification Kit to remove any unwanted debris 
which may be toxic to oocytes during pronuclear injection (see Section 2.1.2.6). 
The recovered DNA was resuspended in filtered microinjection buffer (see 
Section 2.1.1.9.3). The concentration of DNA was determined using NanoDrop 
(see Section 2.1.2.3) and the integrity of DNA was assessed by running on 
agarose gel (see Section 2.1.2.5). Finally, the concentration of DNA was adjusted 
to 1-2 ng/µl with microinjection buffer just before microinjection. 
2.3.1.4 Preparation of mice for microinjection 
Mature C57 female mice were superovulated by inducing injection of 5 IU of 
PMSG (Intervet) and 48 hours latter, 5 IU injection of hCG (Intervet). Female 
mice were then mated with C57 male mice to yield fertilized embryos for 
pronuclear microinjection. The embryos were microinjected with the DNA 
construct into the pronuclei of fertilized mouse embryos and 40-50 normal-
appearing 2-cell embryos were then transferred to each pseudopregnant recipient 
and their pregnancies were monitored. All microinjection and routine care were 
done by the Small Animal Colony (SAC), AgResearch, Ruakura, Hamilton, New 
Zealand. The resulting founder Tg pups were separated upon weaning 3-4 weeks 
after birth.  
2.3.1.5 Screening of mice by PCR genotyping 
The gDNA was isolated from putative Tg mouse tails and prepared for PCR as 
described in Section 2.1.2.2.3. Primers (GL 746 and 747) to amplify miRNA, GL 
732 and 733 to amplify bBLG and GL 727 and 728 to amplify oBLG insert (Table 
2-3) were designed as described in Section 2.1.2.8.1. For each set of oligos a 
gradient PCR was performed to determine the optimal primers annealing 
temperature for the PCR reaction. PCR was performed using the diluted gDNA as 
a template with appropriate primer pairs. A standard PCR reaction was set up as 
described in Section 2.1.2.8 and PCR products were run on an agarose gel (see 
Section 2.1.2.5). A 2% agarose gel was used to run miRNA amplicons for better 
resolution as they are small fragments (160-310 bp). For the larger BLG 
amplicons (400-650 bp) a 0.8% agarose gel was used (see Section 2.1.2.5). Tg 
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mice were characterized by the presence of a PCR band corresponding to the 
junction of the two oligos. Tg mouse lines were established by breeding Tg 
founders with wild type FVB/C57 mice.  
2.4 Methods Relating to Chapter Five: 
Knockdown of BLG In Vivo 
2.4.1 Generation of Tg miRNA-BLG mice 
The Tg mouse lines expressing single or double miRNAs were crossed with mice 
expressing bBLG/oBLG to generate Tg miRNA-BLG mice.  
2.4.2 PCR genotyping of Tg miRNA-BLG mice 
Tail tips from putative Tg miRNA-BLG mice were collected and gDNA was 
isolated for PCR to identify mice carrying both miRNA and BLG transgenes. The 
primer pairs GL 746 and 747, GL 732 and 733 and GL 727 and 728, respectively 
(Table 2-3) were used to identify mice positive for the integration of miRNA, 
bBLG and oBLG, respectively. A standard PCR reaction was set up as described 
in Section 2.1.2.8 followd by running miRNA PCR products on 2% and BLG 
PCR products on 0.8% of agarose gel (see Section 2.1.2.5). The Tg mice showed 
correct size of band on gel for both miRNA and BLG were kept for crossing with 
wild type FVB/C57 mice.  
2.4.3 Milking of mice 
The Lactating Tg miRNA-BLG mice were separated from their litters for 4 hours 
before milking. Mice were then anesthetized by intraperitoneal injection of 1 ml 
of avertin (20 mg/ml) immediately prior to milking. After being anesthetized the 
mice were injected intramuscularly with 0.5 ml of oxytocin (200 IU/ml). Milking 
was started 2-3 minutes after oxytocin administration and milk was collected 
manually by gentle massage of teats into capillary tubes and subsequently 
expelled into eppendorf tubes. After milking the mice were returned gently onto 
their pups. Mouse milk was stored at -20 ºC until further analysis. Collected milk 
was diluted to 1:100 with PBS followed by centrifugation at 4°C for 30 minutes at 
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12,000 rpm. After centrifugation, fat was discarded and the supernatant (defatted 
milk fraction) was used for further analysis. Milking of mice was done by the 
SAC, AgResearch, Ruakura, Hamilton, New Zealand. 
2.4.4 In vivo knockdown analysis by coomassie blue staining 
Coomassie blue staining is a simple and reasonably sensitive method to stain 
protein in SDS-PAGE gels. Mouse milk is highly concentrated and it was diluted 
in PBS. The concentration of milk protein was measured as described in Section 
2.1.2.18.2. Milk samples were prepared as described in Section 2.1.2.18.3. A total 
milk protein of 10 µg was loaded on SDS gel along with positive and negative 
controls and Benchmark
TM
 pre-stained protein ladder (Invitrogen, USA) (see 
Section 2.1.1.1). The SDS-PAGE gel was washed in MilliQ H2O for 5 minutes. 
The gel was then fixed in gel-fixing solution (see Section 2.1.1.12) and soaked in 
that solution for 1 hour. The purpose of this step was to wash the SDS-containing 
buffers out of the gel and during this fixing step the bromophenol blue dye 
changed colour from blue to yellow. The gel was rinsed in gel-washing solution 
(see Section 2.1.1.12) and the fixation of the proteins in the gel continued by 
incubating for 4 hours at room temperature. The gel was covered with staining 
solution (see Section 2.1.1.12) and incubated overnight at room temperature with 
shaking throughout the incubation period. The gel was destained in destaining 
solution (see Section 2.1.1.12) until the protein bands are seen without 
background staining of the gel. Thus BLG knockdown can be directly measured 
from Coomassie-stained SDS-gels. Signal intensities of proteins in the gel were 
measured by Quantity One software (Bio-Rad). The expression level of BLG was 
normalized to an internal control protein (α casein) that was well separated on the 
SDS gel from other proteins (Figure 5-1). Normalization of the expression of the 
protein of interest improves the accuracy of quantification by taking sample 
loading differences into account. 
2.4.5 In vivo knockdown analysis by western blot 
Western blot analysis was used as an alternative method to validate the 
knockdown results observed after coomassie staining of mouse milk. The total 
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milk protein concentration was measured as described in Section 2.1.2.18.2. Milk 
Sample preparation for SDS-PAGE was performed as described in Section 
2.1.2.18.3. Identical to commassie staining, 10 µg of total milk protein was 
subjected to SDS-PAGE with controls (positive and negative) and Benchmark
TM
 
pre-stained protein ladder (Invitrogen, USA) (see Section 2.1.1.1). After 
electrophoresis, the proteins were transferred to membrane using iBlot gel transfer 
device (Invitrogen, USA). The transfer membrane was checked for protein 
transfer efficiency by staining with Ponceau (see Section 2.1.2.18.4). In order to 
reduce non-specific binding of the antibodies, the membrane was blocked using 
blocking buffer for 2 hours at room temperature. The membrane was then 
incubated with rabbit anti-bBLG, (1:10,000 dilutions with antibody inculation 
solution) for overnight incubation at room temperature. The antigen-antibody 
bindings were detected by incubating the membrane with goat anti-rabbit HRP 
conjugate antibody (1:20,000 dilution with antibody incubation solution) at room 
temperature for 2 hours (see Section 2.1.2.18.5). Finally, the membrane was 
incubated with ECL detection reagents (A and B) from Amersham (UK) for 5 
minutes at room temperature and protein signals were detected using an X-ray 
film (KOdak) in a dark room (see Section 2.1.2.18.6). 
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Chapter Three: In Vitro Validation 
of MiRNA Constructs  
3.1 Introduction 
The allergenicity of BLG was first discovered in the 1960‟s. Although the 
physical and chemical properties of BLG are well characterized, no report has 
shown yet how the expression of the milk allergen is regulated at the transcript 
level. Moreover, no study has reported yet how to reduce the presence of BLG in 
cow‟s milk except for the dairy industries milk treatments of conventionally 
denaturing BLG using high temperature short time (HTST) (147) or enzymatic 
hydrolysis (44). Unfortunately these available treatments affect both macro 
(protein, carbohydrate and fat) and micro nutrients (vitamins and minerals) in 
milk and the taste of milk differs from original milk due to exposure of 
hydrophobic amino acids (47) (48). Moreover, the processing techniques are 
highly expensive, which led me to use RNAi technique as an alternative way to 
reduce BLG expression in milk. The discovery of RNAi and its recent advances in 
gene knockdown in a variety of different animal species including mammals 
provide us with the opportunity to knockdown BLG in order to improve milk 
quality. This chapter focuses on the identification of effective miRNAs with high 
knockdown activity against bBLG and oBLG through screening of ten miRNAs in 
cell cultures. In order to demonstrate BLG knockdown in vitro, ten synthetic 
miRNA oligonucleotides against BLG mRNA containing different target 
sequences were designed using available online tools (see Section 2.2.1.1). The 
algorithms available to select candidate sequences are helpful but they are still not 
accurate enough to predict a specific miRNA that will indeed knockdown its 
target mRNA (148). Therefore, it is important to reduce the number of putative 
miRNAs and identify the most effective candidates on the basis of their 
knockdown efficiencies in cell culture experiments (149) before applying them in 
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the in vivo system. The vector system used in this study allows assessing the 
transfection efficiency of cells by monitoring GFP expression using FACS 
analysis (see Section 2.2.3.3). In this chapter results obtained on establishment of 
best transfection condition are presented. This chapter also includes evaluation of 
single miRNA constructs in comparison with tandem miRNAs using the 
optimized transfection condition to knockdown the expression of bBLG and 
oBLG in vitro. 
3.2 Results 
3.2.1 Optimization of transfection efficiency in COS7 cells 
In RNAi experiments, the transfection of cells plays a major role to identify 
potential candidates. Cationic liposome-based transfer of transgenes has shown 
before in cell culture experiments (150) (151) (152). In order to maximize the 
delivery of the candidate miRNAs and target BLG plasmid DNA into COS7 cells, 
transfection of COS7 cells was optimized using three commercially available 
transfection reagents (Lipofectamine 2000, Lipofectamine LTX and FuGENE 6). 
The success of transfection efficiency depends on the ratio of DNA and liposome 
and cellular development stages (153). So, initially cells were transfected with 
GFP expression plasmid DNA (pGL 195) (Table 2-4) (Figure 3-3) using three 
different ratios of DNA and transfection reagent (condition 1-3) to identify the 
best transfection reagent and the ratio for further transfection experiments. 
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Figure 3-3: Schematic depiction of plasmid DNA expression constructs for 
transfection assay. 
A. A schematic representation of GFP expression plasmid used for transfection 
optimization experiments. B. A schematic representation of bBLG and oBLG expression 
plasmids and single and tandem miRNA expression plasmids. Single or tandem miRNA 
constructs were evaluated using co-transfection assay to test their effectiveness against 
the expression of bBLG/oBLG in cells. 
Cells expressing GFP were analysed by FACS analysis and the transfection 
efficiency of cells was calculated by dividing the number of cells expressing GFP 
and the total number of viable cells. Overall, the transfection efficiency of COS7 
cells ranged from 13-59% among transfection reagents tested (Table 3-7). The 
transfection assay was done in triplicates and Lipofectamine 2000 resulted in 
mean transfected cells of 44%±2 (condition 1), 58%±10 (condition 2) and 51%±3 
(condition 3), respectively. Lipofectamine LTX resulted in 17%±6 (condition 1), 
51%±4 (condition 2) and 58%±4 (condition 3), respectively. FuGENE 6 resulted 
in mean transfected cells of 36%±6 (condition 1), 30%±1 (condition 2) and 
20%±4 (condition 3), respectively (Figure 3-4). Of the three transfection reagents 
tested, the most efficient reagents were Lipofectamine 2000>Lipofectamine LTX 
>FuGENE 6. The optimized transfection condition 2 for Lipofectamine 2000 was 
chosen for the subsequent co-transfection assays. 
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Table 3-7: Effect of different transfection conditions on transfection efficiency of 
COS7 cells. 
Transfection 
reagent 
Transfection 
condition 
DNA:rearent DNA 
(µg) 
Reagent 
(µl) 
Transfection 
efficiency (%) 
 
Lipofectamine 
2000 
1 1:1 0.8 0.8 42 
2 1:2.5 0.8 2.0 52 
3 1:5 0.8 4.0 49 
 
Lipofectamine 
LTX 
1 1:1 0.5 1.25 13 
2 1:2.5 0.5 3.13 53 
3 1:5 0.5 6.25 59 
 
FuGENE 6 
1 1:2 0.4 0.8 40 
2 1:3 0.4 1.2 28 
3 1:6 0.4 2.4 22 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4: Effect of DNA:transfection reagent on transfection efficiency of COS7 
cells.  
COS7 cells were grown in 24-well plates and transfected with GFP reporter plasmid 
DNA and different amounts of transfection reagent. The transfection efficiency of cells 
 
P=0.001 
P=0.0004 
P=0.011 
P=0.017 
P=0.035 
Chapter Three: In Vitro Validation of MiRNA Constructs 
 
76 
 
was measured by FACS analysis. Each bar represents a different ratio of reagent: DNA 
tested and mean and standard error of transfection efficiency for each reagent obtained 
after three independent replicates. Statistical significance among means was determined 
using a paired two sample t-test (p<0.05). Error bars represent SEM determined from n = 
3 repeats. 
Once the optimal transfection condition was determined, the transfection 
condition was tested in a co-transfection assay by transfecting cells with bBLG 
(pGL 297) and miRNA expression plasmid 1-3 (pGL 274-276). GFP positive 
cells were analysed by FACS analysis and the transfection efficiency of cells was 
measured as mentioned above. The result of the co-transfections is shown in 
(Table 3-1). The transfection efficiencies were lower than for the single 
transfection and ranged from 33-40%. The co-transfection assay was done in 
triplicates and inspection in the GFP channel showed that miRNAs had variability 
in transfection efficiency of 32%±0.2 (miRNA 1), 33%±7 (miRNA 2) and 35%±4 
(miRNA 3). There was no significant difference in transfection efficiency 
between miRNAs (P>0.05) (Figure 3-5). 
Table 3-1: Effect of Lipofectamine 2000 on co-transfection efficiency of COS7 cells. 
Constructs Transfection efficiency (%) 
bBLG and miRNA 1 33 
bBLG and miRNA 2 40 
bBLG and miRNA 3 37 
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Figure 3-5: FACS analysis of co-transfection of COS7 cells using Lipofectamine 
2000. 
Cells were transfected with miRNA and bBLG expression plasmid DNA using 
Lipofectamine 2000 (condition 2). The transfection efficiency of cells was measured by 
FACS analysis. Each bar represents the transfection efficiency of cells after co-
transfection. The mean and standard error of transfection efficiency for each miRNA are 
calculated from three independent replicates. Error bars represent SEM determined from 
n= 3 repeats. 
As high transfection efficiencies are very important to obtain optimal results in the 
downstream knockdown experiments and the transfection efficiency of cells after 
co-transfection was very low, cells were given a post-transfection 10% glycerol 
shock (v/v) to increase the chances to transfect cells with higher percentage (see 
Section 2.2.3.2). Cells positive for GFP were analysed by FACS and the 
transfection efficiency of cells was measured as mentioned above. The glycerol 
shock played an important role in transfection and increased the transfection 
efficiency up to 74%. In other words, there was 85 to 112% enhancement in 
transfection efficiency of cells (Table 3-2). Glycerol acts on disruption of cell 
membrane and release of DNA into the interior of cells (154). The co-transfection 
assay with the additional glycerol treatment was done in triplicates and the 
transfection efficiencies were 72%±3 (miRNA 1), 70%±11 (miRNA 2) and 
76%±7 (miRNA 3) (Figure 3-6). There was no significant difference between 
miRNAs in transfection efficiency of cells using the co-transfection assay with the 
additional glycerol treatment (P>0.05). 
Chapter Three: In Vitro Validation of MiRNA Constructs 
 
78 
 
Table 3-2: Effect of post-transfection glycerol treatment on co-transfection 
efficiency of COS7 cells. 
Constructs Transfection efficiency (%) 
bBLG and miRNA 1 70 
bBLG and miRNA 2 74 
bBLG and miRNA 3 70 
 
 
Figure 3-6: Effect of post-transfection glycerol shock on transfection efficiency of 
COS7 cells. 
Cells were co-transfected with miRNA and bBLG expression plasmid DNA using 
Lipofectamine 2000 (condition 2). The transfection efficiency of cells was measured by 
FACS analysis. Each bar represents the transfection efficiency of cells after co-
transfection and glycerol treatment. The mean and standard error of transfection 
efficiency for each miRNA are calculated for three independent replicates. Error bars 
represent SEM determined from n= 3repeats. 
3.2.2 Screening of miRNAs to suppress BLG expression in 
vitro 
The miRNAs targeting bBLG (variant A) and oBLG (variant B) were designed 
based on the bBLG mRNA sequence (isoform B). Isoform B of bBLG mRNA is 
more prevalent and since the ultimate goal is to knockdown BLG in cattle, I 
designed miRNAs based on the more common B isoform. Both BLG isoforms are 
highly conserved although a few polymorphisms exist. For the in vitro 
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knockdown of oBLG and bBLG experiments ten candidate miRNA sequences 
were selected based on the selection criteria set up by Invitrogen miRNA 
designer‟s tool. The engineered pre-miRNA sequences were cloed into the 
miRNA expression vector (pGL273) which is flanked with sequences derived 
from miR-155 for proper processing of the engineered pre-miRNA sequences 
(Figure 3-7). 
 
 
 
 
 
Figure 3-7: Structure of an engineered pre-miRNA sequence on murine miR-155 
sequence. 
5‟ 5 nucletides (UGCUG), 3‟4 nucletides (CAGG) and 19 nucletides to form a terminal 
loop are derived from miR-155 transcript. There is an Msc I site incorporated in the 
terminal loop to aid in sequence analysis. The position of antisense and sense target 
sequences are shown as lower case xx marked in green and red, respectively. Absence of 
2 nucleotides at the position of 9
th
 and 10
th
 in the sense target sequence creates an internal 
loop for better knockdown efficiencies. 
 
Among the designed miRNAs, all miRNAs except miRNA 6 and 8 were perfect 
matches with bBLG isoform A that was used in the in vitro and in vivo 
knockdown studies. Moreover, miRNA 1, 3, 5 and 6 contained one or two 
nucleotide polymorphisms compared to the oBLG coding sequence and the rest 
was conserved to the target sequence (Figure 3-8). In order to screen ten miRNAs 
for BLG knockdown efficiency to identify the most potent miRNAs, ten miRNA 
constructs were evaluated by co-transfection of COS7 cells with bBLG or oBLG 
expression plasmid DNAs. A representative western blot analysis of bBLG and 
oBLG knockdown by the single miRNAs is shown in Figure 3-9. Each 
experiment was conducted in triplicates and the expression of BLG was detected 
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by western blot analysis. The intensity of BLG and control GFP signal was 
measured by Quantity One software (Bio Rad). The expression level of BLG was 
normalized with the expression of GFP to account for transfection variability 
between the samples. BLG knockdown by miRNAs was calculated based on the 
negative scrambled miRNA control which was set as 100% BLG expression (no 
knockdown). The efficiency of the ten miRNAs (designated miRNA 1-10) against 
bBLG expression was in the range of -72 to 97%. Seven miRNAs (miRNA 1-6 
and 8) showed high knockdown of bBLG ranging from 78-97%. MiRNA 
construct 10 showed medium bBLG knockdown (70%) compared to the low 
efficient miRNA 9 (30%). Among the miRNAs only miRNA 7 showed no effect 
on bBLG expression (Figure 3-10). The statistical analysis of the raw data from 
three independent experiments showed that candidate miRNAs had variability in 
bBLG knockdown of 81%±16 (miRNA 1), 92%±12 (miRNA 2), 78%±29 
(miRNA 3), 94%±3 (miRNA 4), 80%±23 (miRNA 5), 97%±5 (miRNA 6), -
72%±73 (miRNA 7), 78%±13 (miRNA 8), 30%±24 (miRNA 9) and 70%±28 
(miRNA 10) (Figure 3-10). Highly effective miRNAs were significantly different 
to the low effective miRNAs in knocking down bBLG expression (P<0.05), with 
the exception of miRNA 3 and 5 which showed significant difference to miRNA 7 
and but not miRNA 9 (P>0.05). In almost the same way, medium efficient 
miRNA 10 was significantly different to miRNA 7 (P<0.05) but not miRNA 9 
(P>0.05). Against oBLG, the ten miRNAs appeared to be effective within a 
similar range as seen for bBLG with knockdown ranging from -46 to 94%. 
However, there were some clear differences among miRNAs in silencing of 
oBLG expression as compared to bBLG. Some of the miRNAs (miRNA 2, 4, 6 
and 9) showed high activity against oBLG expression ranging from 78-94%. 
MiRNA 8 (66%) showed medium knockdown of oBLG compared to those 
miRNAs were low (miRNA 1, 3 and 5) (12-33%). However, miRNA 7 and 
miRNA 10 did not show an effect on oBLG expression (Figure 3-10). The 
statistical analysis of the raw data obtained from three independent experiments 
showed that candidate miRNAs had variability in oBLG knockdown of 12%±33 
(miRNA 1), 94%±4 (miRNA 2), 33%±24 (miRNA 3), 78%±15 (miRNA 4), 
31%±28 (miRNA 5), 93%±2 (miRNA 6), -46%±85 (miRNA 7), 66%±13 
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(miRNA 8), 83%±14 (miRNA 9) and -9%±77 (miRNA 10). Moreover, some of 
the highly effective miRNAs (miRNA 2 and 6) were significantly different to the 
low effective miRNAs (miRNA 3 and 5) (P<0.05). Similarly, medium efficient 
miRNA (miRNA 8) was also significantly different to highly effective miRNAs 
(miRNA 2 and 6) in knocking down oBLG (P<0.05) (Figure 3-10). 
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Figure 3-8: Position of miRNAs targeting BLG mRNA sequence.  
A Schematic representation depicts the position of miRNA 1-10 on the BLG mRNA 
sequence. The miRNA sequences were generated using RNAi design tool, Invitrogen 
based on the published bBLG mRNA sequence (variant B). Lane 1-3 represents bBLG 
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variant A, bBLG variant B and oBLG variant B gene sequence, respectively. The inbox 
bases refer polymorphisms among the BLG mRNA sequences.  
Among the ten miRNAs, miRNA 1, 3, 5 and 10 were very specific to bBLG 
knockdown, whereas, miRNA 9 was very specific to only oBLG. In contrast, 
miRNA 2, 4, 6 and 8 commonly showed effective knockdown of both bBLG and 
oBLG. In addition, miRNA 7 had no effect to silence bBLG and oBLG 
expression. It has been reported that linking up miRNAs targeting different 
regions of a gene can enhance the knockdown of the target gene (155). To 
validate this idea, three miRNA constructs which showed good knockdown 
activity for both bBLG and oBLG (miRNA 2, 4, and 6) were selected along with 
miRNA 3 that achieved up to 78% of bBLG and 33% of oBLG knockdown, 
respectively, to generate tandem miRNA constructs in order to compare their 
BLG knockdown activity using a co-transfection assay in cells. 
 
Figure 3-9: Screening of miRNA expression constructs against the expression of 
bBLG and oBLG. 
A. A representative western blot detection of bBLG expression. B. A representative 
western blot detection of oBLG expresssion. The bBLG or oBLG expression plasmids 
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were transfected with miRNA control or miRNA expression plasmid into COS7 cells. 
Forty-eight hours after transfection, cells were lysed in lysis buffer and whole cell lysate 
was run on gel as described in Materials and Methods (Section 2.1.2.18). The western 
blot was probed as indicated with either rabbit anti bBLG or rabbit anti-GFP as described 
in Materials and Methods (Section 2.1.2.18). M: pre-stained protein marker (Invitrogen), 
NT: non-transfected cell, miRNA ctrl: scrambled miRNA control, miRNA 1-10: different 
single miRNA constructs and kD: kilo daltons.  
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Figure 3-10: Effect of single miRNA constructs against BLG expression in vitro.
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All data are presented as the percent reduction of bBLG (red bars) or oBLG (green bars) 
compared with the non-related miRNA control. Knockdown percentages are an average 
of three independent experiments. Statistical significance among means was determined 
using a paired two sample t-test (p<0.05). Error bars represent SEM determined from n= 
3 repeats. 
a
significant difference between miRNA 1 and 7 and miRNA 1 and 9, 
b 
significant difference between miRNA 2 and 7 and miRNA 2 and 9, 
c
significant 
difference between miRNA 3 and 7, 
d
significant difference between miRNA 4 and 7 and 
miRNA 4 and 9, 
e
significant difference between miRNA 5 and 7, 
f
significant difference 
between miRNA 6 and 7 and miRNA 6 and 9, 
g
significant difference between miRNA 7 
and 8 and miRNA 7 and 10 and 
h
significant difference between miRNA 8 and 9 for 
bBLG knockdown. For oBLG knockdown-
 i
significant difference between miRNA 1 and 
2, miRNA 1 and 4 and miRNA 1, and 6, 
j
significant difference between miRNA 2 and 3, 
miRNA 2 and 5 and miRNA 2, and 8, 
k
significant difference between miRNA 3 and 6, 
l
significant difference between miRNA 5 and 6 and 
m
significant difference between 
miRNA 6 and 8. 
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3.2.3 Comparison of single and tandem BLG specific 
miRNAs in vitro 
The most effective miRNAs were linked up to generate tandem constructs which 
express two miRNAs targeting different sequences of the BLG mRNA (see 
Appendix 2). To determine if tandem miRNA transcripts can enhance the 
knockdown efficiency in cells, single miRNA constructs and their tandem 
combinations including a scrambled miRNA control expressing plasmids and 
bBLG or oBLG-expressing plasmids were introduced into COS7 cells by 
transfection (see Section 2.2.3). The co-transfection experiment was repeated in 
two other independent experiments and the expression of BLG was analysed by 
western blot assay. A representative western blot result is shown in Figure 3-11 
where the blot shows substantial BLG knockdown by all of the selected single 
miRNA constructs and their combinations. Some of miRNA constructs showed 
almost complete BLG knockdown. The intensity of BLG and control GFP signal 
was measured by Quantity One software (Bio Rad). The expression level of BLG 
was normalized with the expression of GFP and BLG knockdown by miRNAs 
was calculated based on the negative scrambled miRNA control (100% BLG 
expression, no knockdown). The results showed high bBLG knockdown by both 
single and tandem miRNA constructs ranging from 74-99% (Figure 3-12). The 
statistical analysis of the raw data showed that tandem and single miRNAs had 
variability in bBLG knockdown of 98%±1 (miRNA 2-3), 90%±16 (miRNA 2-6), 
95%±8 (miRNA 3-6), 95%±2 (miRNA 2-4), 99%±0 (miRNA 6-4), 88%±9 
(miRNA 3-4), 96%±4 (miRNA 2), 94%±3 (miRNA 3), 74%±21 (miRNA 4) and 
92%±7 (miRNA 6) (Figure 3-12). In general, tandem miRNA constructs showed 
greater activity (89-98%) than singles (67-92%) to knockdown oBLG, but the 
differences between single and tandem miRNA constructs were not significant 
(P>0.05). The statistical analysis of the raw data showed that tandem and single 
miRNAs had variability in oBLG knockdown of 95%±5 (miRNA 2-3), 98%±2 
(miRNA 2-6), 93%±7 (miRNA 3-6), 94%±8 (miRNA 2-4), 90%±17 (miRNA 6-
4), 89%±11 (miRNA 3-4), 90%±12 (miRNA 2), 67%±29 (miRNA 3), 69%±45 
(miRNA 4) and 92%±10 (miRNA 6) (Figure 3-12). This study utilized a 
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bicistronic expression construct that expresses miRNA and GFP. The GFP 
expression analysed by western blot analysis showed similar GFP expression for 
both tandem and single miRNA constructs as expected. A representative blot 
showing GFP expression analysed by western blot analysis is shown in Figure 3-
13. Quantification of GFP expression from three independent experiments showed 
that for bBLG knockdown experiments miRNA 2-3, miRNA 2-6, miRNA 3-6, 
miRNA 2-4, miRNA 6-4, miRNA 3-4, miRNA 2, miRNA 3, miRNA 4 and 
miRNA 6 showed an average GFP expression of 187±59, 162±38, 147±32, 
192±90, 235±53, 211±36, 180±64, 169±33, 167±124 and 143±96. In addition, for 
oBLG knockdown experiments miRNA 2-3, miRNA 2-6, miRNA 3-6, miRNA 2-
4, miRNA 6-4, miRNA 3-4, miRNA 2, miRNA 3, miRNA 4 and miRNA 6 
showed an average GFP expression of 144±60, 167±50, 148±61, 153±97, 251±60, 
191±40, 214±61, 155±58, 191±62 and 249±57. The statistical analysis of the raw 
data from three independent experiments for GFP expression in BLG gene 
knockdown experiments revealed that both tandem and single miRNA constructs 
expressed similar levels of GFP (P>0.05) (Figure 3-13). Given this small but 
statistically insignificant difference in knockdown efficiency between single and 
tandem miRNA constructs, one tandem construct, miRNA 6-4, was chosen as one 
of the best constructs for subsequent exeriments in vivo. In addition, miRNA 4 
and miRNA 6 were also chosen to compare their contribution to knockdown BLG 
expression with the miRNA 6-4 in the in vivo system.  
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Figure 3-11: Comparison of single miRNA and their combinations with bBLG and 
oBLG knockdown activity by western blot analysis. 
A. A representative western blot analysis of bBLG expression. B. A representative 
western blot analysis of oBLG expression. Plasmid DNA of bBLG or oBLG was co-
transfected with non-specific miRNA control or single miRNA expression plasmids: 
miRNA 2, 3, 4 and miRNA 6 or miRNA tandem combinations: miRNA 2-3, miRNA 2-6, 
miRNA 3-6, miRNA 2-4, miRNA 6-4 and miRNA 3-4 into COS7 cells. Transfected cells 
were analysed by western blot assay as described in Materials and Methods (Section. 
2.1.2.18). The western blot was probed as indicated with either rabbit anti bBLG or rabbit 
anti-GFP as described in Materials and Methods (Section. 2.1.2.18). M: pre-stained 
protein marker (Invitrogen), NT: non-transfected cell, miRNA ctrl: non-specific miRNA 
control, lanes 4-9 represent different tandem miRNA constructs, lanes 10-13 represent 
different single miRNA constructs and kD: kilo daltons.  
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Figure 3-12: Effect of single and tandem miRNA constructs against BLG expression. 
All data are presented as the percent reduction of bBLG (red bars) or oBLG (green bars) compared with the non-related miRNA control. Knockdown percentages are 
an average of three independent experiments. Error bars represent SEM determined from n= 3 repeats. 
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Figure 3-13: Comparison of GFP expressioin in tandem and single miRNA constructs. 
All data are presented as the average expression of GFP in bBLG (red bars) or oBLG (blue bars) knockdown experiments. Average values are calculated from three 
independent experiments. Error bars represent SEM determined from n= 3 repeats. 
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3.3 Discussion 
In this section I will discuss the key findings involved in establishment of 
transfection condition for BLG knockdown experiments in cells and evaluation of 
BLG knockdown efficiency of single and tandem miRNA constructs. 
3.3.1 Transfection efficiency of cells 
The knockdown potential of RNAi molecules is most easily tested by transient 
transfections. Achieving high transfection efficiency of cells is a prerequisite in 
order to evaluate selected miRNA constructs and the expression of the gene of 
interest. This study demonstrated that a small selection of three commercially 
available lipid-based transfection reagents were able to transfer exogenous genes 
efficiently to COS7 cells. Cationic liposomes are produced based on different 
proprietary lipid compositions and designed to be suitable for particular cell types. 
In my work the most efficient reagent was Lipofectamine 2000, Invitrogen which 
showed transfection of COS7 cells up to 58% for single plasmid DNA 
transfection. This is lower than the published 73% of COS7 cell transfection 
efficiency (156). The transfection efficiency of cells was even lower after co-
transfection of cells (up to 35%). A number of reasons can influence transfection 
efficiency of cells such as use of plasmid vectors of different structure, sizes and 
purity, cell confluence and vector promoter (157). Reliable evaluation of 
candidate miRNAs depends on a high transfection efficiency of cells. Higher 
transfection efficiency of cells increases chances to identify candidate RNAi 
molecules with high knockdown efficiency against the target gene. To increase 
the transfection efficiency, an additional post-transfection glycerol shock step was 
applied. Glycerol helps to disrupt the cellular membrane and to release of DNA 
into the interior of cells (154) and in this study transfection efficiency of COS7 
cells was increased from 35% to 76%.  
3.3.2 MiRNA-mediated knockdown of BLG expression in 
vitro 
Silencing of gene expression by RNAi has become a widely used tool to 
understand the function of genes in mammalian cells. RNAi is a sequence-specific 
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gene silencing mechanism that targets the gene at the mRNA level. Recent 
advances in the design and delivery of RNAi molecules make it possible to induce 
a transient knockdown of target gene function within a short period of time in 
cultured cells. In this study, miRNA sequences targeting BLG gene were designed 
using Invitrogen‟s optimized proprietary algorithm. The miRNA sequences were 
selected based on the coding sequence of BLG avoiding 5′ and 3′ UTRs and 
starting 100 nt downstream of the BLG start codon (158) assuming that the UTR 
binding proteins sites and/or translation start sites may interfere with the binding 
of the RISC to the target gene. Moreover, the UTRs may resemble other 
transcripts and miRNAs selected based on the UTR sequences may suppress other 
genes in addition to BLG. MiRNA oligos were cloned into the vector system 
where the vector-derived transcripts contain a sense and an antisense region that is 
complementary to the target BLG mRNA sequence. The resulting vectors provide 
a useful tool for studying the effectiveness of BLG-specific miRNAs in knocking 
down BLG expression. Rules for selecting RNAi molecules are established and 
defined. However, despite of numerous efforts on RNAi molecule design, the 
accuracy of prediction still remains inadequate. Several different parameters 
contribute to the efficient design of miRNAs. The miRNA design guidelines are 
not absolute and there is no guarantee that the particular miRNA will work in all 
systems. So, in any given experiment a number of miRNAs targeting different 
regions of the target mRNA needs to be tested. Sequence complementary of the 
siRNA particularly at the centre of the molecule contributes to target recognition 
in drosophila and any mismatch with the target mRNA may reduce target 
detection (159). This finding fits with the oBLG knockdown results by miRNA 1, 
3 and 5 that have one or more polymorphisms at the centre of the miRNA 
molecule. Mismatches (up to four nucleotides) in the sequence of siRNAs to the 
target mRNA at the most 3‟ terminal positions have been shown to still result in 
efficient gene knockdown in HeLa cells (160). In my work, miRNA 6 showed 
high efficacy to silence both bBLG and oBLG expression although the miRNA 
molecule has one or two nucleotide mismatch (es) at the 3‟ terminal position. 
However, three miRNAs (miRNA 7, 9 and 10) showed variable BLG knockdown 
although they have perfect homology with both bBLG and oBLG mRNA. Among 
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these miRNAs, miRNA 7 had no effect on both BLG expression and surprisingly 
miRNA 10 showed medium bBLG knockdown although it had no effect on oBLG 
expression. Both miRNA 7 and miRNA 10 have a similarity in the sequence that 
both have three consequitive Cs. It is recommended to avoid strings of 3 or more 
G/C residues in the siRNA sequence (161) because poly G or poly C sequences 
may hyperstack to form agglomerates which can potentially interfere miRNA-
mediated gene silencing, a criterium that is surprisingly not taken into account by 
Invitrogen‟s RNA designer tool. It is unclear as to why miRNA 10 had a moderate 
effect on bBLG but failed to show any effect on oBLG expression. Another 
criterium to judge the knockdown efficiency of miRNAs is referred to as „seed 
region‟. Seed regions consists of 2-8 nucleotides in the miRNA sequence and 
determine the specificity of the target recognition by the interfering molecules 
(162). The miRNA 1 and 5 have a single nucleotide mismatch in the seed region 
of oBLG gene only and that‟s why they showed low oBLG knockdown in this 
study. It is reported that the GC content in the miRNA sequence plays an 
important role for RNAi activity and high GC% has negative effect on RNAi 
activity. A high GC content slows down the unwinding process of the ds duplexes 
by the helicase enzyme present in RISC. As a result, the efficiency of the target 
mRNA recognition and binding of the interfering RNA molecules are reduced 
(163). However, Amarzguioui et al., (164) reported no correlation between GC 
content of the siRNA molecule and its functionality. The results of the miRNA 
induced BLG knockdown data do not support the result showed by Chan et al., 
(163) on the effect of high GC% of siRNA molecules and their potency on RNAi. 
A GC content of 35-55% has been recommended by the Invitrogen RNAi 
designer tool. The majority of the miRNA sequences used in this work had a GC 
content of above 50%, except miRNA 8 and 9 (<50% GC content). Unfortunately 
miRNA 8 and 9 were not among the most effective miRNAs though they contain 
GC content of the recommended level. Moreover, the GC contents of the highly 
effective miRNA sequences ranged from 52-57%.  
In this study, I used a vector system for mammalian RNAi based on miR-155 
miRNA precursor. In this vector system the expression of the synthetic miRNA 
transgenes was directed by CMV promoter and provides effective inhibition of the 
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target gene in vitro. The vector system allows expression of two different 
synthetic miRNAs from a single transcript for increased inhibition of the target 
gene. As tandem miRNAs target two separate regions of the target mRNA, 
induction of increased gene knockdown is expected. In my study, it was found 
that tandem miRNAs showed greater but non-significantly enhanced BLG 
knockdown as compared to the respective single miRNA constructs. However, 
many researches have shown considerably increased knockdown of the target 
gene by the tandems compared to the respective single miRNAs. Sun, D et al., 
(165) showed profound reduction of GFP in cells using miRNA-30 based one-, 
two-, and three hairpin constructs. It was revealed from the research that the 
efficiency of single miRNA was further improved to near complete knockdown 
by multimerization with a second hairpin, but addition of a third hairpin only 
showed modest knockdown improvement. Chung et al., (80) reported that RNAi 
activity can be increased gradually using up to eight miR-155 based miRNAs 
against the expression of luciferase reporter gene. McLaughlin et al., (155) 
showed the increased knockdown efficiency of combined miRNAs targeting 
different regions within the Abl-coding sequences as a treatment of leukemia. 
Previously, this group tried to knockdown in vivo leukemogenic activity by 
knocking down the Bcr-Abl gene using shRNAs, but significant level of Bcr-Abl 
kinase activity remained. Later on, they introduced single and tandem (double and 
triple) anti-Abl miRNAs using a lentiviral vector system. They found the triple 
combination of anti-Abl miRNAs was effective to suppress oncogene expression 
and activation of kinase pathway in order to stop regrowth of leukemic cells in 
vitro and in vivo. In contrast to the improvement of gene knockdown by multiple 
miRNA approach, a report has been published showing negative effect on gene 
knockdown by the multiple miRNAs compared to singles. Zhou et al., (69) 
studied the isoform redundancy of cAMP-dependent kinases and they used 
multiple miR-30 based synthetic miRNAs in a single transcription unit targeting 
human superoxide dismutase 1 (SOD1) gene. They experienced the completely 
opposite scenario than expected as the tandem miRNA construct was less 
effective than the respective single miRNA.  
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The western blot analysis of single miRNA-based knockdown showed that the 
level of the reduction of oBLG and bBLG ranged from -46 to 94% and -72 to 
97%, respectively. There was some variation between independent experiments as 
evidenced by relatively high standard deviations for all runs. I also observed 
considerably different knockdown of oBLG by miRNA 3 while comparing the 
results from the single miRNA knockdown comparison (miRNA 3 33%±24, 
Figure 3-10) with that of the single/tandem comparison (miRNA 3 67%±29, 
Figure 3-12). It has been revealed in this study that tandem miRNAs were not 
significantly different to the single miRNAs in knocking down both bBLG and 
oBLG in vitro, although tandem constructs showed somewhat greater BLG 
knockdown over singles. The in vitro screening of miRNAs against oBLG and 
bBLG expression in cells revealed some important answers: difference in the 
BLG knockdown efficiency among single miRNAs, no significant difference 
between single and tandem miRNAs to knockdown BLG and variability among 
experimental repeats. 
The following studies (Chapter Four: Generation of Transgenic Mice) are focused 
on generating transgenic mouse lines that stably express specific miRNAs that can 
be used to demonstrate BLG knockdown in vivo. 
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Chapter Four: Generation of 
Transgenic Mice 
4.1 Introduction 
The use of Tg mice has become a useful model since the first Tg mouse was born 
in 1980 (166) because mice have a shorter generation interval and are much faster 
and less expensive to evaluate than large animals. As the cell culture experiments 
showed substantial BLG knockdown by synthetic miRNAs, it was expected that 
miRNAs would be also efficient in down regulating BLG expression in mice. 
Normally however, BLG is not produced in mice. Thus, in order to study miRNA-
mediated knockdown in mice, the gene encoding BLG had to first be introduced 
into mice. Hemizygous mice expressing oBLG were obtained from Roslin 
Institute, UK and a mouse line expressing bBLG was generated. In order to 
determine the effect of miRNA expression on production of BLG in vivo, several 
Tg miRNA mice were produced and crossed with BLG mice to generate miRNA-
BLG mice which allowed assessing BLG knockdown in milk.  
4.2 Results 
4.2.1 Characterization of bBLG founder mouse lines 
In order to generate a mouse line expressing bBLG, I needed to introduce a bBLG 
expression construct harbouring bBLG cDNA. The expression of bBLG was 
intended to be restricted to the mammary gland. Therefore, a vector system 
designed specifically for mammary gland expression was obtained from GTC 
Biotherapeutics, USA. The vector system has the unique feature of limiting the 
transgene expression to the mammary gland by genomic sequences from goat β-
casein promoter. It also contains two tandem copies of chicken β-globin insulator 
sequences located immediately upstream of the β-casein promoter (Figure 4-1). 
The insulator sequences shield the transgene expression from position effects that 
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may arise from the transgene integration into a random site in the genome (167). 
The 3‟ UTR contains genomic sequences of β-casein (exons and introns) and the 
pA sequences necessary for transcription termination and polyadenylation of the 
gene of interest. The bBLG cDNA (variant A) was cloned in between exons 2 and 
7 of goat β-casein promoter sequence. The mammary gland tissue-specific bBLG 
construct was supplied to the SAF, AgResearch for microinjection and production 
of Tg bBLG founders.  
 
Figure 4-1: Schematic depiction of bBLG construct used to generate transgenic 
bBLG mouse lines. 
The figure shows the sequence of the DNA fragment as represented in boxes used for 
microinjection into mouse embryos. It consists of 2X chicken β-globin insulator 
sequences immediately before the β-casein promoter, bBLG cDNA and β-casein 3‟ UTR 
sequence, respectively.  
PCR genotyping of putative Tg bBLG mice showed that among 16 putative Tg 
mice 3 founder mice (1 male and 2 females) were positive for the transgene 
integration (Figure 4-2). Founder animals generated by microinjection may carry 
the transgenes only in a subset of cells (mosaics) (168) (169) and the transgenes 
may fail to transmit through the germline (170). To test the germline transmission 
ability, Tg bBLG founder mouse lines were bred with wild-type mice for the 
production of F1 generation mice. The bBLG founder lines were able to transfer 
the transgene to 54% (of 13), 40% (of 10) and 50% (of 12) of offspring, 
respectively (Table 4-1).  
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Figure 4-2: PCR genotyping to identify bBLG founder mice. 
A band at 650 bp represents an amplified bBLG gene using GL 732 and 733 as compared 
to a WT mouse thus indicating the presence of the transgene. M represents 1kb
+
 DNA 
marker (Invitrogen), W: water negative control, WT: wild type mouse gDNA negative 
control, numbers 1-16 represent individual mouse gDNA sample, P: plasmid DNA 
positive control and (*), indicates positive bBLG mice. The arrow indicates the position 
of bBLG. 
Table 4-1: Germ line transmission in Tg bBLG mice. 
Tg founder lines No. of born mice No. of Tg F1 mice (%) 
Line 10 13 7 (54) 
Line 13 10 4 (40) 
Line 14 12 6 (50) 
 
BLG is expressed in milk and for analysis of bBLG expression; bBLG female 
mice were bred with WT male mice to get females into lactation. To determine 
BLG expression at the protein level in milk, milk samples were collected by SAF 
from F1 Tg bBLG mice on day 8 of lactation and analyzed by SDS-PAGE. The 
coomassie staining of total milk proteins showed high bBLG expression in Tg 
bBLG line 14 but the other two lines (Tg bBLG line 10 and line 13) failed to 
demonstrate detectable levels of bBLG (Figure 4-3). The presence of bBLG was 
confirmed further by a more sensitive assay (western blot assay) using a 
polyclonal anti-rabbit bBLG antibody and a weak BLG expression was seen in 
line 10 and no detectable BLG expression was seen in line 13 (Figure 4-3). The 
results clearly demonstrated that Tg bBLG line 14 produced bBLG as the most 
abundant milk protein in milk. Moreover, the expressed protein had no adverse 
      650 bp  
      bBLG 
 
15 1 12 9 10* 13* 14* 3 2 5 4 6 7 8 11 16 W WT M   P  
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effects on the lactation as Tg females were able to feed their pups with milk 
containing bBLG. The behaviour of the pups was normal. Thus Tg bBLG line 14 
fulfilled the requirements for evaluating bBLG KD in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3: Comparison of the expression of bovine BLG protein in different mouse 
lines. 
The top panel of this figure shows the coomassie staining of mouse total milk protein on 
SDS gel. Equal amount of total milk protein (10 µg) was loaded onto each lane of SDS 
gel and the gel was stained with 0.4% coomassie stain. The bottom panel of this figure 
shows a western blot analysis of bBLG expression of Tg mouse milk. Total milk protein 
(10 µg) from three lines was loaded onto each lane of SDS gel and the bBLG expression 
was detected using an antibody directed against bBLG (anti-rabbit bBLG) as described in 
Materials and Methods. M: pre-stained protein maker (Invitrogen), -/-: Wild type mouse, 
-/Tg bBLG line 10: hemizygous bBLG mouse line 10, -/Tg bBLG line 13: hemizygous 
bBLG mouse line 13 and -/Tg bBLG line 14: hemizygous bBLG mouse line 14. The 
arrow indicates the position of bBLG and the number indicates the size of the molecular 
weight marker in kD. 
 
 
Chapter Four: Generation of Transgenic Mice 
 
101 
 
4.2.2 Identification of transgenic miRNA founder mice 
In the in vitro experiments, tandem miRNA constructs were equally efficient with 
single miRNA constructs against BLG expression. One of the tandem constructs 
(miRNA 6-4) showed insignificant but slightly higher efficiency to knockdown 
BLG. The miRNA 6-4 construct targets two different regions of BLG gene which 
can enhance the effectiveness of the construct in vivo. So, the tandem construct 
was chosen to generate Tg mouse lines. The constitute single miRNA constructs 
(miRNA 4 and 6) were also chosen to generate Tg mouse lines in order to 
compare their efficiency with the tandem construct in vivo. The miRNA 
constructs used in the in vitro experiments were driven by a CMV promoter, a 
PolII promoter that enables the gene to be expressed constitutively in all tissues of 
the body. This project aimed to restrict the expression of miRNAs to mammary 
gland tissues during lactation. The CVM promoter of miRNA constructs was 
replaced by mouse whey acidic protein promoter (pWAP) in order to minimize 
potential off target effects by the miRNAs. 
In has been reported that the knockdown effect of siRNA can be enhanced by 
adding a single-stranded poly A (pA) tail to the end of the antisense strand (171). 
An opposite report was published in the same year by Chung et al., (80) and they 
reported that SV40 pA is not necessary for efficient production of miR-155. In my 
study, I also used miR-155-based vector system and I was interested to investigate 
the knockdown efficiency of miRNA with or without transcription termination 
signal. So, the miRNA 6-4 construct that showed high efficiency to knockdown 
both oBLG and bBLG in vitro was processed by restriction enzymes to delete the 
thymidine kinase (TK) pA signal. The miRNA 6-4 construct with or without TK 
pA (ΔpA) signal was microinjected into mouse embryos. To check the 
functionality of single miRNAs against BLG expression in mice, the mammary 
gland tissue-specific single miRNA constructs (miRNA 6 and 4) were processed 
using restriction digests and linearized miRNA constructs with TK pA signal were 
microinjected into mouse embryos. Chicken β-globin insulators that shield the 
genome-integrated miRNAs from potentially silencing heterochromatic regions 
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were also processed for microinjection (Figure 4-4). The microinjection was 
performed by SAF, AgResearch.  
 
Figure 4-4: Schematic depiction of miRNA constructs used to generate Tg miRNA 
mouse lines. 
The figure shows the DNA fragments as represented in boxes used for microinjection into 
mouse embryos. The miRNA 6-4 construct was linearized into a fragment containing 
WAP promoter and miRNA 6-4 sequence with and without (Δ) thymidine kinase (TK) 
poly A (pA) sequence. The single miRNA constructs (miRNA 4 and miRNA 6) were also 
processed into fragments including WAP promoter followed by miRNA 4 or miRNA 6 
and TK pA tail sequences. Each of the processed miRNA constructs was microinjected 
into mouse embryos with 1X chicken β-globin insulator sequence. 
Offspring produced from microinjected embryos were screened by PCR 
genotyping to identify Tg founder mice. PCR genotyping of founder miRNA mice 
revealed that 25% (of 16), of mice were positive for the integration of the miRNA 
6-4 ΔpA construct. For miRNA 6-4 construct, 40% (of 5) of mice were positive 
for the transgene integration and 20% (of 5) and 38% (of 13) of mice were 
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positive for miRNA 6 and miRNA 4 integration, respectively (Figure 4-5) (Table 
4-2).  
Table 4-2: Production of Tg founder miRNA mouse lines. 
Construct No. of born mice No. of Tg mice (%) 
miRNA 6-4 ΔpA 16 4 (25) 
miRNA 6-4 5 2 (40) 
miRNA 6 5 1 (20) 
miRNA 4 13 5(38) 
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Figure 4-5: PCR genotyping of putative miRNA mice. 
A. A PCR gel for genotyping putative Tg miRNA 6-4 ΔpA mice amplifying a band at 
310 bp using GL 746 and 747 oligonucleotides containing the miRNA 6-4 sequence. B. 
miRNA 6-4 PCR gel for genotyping putative Tg miRNA 6-4 mice amplifying a band at 
310 bp GL 746 and 747 oligonucleotides containing the miRNA sequence. C. and D. 
miRNA 6 and miR 4 gel for genotyping putative Tg miRNA mice, amplifying a band at 
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160 bp GL 746 and 747 oligonucleotides containing the miRNA 6 or miRNA 4 region. 
M: represents 1kb
+
 DNA marker (Invitrogen, USA), W: water negative control, WT: wild 
type mouse gDNA negative control, numbers represent individual putative Tg mouse 
gDNA, +Ctrl: plasmid DNA positive control and (*): indicates all positive Tg mice by 
PCR. 
The Tg founder miRNA mice were bred with wild-type mice to test their ability 
for germline transmission because the founders can potentially be mosaic and to 
establish stable Tg miRNA mouse lines. Among the Tg miRNA 6-4 ΔpA mouse 
line only line 11 transfered the transgene to 80% of the offspring (of 11) while the 
other three founder lines failed to produce any Tg offspring. The transfer rate of 
the miRNA 6-4 transgene by line 1 was 36% (of 22) to the offspring. A second 
line could not be tested for transgene transmission since the respective animal 
died at four weeks of age. The Tg mouse line 4 carrying miRNA 6 was able to 
transfer the transgene to 53% (of 19) of offspring. Of the three mouse lines of Tg 
miRNA 4, 46% (of 24), 24% (of 21) and 43% (of 30) offspring were Tg for line 1, 
6 and 7, respectively (Table 4-3). 
Table 4-3: Germ line transmission in miRNA Tg mice. 
Construct Tg founder lines No. offspring No. Tg (%) 
 
 
miRNA 6-4 ΔpA 
miRNA 6-4 ΔpA line 1 5 0 (0) 
miRNA 6-4 ΔpA line 2 6 0 (0) 
miRNA 6-4 ΔpA line 11 11 9 (80) 
miRNA 6-4 ΔpA line 15 7 0 (0) 
miRNA 6-4 miRNA 6-4 line 1 22 8 (36) 
miRNA 6 miRNA 6 line 4 19 10 (53) 
 
miRNA 4 
miRNA 4 line 1 24 11 (46) 
miRNA 4 line 6 21 5 (24) 
miRNA 4 line 7 30 13 (43) 
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4.2.3 Identification of miRNA-BLG mice 
The final goal of this project was to test the feasibility of the miRNA-mediated 
knockdown of BLG in mice. That‟s why a miRNA-BLG mouse model harbouring 
bBLG or oBLG and miRNA transgenes was generated. In order to generate 
miRNA-BLG mice, Tg miRNA mouse lines were crossed with hemizygous bBLG 
or oBLG mice. Offspring from such matings were genotyped by PCR to identify 
miRNA-BLG mice (Figure 4-6).  
 
Figure 4-6: PCR genotyping of putative miRNA-BLG mouse. 
The representative PCR results of miRNA-BLG mouse show an amplification of miRNA 
6-4 as compared to a WT mouse thus indicating the presence of the transgene. A band at 
310 bp represents an amplification of miRNA using GL 746 and 747 oligonucleotides as 
compared to a WT mouse. A band at 650 bp represents an amplification of bBLG gene 
and a 400 bp band represents an amplification of oBLG using GL 732 and 733 
oligonucleotides as compared to a WT mouse thus indicating the presence of the 
transgenes. M: represents 1kb
+
 DNA marker (Invitrogen, USA), W: water negative 
control, WT: wild type mouse gDNA negative control, miRNA-BLG: a mouse positive 
for both miRNA and BLG transgenes and -/BLG: a mouse positive for only BLG. 
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Tail samples of putative miRNA-BLG mice were collected by SAF, AgResearch. 
PCR genotyping of putative miRNA-BLG mice revealed that 36% (of 14) of mice 
were positive for both bBLG and miRNA 6-4 ΔpA transgenes (Table 4-4) and 
53% (of 15) of mice showed positive for the presence of both oBLG and miRNA 
6-4 ΔpA transgenes (Table 4-5). The other tandem construct containing the pA 
signal showed positive in 17% (of 12) of bBLG mice (Table 4-4) and 30% (of 10) 
of oBLG mice (Table 4-5). For the single miRNA construct, miRNA 6, 22% (of 
9) of mice were positive for bBLG and miRNA 6 transgenes (Table 4-4) and 42% 
(of 12) of mice showed presence of oBLG and miRNA 6 transgenes (Table 4-5). 
The presence of miRNA 4 and bBLG transgenes in different mouse lines of 
miRNA 4 construct ranged from 14-45% (of 11-21) (Table 4-4), whereas, 18-56% 
(of 9-13) of mice showed positive for both miRNA 4 and oBLG transgenes (Table 
4-5). 
Table 4-4: Germline transmission of transgenic miRNA-bovine BLG mice. 
Construct Tg miRNA X bBLG mouse No. offspring No. Tg (%) 
miRNA 6-4 ΔpA miRNA 6-4 ΔpA X bBLG 14 5 (36) 
miRNA 6-4 miRNA 6-4 X bBLG 12 2 (17) 
miRNA 6 miRNA 6 X bBLG 9 2 (22) 
 
miRNA 4 
miRNA 4 line 1 X bBLG 11 5 (45) 
miRNA 4 line 6 X bBLG 11 3 (27) 
miRNA 4 line 7 X bBLG 21 3 (14) 
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Table 4-5: Germline transmission of transgenic miRNA-ovine BLG mice. 
Construct Tg miRNA X oBLG mouse No. offspring No. Tg (%) 
miRNA 6-4 ΔpA miRNA 6-4 ΔpA X oBLG 15 8 (53) 
miRNA 6-4 miRNA 6-4 X oBLG 10 3 (30) 
miRNA 6 miRNA 6 X oBLG 12 5 (42) 
 
miRNA 4 
miRNA 4 line 1 X oBLG 13 4 (31) 
miRNA 4 line 6 X oBLG 11 2 (18) 
miRNA 4 line 7 X oBLG 9 5 (56) 
 
4.3 Discussion 
In order to study the knockdown of BLG in mouse by miRNAs, I needed to 
generate Tg miRNA mouse lines and a mouse line expressing BLG in milk. Mice 
expressing oBLG were obtained from Roslin Institute, UK. I also wanted to test 
the effect of miRNAs to silence bBLG as it is our main target in further studies in 
cows. I generated bBLG mouse lines in which the expression of bBLG was 
restricted to the mammary gland. Tg bBLG and miRNA (single and tandem) mice 
were generated by pronuclear microinjection of linear transgenes for mammary 
gland specific expression of bBLG and miRNAs into mouse embryos. The 
restriction in the expression of the miRNA transgenes to the mammary gland 
provides a tool to achieve gene silencing exclusively during lactation of the 
double Tg mice and limits potential off-target effects. The microinjection method 
results in random integration of the transgene into the genome of the embryo and 
essentially provides no control over the expression level of the transgene. 
Integration of the transgene into one of the embryonic chromosomes results in 
animals with a copy of the transgene in every cell only if the transgene integrates 
at the one cell stage. However, if the transgene fails to integrate into the host 
genome before doubling of the genetic material, mosaic mice can be produced 
where many cells do not contain the transgene. So, for the knockdown study the 
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F1 generation of Tg mice were generated by breeding of founder mouse lines with 
wild type mice and Tg F1 offsprings because F1 mice are genitically uniform to 
each other as every cell will contain the transgene.  
The survival rate of embryos up to the generation of live pups after pronuclear 
microinjection of bBLG construct was 16% and transgene integration was only 
3%. In 1985, Brinster and colleagues (172) worked on different parameters of 
pronuclear microinjection methods and they demonstrated that the sticky ended 
transgene integrated in 6% of the mouse embryos microinjected. Moreover, I also 
obtained fewer Tg mice than reported for a method using fresh or frozen mouse 
zygotes (5%) (173). There are several reasons that can cause embryo damage and 
death of embryos at early embryonic development stage such as the amount and 
quality of DNA, integration of the transgenes in important gene sites and 
interruption of essential genes expression. The three confirmed lines of Tg bBLG 
transmit the transgene to their offspring according to the Mendelian law of 
inheritance. Most likely, the Tg bBLG mouse lines contain randomly integrated, 
variable numbers of copies integrated into unknown chromosome locations as 
they were generated by microinjection. As a consequence, the three Tg bBLG 
mouse lines showed variable amounts of bBLG expression at the protein level. On 
the other hand, the efficiency of producing miRNA mouse lines ranged from 1.6-
10%. I was able to generate a few Tg miRNA mouse lines for miRNA 6-4 ΔpA 
and miRNA 4 but for miRNA 6-4 and miRNA 6 contructs only one Tg line was 
generated. Unexpectedly, three Tg founder lines carrying miRNA 6-4 ΔpA failed 
to transfer the transgene to their offspring after crossing with a WT mouse. It was 
observed that the founder Tg mice produced very few live pups compared to other 
miRNA founders and this suggests that the miRNA construct may somehow be 
toxic to the embryos and caused embryonic lethality. However, one of Tg miRNA 
6-4 ΔpA founder lines transmited the transgene efficiently to 80% of the 
offspring. The Tg mouse lines carrying miRNA 6-4 and miRNA 4 constructs 
showed germline transmission ranging from 24-46%. In contrast, Tg miRNA 6 
mice showed germline transmission rate of 53% and the small number of mice 
analysed showed higher germline transmission rate than expected Mendelian 
ratio.  
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Chapter Five: Knockdown of BLG 
In Vivo 
5.1 Introduction 
The generation of a Tg mouse carrying the specific miRNA and the target gene 
provides us with an opportunity to evaluate the efficiency of the miRNA against 
the gene expression in vivo. The aim of this chapter is to describe the results on 
testing the feasibility of miRNAs to reduce BLG in milk in a mouse model. In 
order to demonstrate BLG reduction in milk of miRNA-BLG mice, F1 female 
miRNA-BLG mice were crossed with wild type mice to get mice into lactation. 
Milk samples of miRNA-BLG mice were run on SDS gels and coomassie stained 
to visualize the protein bands and to analyse the effectiveness of the miRNAs to 
knockdown BLG in vivo. In addition, BLG knockdown was also analyzed by 
western blot analysis. Further, to also determine, whether miRNAs perform 
knockdown persisitently all over the lactation period, milk of miRNA-BLG mice 
was analysed on day 5, 10 and 15 by coomassie stain of SDS gels and western 
blot assays. 
5.2 Results 
5.2.1 Demonstration of miRNA-mediated reduction of BLG 
expression  
In order to evaluate the efficiency of miRNA constructs against BLG expression 
in vivo, milk from miRNA-BLG mice was compared with milk from mice only 
expressing BLG but no miRNAs. It has been mentioned earlier that BLG is a 
ruminant specific protein and does not exist in mouse. The protein banding pattern 
looks identical for both Tg and non-Tg mouse except for an extra BLG expression 
band in oBLG and miRNA-oBLG mouse milk (Figure 5-1). Several proteins of 
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different sizes show up after coomassie staining of SDS gels but fortunately there 
is no protein visible at the size of BLG protein (18 kD) in wild type and miRNA 
mouse milk. The activity of miRNAs in vivo was calculated based on the BLG 
expression of the mice only expressing BLG which was set as 100% of BLG 
expression. 
 
 
 
 
 
 
 
 
 
 
Figure 5-1: Coomassie staining of proteins in milk collected from mice on day 5 of 
lactation. 
Equal amount of total milk protein was loaded onto each lane of gel and the gel was 
visualized by coomassie stain. M: pre-stained protein maker (Invitrogen), oBLG/-: 
hemizygous oBLG mouse (positive control), -/-: WT mouse (negative control), -/miRNA: 
miRNA mouse (negative control), Lf: lactoferrin, SA: serum albumin, αs1: α s1-casein, ß: 
ß-casein and γ: γ-casein. 
Initially milk from Tg and non-Tg mouse was collected on day 5 of lactation to 
get an idea on the effectiveness of the miRNA constructs in vivo. Total milk 
proteins were separated by SDS-PAGE and protein bands were visualized by 
staining with coomassie blue. Representative coomassie-stained gels show the 
effect of single and tandem miRNA constructs on the expression of oBLG in milk 
(Figure 5-2). The expectation for this experiment was to see reduction of oBLG 
expression in milk of oBLG-miRNA mice at different levels based on the 
effectiveness of the miRNA constructs. The experiments were repeated three 
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times to verify their reproducibility. The knockdown calculations were done as 
mentioned above. The average of the three independent experiments showed that 
among the miRNAs, the miRNA 6-4 ΔpA construct showed high oBLG 
knockdown of 96%. The other tandem construct with the pA sequence showed 
suppression of oBLG by 45%. The oBLG knockdown efficiency by the single 
miRNA constructs ranged from 43-54%. The knockdown efficiency of miRNA 6 
to reduce oBLG expression was 54%. Among the three Tg lines of miRNA 4, line 
1, 6 and 7 showed 52, 43 and 48%, respectively of oBLG knockdown. The 
reduction of oBLG by the miRNA 6-4 ΔpA construct was significantly different 
from the miRNAs 6-4, miRNA 6 and miRNA 4 (lines 1, 6 and 7) constructs 
(P<0.05) (Figure 5-3). The statistical analysis of the raw data from three 
independent experiments showed that single and tandem miRNAs had variability 
in oBLG knockdown of 96%±4 (miRNA 6-4 ΔpA), 45%±23 (miRNA 6-4), 
54%±25 (miRNA 6), 52%±16 (miRNA 4 line 1), 43%±7 (miRNA 4 line 6) and 
48%±18 (miRNA 4 line 7) (Figure 5-3). 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Five: Knockdown of BLG in vivo 
 
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2: Knockdown of ovine BLG by miRNAs using SDS-PAGE analysis and 
detection by coomassie blue. 
This figure shows the coomassie staining of total milk protein of miRNA-BLG mouse 
containing miRNA and oBLG transgenes. Equal amount of total milk protein was loaded 
onto each lane of gel and the gel was stained with coomassie stain. A-F represent 
knockdown of oBLG by miRNA 6-4 ΔpA, miRNA 6-4, miRNA 6, miRNA 4 line 1, 
miRNA 4 line 6 and miRNA 4 line 7, respectively. M: pre-stained protein maker 
(Invitrogen), oBLG/-: hemizygous oBLG mouse (positive control), -/-: WT mouse 
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(negative control), -/miRNA: miRNA mouse (negative control), and oBLG/miRNA: 
miRNA-BLG mouse positive for both oBLG and miRNA transgenes. 
 
Figure 5-3: Comparison of ovine BLG knockdown by miRNA constructs using SDS-
PAGE analysis and detection by coomassie blue. 
All data are presented as the percent reduction of oBLG in milk on day 5 compared with 
the positive control. Experiment results were an average of three independent 
experiments. Statistical significance among means was determined using a paired two 
sample t-test (p<0.05). Error bars represent SEM determined from n= 3 repeats. 
Mice have a lactation period of about three weeks. In order to check the stability 
in the expression of miRNAs and their ability to inhibit oBLG expression over the 
whole lactation period, milk of miRNA 6-4 ΔpA-oBLG mice was collected on 
various days of lactation (day 5, 10 and 15) from two mice of the same litter. 
Expectations from this experiment were that miRNA 6-4 ΔpA would be effective 
against oBLG expression over the lactation period with no major differences 
between littermates. A representative gel stained by coomassie blue is shown in 
Figure 5-4 and firstly reveals that miRNA 6-4 ΔpA construct knocked down 
oBLG substantially as compared to the mouse expressing only oBLG. Moreover, 
no major difference in oBLG expression was found during different time points in 
two littermates. The SDS-PAGE analysis of milk protein was done in three 
independent experiments and the knockdown efficiency of miRNA 6-4 ΔpA was 
calculated as mentioned above. One (marked as a in Figure 5-4) of the littermates 
showed an average of 96%, 97% and 97% of oBLG knockdown on day 5, 10 and 
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15, respectively. The other (as marked as b in Figure 5-4) showed 97%, 97% and 
97% of oBLG knockdown on those days as mentioned above (Figure 5-5). There 
was no significant difference between littermates in terms of oBLG knockdown 
on different lactation days (P>0.05). In addition, the difference in oBLG 
knockdown among day 5, 10 and 15 lactation periods was also insignificant 
(P>0.05). The statistical analysis of the raw data from three independent 
experiments showed that miRNA 6-4 ΔpA construct had variability in oBLG 
knockdown on different days of lactation in both littermates of 96%±4, 97%±2 
and 97%±2, respectively (littermate a) and 97%±3, 97%±3 and 97%±1, 
respectively (littermate b) (Figure 5-5). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4: Analysis of ovine BLG knockdown by miRNA 6-4 ΔpA construct using 
SDS-PAGE analysis and detection by coomassie blue. 
The figure shows the coomassie staining of total milk protein of Tg and non-Tg mice on 
day 5, 10 and 15 of lactation. Equal amount of total milk protein was loaded onto each 
lane of gel and the gel was stained with coomassie stain. M: pre-stained protein maker 
(Invitrogen), oBLG/-: hemizygous oBLG mouse (positive control), -/-: WT mouse 
(negative control), -/miRNA 6-4 ΔpA: Tg mouse carrying miRNA 6-4 ΔpA (negative 
control) and oBLG/miRNA 6-4 ΔpA: Tg mouse positive for both oBLG and miRNA 6-4 
ΔpA transgenes. a and b represent littermates and both carrying oBLG and miRNA 6-4 
ΔpA transgenes. 
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Figure 5-5: Knockdown of ovine BLG during the lactation period by miRNA 6-4 
ΔpA construct using SDS-PAGE analysis and detection by coomassie blue. 
All data are presented as the percent reduction of oBLG in milk of miRNA 6-4 ΔpA-
oBLG mice on day 5, day 10 and day 15 of lactation as compared to the positive control. 
Experiment results were an average of three independent experiments. Error bars 
represent SEM determined from n= 3 repeats. 
The oBLG knockdown results obtained from the coomassie staining of total milk 
protein of Tg and non-Tg mice collected on day 5 of lactation were further 
verified by highly sensitive western blot assay which will allow to compare with 
the oBLG knockdown results obtained from the coomassie staining. Initially milk 
from both Tg and non-Tg mouse was analysed by western blot assay for the 
detection of oBLG and there was no oBLG signal for the negative controls (WT 
and miRNA mouse) but a bright signal for the positive control (oBLG mouse) as 
expected (Figure 5-6). The signal intensities of oBLG on exposure film were 
measured by Quantity One software (Bio-Rad). The efficiency of miRNAs to 
down regulate the expression of oBLG in vivo was calculated based on the BLG 
expression by the mice only expressing oBLG which was set as 100% of BLG 
expression. 
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Figure 5-6: Western blot analysis of proteins in milk collected from mice on day 5 of 
lactation. 
This figure shows the western blot analysis of total milk protein on day 5 of lactation of 
Tg and non-Tg mice. Equal amount of total milk protein was loaded onto each lane of gel 
and the oBLG expression was detected using an antibody directed against BLG (rabbit 
anti-BLG) as described in Materials and Methods. M: pre-stained protein maker 
(Invitrogen), oBLG/-: hemizygous oBLG mouse (positive control), -/-: WT mouse 
(negative control) and -/miRNA: miRNA mouse (negative control). 
Representative western blots showing the effectiveness of single and tandem 
miRNA constructs against oBLG expression are shown in Figure 5-7. The 
expectation from this analysis was to see similar reduction of oBLG expression in 
milk as I found by coomassie staining. The experiments were repeated three times 
as done for coomassie-stained SDS gels to verify the reproducibility of the 
western blot assay. The knockdown calculations were done as mentioned above. 
The western analysis showed that the average oBLG knockdown by the tandem 
constructs (miRNA6-4 ΔpA and miRNA 6-4) were 88% and 54%, respectively. 
The single miRNA constructs showed an average oBLG knockdown efficiency 
ranging from 38-50%. The miRNA 6 construct yielded 38% oBLG knockdown. 
The three Tg lines (lines 1, 6 and 7) carrying miRNA 4 showed 50%, 38% and 
45% of oBLG knockdown, respectively. As seen in coomassie stain knockdown 
analysis, the miRNA 6-4 ΔpA construct was also significantly different to other 
miRNA constructs in case of oBLG knockdown (P<0.05) (Figure 5-8). The 
statistical analysis of the raw data from three independent experiments showed 
that single and tandem miRNAs had variability in oBLG knockdown of 88%±14 
(miRNA 6-4 ΔpA), 54%±13 (miRNA 6-4), 38%±17 (miRNA 6), 50%±17 
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(miRNA 4 line 1), 38%±22 (miRNA 4 line 6) and 45%±12 (miRNA 4 line 7) 
(Figure 5-8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-7: Knockdown of ovine BLG by single and tandem miRNAs using western 
blot analysis. 
This figure shows the western blot analysis of total milk protein on day5 of lactation of 
Tg and non-Tg mice. Equal amount of total milk protein was loaded onto each lane of gel 
and the oBLG expression was detected using an antibody directed against BLG (rabbit 
anti-BLG) as described in Materials and Methods. A-F represent knockdown of oBLG by 
miRNA 6-4 ΔpA, miRNA 6-4, miRNA 6, miRNA 4 line 1, miRNA 4 line 6 and miRNA 
4 line 7, respectively. M: pre-stained protein maker (Invitrogen), oBLG/-: hemizygous 
oBLG mouse (positive control), -/-: WT mouse (negative control), -/miRNA: miRNA 
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mouse (negative control), and oBLG/miRNA: miRNA-BLG mouse positive for both 
oBLG and miRNA transgenes. 
 
Figure 5-8: Comparison of ovine BLG knockdown by miRNA constructs using 
western blot analysis. 
All data are presented as the percent reduction of oBLG in milk on day 5 compared with 
the positive control. Experiment results were an average of three independent 
experiments. Statistical significance among means was determined using a paired two 
sample t-test (p<0.05). Error bars represent SEM determined from n= 3repeats.  
In order to verify the oBLG knockdown results obtained by coomassie staining 
during different lactation time points and littermates carrying both miRNA 6-4 
ΔpA and oBLG transgenes, milk of miRNA 6-4 ΔpA-oBLG was further analysed 
by western blot assay. The expectations of this analysis were to see similar 
knockdown results by the miRNA 6-4 ΔpA construct across the lactation period 
with no variations between littermates. A representative western blot knockdown 
analysis by the miRNA 6-4 ΔpA construct is shown in Figure 5-9. The western 
blot showed a detectable but much weaker oBLG signal than for the control which 
means miRNA 6-4 ΔpA construct knocked down the gene very efficiently. In 
addition, the oBLG knockdown ability of the miRNA 6-4 ΔpA construct was 
consistent over the lactation period and there were no differences in oBLG 
knockdown between littermates. In order to verify the reliability of the western 
blot results of oBLG knockdown by miRNA 6-4 ΔpA construct, this experiment 
was repeated in two other independent experiments and the knockdown efficiency 
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of miRNA 6-4 ΔpA was calculated as mentioned above. The average of the three 
experiments showed that miRNA 6-4 ΔpA construct silenced oBLG of 88%, 90% 
and 93% on day 5, 10 and 15, respectively in one littermate (as marked as a in 
Figure 5-9). The other littermate (marked as b in Figure 5-9) was equally efficient 
to its littermate showing oBLG knockdown of 91%, 91% and 95% on day5, 10 
and 15, respectively (Figure 5-10). The western blot analysis of oBLG 
knockdown by the miRNA 6-4 ΔpA construct showed insignificant differences 
among various lactation days and between littermates (P>0.05). The statistical 
analysis of the raw data from three independent experiments showed that miRNA 
6-4 ΔpA construct had variability in oBLG knockdown on different days of 
lactation in both littermates of 88%±14, 90%±14 and 93%±8, respectively 
(littermate a) and 91%±12, 91%±11 and 95%±5, respectively (littermate b) 
(Figure 5-10). 
 
 
 
 
 
 
 
 
 
 
Figure 5-9: Analysis of ovine BLG knockdown by miRNA 6-4 ΔpA construct using 
western blot analysis. 
This figure shows a western blot analysis of oBLG expression in Tg and non-Tg mouse 
milk on day 5, day 10 and day 15 of lactation. Equal amount of total milk protein was 
loaded onto each lane of SDS gel and the oBLG expression was detected using an 
antibody directed against BLG (rabbit anti-BLG) as described in Materials and Methods. 
M: pre-stained protein maker (Invitrogen), oBLG/-: hemizygous oBLG mouse (positive 
control), -/-: WT mouse (negative control), -/miRNA 6-4 ΔpA: miRNA mouse (negative 
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control), and oBLG/miRNA 6-4 ΔpA: miRNA-BLG mouse positive for both oBLG and 
miRNA 6-4 ΔpA transgenes. a and b represent littermates and both carrying oBLG and 
miRNA 6-4 ΔpA transgenes. 
 
Figure 5-10: Knockdown of ovine BLG around the lactation period by miRNA 6-4 
ΔpA construct using western blot analysis. 
All data are presented as the percent reduction of oBLG in milk on day 5, 10 and 15 
compared with the positive control. Experiment results were an average of three 
independent experiments. Error bars represent SEM determined from n= 3repeats. 
The aim of using two different assay systems (coomassie stain and western blot) 
was to compare and evaluate miRNAs efficiency against oBLG expression in 
vivo. Theoretically, both assays should produce very similar oBLG knockdown 
results. Both assay systems showed consistent oBLG knockdown by miRNAs as 
expected. Moreover, the most effective tandem construct (miRNA 6-4 ΔpA) was 
found significantly different to other miRNA constructs in both assays. 
The knockdown efficiency of miRNA constructs was also tested in vivo against 
the expression of bBLG. The total milk protein pattern of bBLG-miRNA mice 
was same as oBLG-miRNA mice milk proteins on gels (data not shown). The 
measurement of signal intensities of coomassie stained milk proteins was done 
using Quantity One software (Bio-Rad). The internal control protein (α-casein) 
was considered to normalize the expression of bBLG and the efficiency of 
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miRNAs to knockdown bBLG was calculated based on 100% of bBLG 
expression of the bBLG mice. 
Milk collected on day 5 of lactation from Tg mice (mice expressing bBLG or 
miRNA or bBLG and miRNA) and non-Tg mice (WT) was analysed by 
coomassie stain. A representative coomassie stained gel was shown in Figure 5-11 
showing the potential of the miRNAs to inhibit expression of bBLG. The miRNA 
constructs were expected to reduce bBLG expression at different levels. Milk 
samples were analysed in three independent experiments using coomassie stain 
and the intensities of the control protein and bBLG were used for knockdown 
calculation as mentioned above. Average of the knockdown results obtained from 
three separate experiments showed that the miRNA6-4 ΔpA construct knocked 
down only 46% of bBLG which is unexpectedly lower than the singles. The 
average bBLG knockdown efficiencies were 51%, 71% and 51% by the miRNA 
6, miRNA 4 line 1 and line 6, respectively. However, the miRNA 6-4 construct 
and miRNA 4 line 7 showed a surprising increase in bBLG expression of 15% and 
34%, respectively. The miRNA 6-4 and miRNA 4 line 7 had no knockdown effect 
on bBLG gene and they showed significant difference to other miRNA constructs. 
In addition, miRNA 6-4 ΔpA construct also showed significant difference to 
miRNA 4 line 1 (P<0.05) (Figure 5-12). The statistical analysis of the raw data 
from three independent experiments showed that single and tandem miRNAs had 
variability in bBLG knockdown of 46%±6 (miRNA 6-4 ΔpA),-15%±16 (miRNA 
6-4), 51%±15 (miRNA 6), 71%±2 (miRNA 4 line 1), 51%±18 (miRNA 4 line 6) 
and -34%±41 (miRNA 4 line 7). 
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Figure 5-11: Knockdown of bovine BLG by miRNAs using SDS-PAGE analysis and 
detection by coomassie blue.  
This figure shows the coomassie staining of total milk protein of miRNA-BLG mice 
containing miRNA and bBLG transgenes. Equal amount of total milk protein was loaded 
onto each lane of gel and the gel was stained with coomassie stain. A-F represent 
knockdown of bBLG by miRNA 6-4 ΔpA, miRNA 6-4, miRNA 6, miRNA 4 line 1, 
miRNA 4 line 6 and miRNA 4 line 7, respectively. M: pre-stained protein maker 
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(Invitrogen), bBLG/-: hemizygous bBLG mouse (positive control), -/-: WT mouse 
(negative control), -/miRNA: miRNA mouse (negative control), and bBLG/miRNA: 
miRNA-BLG mouse positive for both bBLG and miRNA transgenes. 
 
Figure 5-12: Comparison of bovine BLG knockdown by miRNA constructs using 
SDS-PAGE analysis and detection by coomassie blue. 
All data are presented as the percent reduction of bBLG in milk on day 5 compared with 
the positive control. Experiment results were an average of three independent 
experiments. Statistical significance among means was determined using a paired two 
sample t-test (p<0.05). Error bars represent SEM determined from n= 3repeats.  
In the same way as for oBLG knockdown analysis by coomassie staining, milk 
from miRNA 6-4 ΔpA-bBLG mice was collected and further analysed by 
coomassie staining in order to compare the potential effect of the miRNA 6-4 
ΔpA on bBLG expression on various days of lactation (day 5, 10 and 15) and also 
to compare the bBLG knockdown efficiency of the miRNA in littermates. 
Expectations from this experiment were that miRNA 6-4 ΔpA would show 
reduced expression of bBLG on day 10 and 15 as like as day 5 without any 
substantial differences in littermates. A representative gel stained by coomassie 
blue is shown in Figure 5-13 and reveals that miRNA 6-4 ΔpA construct knocked 
down bBLG equally on different days of lactation with no substantial differences 
a 
b 
c 
d 
e 
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in littermates as expected. The efficiency of miRNA 6-4 ΔpA to knockdown 
bBLG was calculated based on three independent experiments as mentioned 
above. One (marked as a in Figure 5-13) of the littermates showed an average of 
46%, 43% and 53% of bBLG knockdown on day 5, 10 and 15, respectively. The 
other (marked as b in Figure 5-13) showed 56%, 43% and 57% of bBLG 
knockdown on those days as mentioned above (Figure 5-14). Although there was 
a slight difference in bBLG knockdown on different days of lactation between 
littermates, there was no significant difference between littermates and lactation 
days in terms of bBLG knockdown (P>0.05). The statistical analysis of the raw 
data from three independent experiments showed that miRNA 6-4 ΔpA construct 
had variability in bBLG knockdown on different days of lactation in both 
littermates of 46%±6, 43%±18 and 53%±5, respectively (littermate a) and 56%±4, 
43%±15 and 57%±2, respectively respectively (littermate b) (Figure 5-14). 
 
 
 
 
 
 
 
 
 
 
Figure 5-13: Analysis of bovine BLG knockdown by miRNA 6-4 ΔpA construct 
using SDS-PAGE analysis and detection by coomassie blue. 
The figure shows the coomassie staining of total milk protein of Tg and non-Tg mice on 
day 5, 10 and 15 of lactation. Equal amount of total milk protein was loaded onto each 
lane of gel and the gel was stained with coomassie stain. M: pre-stained protein maker 
(Invitrogen), bBLG/-: hemizygous bBLG mouse (positive control), -/-: WT mouse 
(negative control), -/miRNA 6-4 ΔpA: Tg mouse carrying miRNA 6-4 ΔpA (negative 
control) and bBLG/miRNA 6-4 ΔpA: Tg mouse positive for both bBLG and miRNA 6-4 
 
Chapter Five: Knockdown of BLG in vivo 
 
126 
 
ΔpA transgenes. a and b represent littermates and both carrying bBLG and miRNA 6-4 
ΔpA transgenes. 
 
Figure 5-14: Knockdown of bovine BLG during different lactation time points by 
miRNA 6-4 ΔpA construct using SDS-PAGE analysis and detection by coomassie 
blue. 
All data are presented as the percent reduction of bBLG in milk of miRNA 6-4 ΔpA-
bBLG mice on day 5, 10 and 15 of lactation as compared to the positive control. 
Experiment results were an average of three independent experiments. Error bars 
represent SEM determined from n= 3repeats.  
The bBLG knockdown results obtained from the coomassie staining of total milk 
protein of bBLG-miRNA mice collected on day 5 of lactation were further 
verified by highly sensitive western blot assay. Representative western blots 
showing the effectiveness of single and tandem miRNA constructs against bBLG 
expression are shown in Figure 5-15. The expectation from this analysis was to 
see similar effect of miRNAs on the expression of bBLG in milk as observed by 
coomassie staining. The assay was repeated three times and the efficiency of the 
miRNAs silencing bBLG was quantified as mentioned before. In an unexpected 
result, the tandem miRNA constructs (miRNA 6-4 ΔpA and miRNA 6-4) showed 
up regulation of the bBLG expression by an average of 12% and 7%, respectively. 
However, miRNA 6-4 ΔpA construct showed 46% of bBLG knockdown by 
coomassie staining. Moreover, miRNA 6 also showed up regulating bBLG 
expression by 48% which is the complete opposite of what I observed in 
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coomassie staining results. The miRNA 4 lines 1 and 6 showed some activity 
against bBLG expression (2% and 23%, respectively) but the efficiency is much 
lower than that I observed in coomassie staining results. However, an opposite 
scenario was found for miRNA 4 line 7 where the construct showed an average 
bBLG knockdown of 13% by western blot analysis and 34% up regulation of 
bBLG expression by SDS-PAGE analysis (Figure 5-16). Overall, the knockdown 
results obtained from western blot analysis were unexpected when compared to 
the results obtained from coomassie staining. Investigation of the statistical 
analysis of the bBLG knockdown by miRNA constructs obtained from western 
blot and coomassie staining assays revealed that there was a high variation among 
experiment repeats in western blot analysis compared to coomassie staining thus 
making the western blot knockdown results unreliable. The statistical analysis of 
the raw data from three independent experiments showed that single and tandem 
miRNAs had variability in bBLG knockdown of-12%±28 (miRNA 6-4 ΔpA), -
7%±51 (miRNA 6-4), -48%±97 (miRNA 6), 2%±50 (miRNA 4 line 1), 23%±49 
(miRNA 4 line 6) and 13%±14 (miRNA 4 line 7) (Figure 5-16). 
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Figure 5-15: Knockdown of bovine BLG by single and tandem miRNAs using 
western blot analysis. 
This figure shows the western blot analysis of total milk protein on day 5 of lactation of 
Tg and non-Tg mice. Equal amount of total milk protein was loaded onto each lane of gel 
and the bBLG expression was detected using an antibody directed against BLG (rabbit 
anti-BLG) as described in Materials and Methods. A-F represent knockdown of bBLG by 
miRNA 6-4 ΔpA, miRNA 6-4, miRNA 6, miRNA 4 line 1, miRNA 4 line 6 and miRNA 
4 line 7, respectively. M: pre-stained protein maker (Invitrogen), bBLG/-: hemizygous 
bBLG mouse (positive control), -/-: WT mouse (negative control), -/miRNA: miRNA 
mouse (negative control), and bBLG/miRNA: miRNA-BLG mouse positive for both 
bBLG and miRNA transgenes. 
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Figure 5-16: Comparison of bovine BLG knockdown by miRNA constructs using 
western blot analysis. 
All data are presented as the percent reduction of oBLG in milk on day 5 compared with 
the positive control. Experiment results were an average of three independent 
experiments. Error bars represent SEM determined from n= 3repeats. 
The knockdown efficiency of the miRNA 6-4 ΔpA construct analysed by 
coomassie staining was about 50%. However, no knockdown activity was found 
by this miRNA construct in day 5 milk sample when analysed by western blot 
assay. So, I wanted to see the effect of miRNAs on bBLG expression with regard 
of different stages of lactation and also to compare the results with the results I 
found in coomassie staining. A representative western blot showing the effect of 
miRNA 6-4 ΔpA construct on bBLG expression is shown in Figure 5-17. The 
western blot shows detectable bBLG signals that look alike for both positive 
control and samples. Moreover, the signals for bBLG look consistent over the 
lactation period and there are no differences in littermates. This experiment was 
repeated in three independent experiments and the knockdown efficiency of 
miRNA 6-4 ΔpA was calculated as mentioned above. The average of the three 
experiments showed that miRNA 6-4 ΔpA construct increased the expression of 
bBLG by 12% and 17% on day 5 and 10. However, the construct showed some 
knockdown activity (20%) on day 15 of lactation in one littermate (marked as a in 
Figure 5-17). In contrast, the other littermate (marked as b in Figure 5-17) only 
showed bBLG up regulation on day 5 (16%) and down regulation of bBLG 
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expression by 6% and 44% on day 10 and 15, respectively. There was no 
significant difference between different lactation days for littermate a (P>0.05). 
However, a significant difference was found between day 10 and 15 for littermate 
b (P<0.05). Moreover, the effect of miRNA 6-4 ΔpA on day 10 in littermate a was 
also significantly different to its effect on day 15 in littermate b (P<0.05) (Figure 
5-18). The statistical analysis of the raw data from three independent experiments 
showed that miRNA 6-4 ΔpA construct had variability in bBLG knockdown on 
different days of lactation in both littermates of -12%±28, -17%±19 and 20%±21, 
respectively (littermate a) and -16%±12, 6%±7 and 44%±32, respectively 
(littermate b) (Figure 5-18). 
 
 
 
 
 
 
 
 
 
Figure 5-17: Analysis of bovine BLG knockdown by miRNA 6-4 ΔpA construct 
using western blot analysis. 
This figure shows a western blot analysis of bBLG expression in Tg and non-Tg mouse 
milk on day 5, day 10 and day 15 of lactation. Equal amount of total milk protein was 
loaded onto each lane of SDS gel and the bBLG expression was detected using an 
antibody directed against BLG (rabbit anti-BLG) as described in Materials and Methods. 
M: pre-stained protein maker (Invitrogen), bBLG/-: hemizygous bBLG mouse (positive 
control), -/-: WT mouse (negative control), -/miRNA 6-4 ΔpA: miRNA mouse (negative 
control), and bBLG/miRNA 6-4 ΔpA: miRNA-BLG mouse positive for both bBLG and 
miRNA 6-4 ΔpA transgenes. a and b represent littermates and both carrying bBLG and 
miRNA 6-4 ΔpA transgenes. 
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Figure 5-18: Knockdown analysis of bovine BLG around the lactation period by 
miRNA 6-4 ΔpA construct using western blot. 
All data are presented as the percent reduction of bBLG in milk on day 5, day 10 and day 
15 compared with the positive control. Experiment results were an average of three 
independent experiments. Error bars represent SEM determined from n= 3repeats. 
5.3 Discussion 
Here, I present in vivo knockdown of BLG in a mouse model using mammary 
gland tissue-specific single and multiple BLG specific miRNAs. Several 
approaches were developed previously to perform BLG knockdown, however, no 
report has been published yet showing knockdown of bBLG and oBLG in an in 
vivo system. The ultimate goal of this study was to validate the feasibility of 
reducing BLG levels in milk by expressing a miRNA in the mammary gland 
under the control of a milk protein promoter. For this, I generated Tg mice that 
contain BLG and miRNA transgenes that were shown to possess knockdown 
activity against BLG in an in vitro assay. To see whether miRNAs knockdown 
bBLG and oBLG in vivo, milk of mice carrying both BLG and miRNA transgenes 
were analysed by SDS-PAGE following staining of separated milk proteins with 
coomassie blue. The western blot analysis was used as an alternative method to 
validate results obtained from the coomassie stain. The coomassie staining of day 
5 total milk protein obtained from double Tg mice showed almost complete 
abrogation of oBLG by the tandem miRNA 6-4∆pA construct while the 
a 
b 
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polyadenylated version of miRNA 6-4 and single miRNAs knocked down BLG 
levels by about 50%. The Tg miRNA mice were generated by microinjection 
which contributes random integration of transgenes. As a result the levels of 
miRNA expression can vary which can potentially affect the knockdown 
efficiency of miRNAs. Although the processed miRNA 6 has, in relation to the 
oBLG mRNA, two mismatches at its 3‟ end it showed effectiveness against oBLG 
expression (54%). It has been reported that nucleotide mismatches (up to four) at 
the most 3‟ terminal positions of siRNAs sequence to the target mRNA have been 
shown to still result in efficient gene knockdown in HeLa cells (160). In contrast 
to the oBLG knockdown, the SDS-PAGE analysis of knockdown of the bovine 
form, bBLG, showed that tandem miRNA 6-4∆pA construct knocked down 
bBLG by about 50% while surprisingly the polyadenylated form of miRNA 6-4 
construct did not show any knockdown activity on bBLG expression at all. Two 
of the miRNA 4 Tg lines, line 1 and 6 showed bBLG knockdown activity (71% 
and 51%, respectively) while line 7 showed unexpected enhancement of bBLG 
expression by about 35%. The second miRNA forming part of the tandem 
construct (miRNA 6) showed about 50% knockdown efficiency for bBLG. The 
observed knockdown difference between miRNA 6-4 with or without pA is in 
accord with results by Chung et al., who also observed greater Bcl-I (80) 
knockdown with a non-polyadenylated synthetic miRNA modeled on the murine 
miRNA-155. The inefficiency of polyadenylated miRNA 6-4 construct to 
knockdown bBLG is most likely due to the difference in the miRNA expression 
levels. Moreover the differences in the knockdown efficiencies of bBLG by 
different miRNAs could be due to the difference in integration site of the 
transgenes into the genome or could be due to the intrinsic activities of the 
miRNAs that may affect the levels of miRNA expression and interference with 
the target mRNA. 
Overall, it appears that the miRNAs trigger greater knockdown of oBLG. The 
reason of the difference in oBLG and bBLG knockdown by the identical miRNAs 
can be assumed to be possibly due to the the difference in the form of BLG gene 
(genomic/cDNA) used to generate BLG mice. The Tg oBLG mice were generated 
from a gDNA construct and bBLG is expressed through a cDNA construct. It has 
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been reported that transgenes that are composed of a genomic sequence (with 
natural intron-exon sequence) produce much higher level of protein in Tg animal 
compared to cDNA-based constructs (174) (175). At similar expression levels of 
the oBLG and bBLG transgenes, protein levels are likely to differ with oBLG 
being expected to be produced at higher levels than the bovine variant due to more 
efficient export of the pre-mRNA from the cell nucleus (176). However, in my 
work both oBLG and bBLG mice showed high BLG expression in milk. 
Furthermore, oBLG and bBLG transcripts exhibit very different secondary 
structures (see Appendix 23) which may affect their accessibility to the RNAi 
machinery (177) (178) (179) (180). It can also be speculated that the data obtained 
from genomic construct of oBLG knockdown analysis are more important and 
meaningful because they are closer to the scenario that we would experience in 
cows. 
The coomassie stain and western blot methods were expected to give fairly similar 
knockdown results which I indeed observed for oBLG knockdown analysis. 
Unexpectedly, however, both assays gave different results for most of the bBLG-
miRNA mouse lines. Coomassie staining-based BLG knockdown results were 
much more reliable than western blot results which were hampered by a lack of 
reproducibility. The bBLG knockdown data obtained by western blot analysis are 
difficult to interpret because of the large deviations that were observed for 
experimental repeats. The western blot assay is comparatively a complex and 
technically challenging procedure. Moreover, I had the opportunity to normalize 
the BLG knockdown results obtained from coomassie stain to the mouse milk 
protein α-casein. Although the western blot analysis in this study were not 
normalized the Ponceau staining of the transfer membrane showed equal protein 
loading and transfer (results not shown).  
It was the ultimate target of this study to demonstrate knockdown of BLG in a 
mouse model. In the in vivo mouse model the expression of the miRNAs and BLG 
was restricted to the mammary glands, whereas the miRNA and BLG expression 
was constitutive in the in vitro cell culture assay. In vitro analysis of miRNA-
mediated knockdown showed great effectiveness for both oBLG and bBLG. 
Although the miRNA 6-4 construct without pA showed about 95% knockdown 
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oBLG the polyadenylated form of miRNA 6-4 construct showed less effectiveness 
to downregulate oBLG in vivo (about 50%) as compared to the in vitro 
experiments (90%). In contrast, the miRNA 6-4 construct failed to show any 
knockdown activity on bBLG expression in vivo. In addition the miRNA 6-4 ΔpA 
construct showed some knockdown activity (about 45%) in vivo. However, the 
miRNA 6-4 construct showed great bBLG knockdown (99%) in vitro. Despite the 
nucleotide mismatch (es) between miRNA and target sequence, miRNA 6 proved 
effective for both BLG genes in in vitro experiments. Therefore it was expected 
that miRNA 6 would achieve similar knockdown efficiencies for both BLG genes 
in vivo. But in vivo miRNA 6 showed about 50% of BLG knockdown as 
compared to the knockdown observed in vitro. Moreover, miRNA 4 is perfectly 
complementary to both BLG genes and the knockdown expectation was also the 
same as in vitro. However, the in vivo knockdown results for both BLG genes by 
the miRNA 4 did not match the expectations as it showed less knockdown activity 
in vivo (about 50%) as compared to in vitro (about 85%). 
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Chapter Six: General Discussion 
and Outlook 
 
Milk is a basic food for humans; particularly infants because it contains all the 
nutritions required for growth and development. Moreover, when breast-feeding is 
not available, cow‟s milk is used as a substitute. Unfortunately cow milk can lead 
to immunological problems because it contains a number of milk allergens 
including the major allergen BLG (181). That‟s why BLG is an attractive target in 
order to make milk amenable to everyone. Until today we have been relying on 
post-harvest processing methods to reduce its presence in milk. Different milk 
processing methods such as heat treatment and enzymatic treatment have shown 
to be effective in reducing milk allergens. Such procedures may still lead to 
presence of residual peptides that can cause allergenicity in children (182). 
Selective breeding has also been found to be of limited value in altering milk 
composition (183). Recently, knockout of bBLG with zinc-finger nucleases was 
attempted (184). Yu et al., introduced short fragment deletions into the BLG gene 
and generated Tg cattle from cell clones that were shown to be bi-allelic BLG 
mutants. Unfortunately, the only remaining live animal does not contain BLG 
knockout alleles but a small in frame deletions and is therefore likely to still 
produce (slightly shorter) BLG protein variants. Genuine BLG knockout animals 
have yet to be generated. The research presented in this thesis is the first 
demonstration of BLG knockdown in an in vivo system. Until my study it has 
only been shown that porcine BLG can be knocked down in vitro using synthetic 
RNAi molecules (130). In this study by Merkl and co-workers, they used the same 
vector system and targeted similar regions of the BLG gene to my study by 
artificial miRNAs. The transfection of miRNA showed 74% of porcine BLG 
knockdown in CHO-K1 cells which is similar to my results. The main objective of 
my study was to test the feasibility of a tissue-specific miRNA-based RNAi 
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approach to reduce the expression of a major suspected milk allergen, BLG, in 
milk using a Tg mouse model. 
The algorithms and programs available to predict interfering molecule sequences 
are helpful but one may have advantages over another. So prediction of a specific 
miRNA is not commonly reliable and difficult to judge its functionality against 
the target gene. In this study, miRNAs were predicted by Invitrogen‟s optimized 
proprietary algorithm and most of the predicted miRNAs showed functionality 
against BLG expression. In vitro studies revealed that sequence complementarity 
between miRNA and the target is important for knockdown efficiency and any 
mismatch can reduce the knockdown efficiency. It becomes clear from the in vitro 
studies that there is still considerable room to improve miRNA design to assess its 
contribution to silence the target gene. Following the identification of the most 
effective miRNAs for BLG, I further examined the efficacy of tandem miRNA 
constructs and their constituent singles against BLG expression. I found tandem 
miRNA constructs were able to achieve slightly higher BLG knockdown 
compared to their singles but the differences were small and statistically 
insignificant. The miRNA constructs used in this study for in vitro studies were 
bicistronic GFP expression constructs. GFP expression correlates with the 
miRNA expression (one bicistronic construct). Quantification of GFP expression 
by western blotting showed similar GFP expression for both tandem constructs 
and their constituent singles (Figure 3-9). Same level of GFP expression thus 
confirmed that the tandem constructs (eg. miRNA 6-4) produced twice as many 
RNAi molecules available for the knockdown as compared to single constructs 
(eg. miRNA 4 and 6). However, I did not see more knockdowns with the tandem 
constructs and it is indeed likely that there was no synergistic effect. The BLG 
knockdown efficiency by the tandem miRNA construct might be different in vivo 
as it targets two different regions of the gene which could potentially improve its 
knockdown efficiency. In order to minimize unwanted off-target effects by the 
miRNAs, expression of miRNAs was under the control of a milk protein promoter 
to restrict their activity to the mammary gland. One of the miRNA constructs 
(miRNA 6-4 ΔpA) showed almost complete oBLG knockdown, while other 
miRNA constructs knocked down oBLG by about half as compared to mice 
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expressing only BLG (control). However, the efficiency of the miRNA 6-4 ΔpA 
construct to reduce bBLG expression was not as great as for oBLG- although the 
miRNA 6-4 ΔpA construct was expected to show similar knockdown efficiency. 
It is worthwhile remembering, though, that ovine and bovine transcripts vary 
considerably. While oBLG is first transcribed as a pre-mRNA from a genomic 
DNA template, bBLG transcription is driven by a cDNA construct. In this study, 
it is revealed that the Tg mouse line carrying the tandem miRNAs without the pA 
signal showed higher BLG knockdown efficiency compared to the tandem 
miRNA construct with polyadenylation signal. The surprising finding of this work 
was miRNA 6-4 showed about 50% knockdown for oBLG but slightly enhanced 
expression (15%) for bBLG in mice. To directly compare the knockdown 
efficiency of different miRNAs for both BLG genes in vivo, it would have been 
necessary to measure miRNA expression levels to judge the relative knockdown 
efficiency of various miRNAs. Several methods of RNA detection could be used 
to detect miRNAs such as, northern blotting, splinted-ligation technique and 
TaqMan MiRNA Assay system (Applied Biosystems). Northern blotting is 
considered the standard technique for small RNA expression analysis and tissue-
specific miRNA expression patterns have been identified using this technique. 
However, poor sensitivity and large amount of starting material (total RNA) are 
the major drawback of Northern blots, especially when analysing the expression 
of small RNAs such as miRNA. So, to detect miRNAs more efficiently, I used the 
splinted ligation method described by Maroney et al., for direct labelling and 
detection of small RNAs present in total RNA (185). The splinted-ligation 
technique is a DNA:RNA hybridization assay that uses a bridge oligonucleotide 
with perfect complementary to a target small RNA and a 5‟-end-radiolabeled 
ligation oligonucleotide. It has been reported that this detection technique is ~50 
times more sensitive than Northern blotting using DNA probes and requires small 
amount of total RNA (0.5-5.0 ug) depending on the abundance of the small RNA. 
Experiments with the DNA and miRNA hybrids to visualize miRNA expression 
failed to perform as anticipated due to technical problems. A SYBR green based 
real-time PCR assay has also been used to detect miRNAs. The highly sensitive 
and sophisticated real-time PCR assay has become a reliable detection technique 
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for the identification of low abundance RNA molecules (186). Although in this 
work real-time PCR showed detection of internal control glyceraldehyde-
3phosphatedehydrogenase (GAPDH) mRNA, small miRNAs were unable to 
detect due to its small size and low abundance (results not shown). 
The data presented in this study validate the RNAi approach and provide valuable 
information on silencing BLG expression both in vitro and in vivo which 
encourages further research on the improvement of milk quality using tissue-
specific miRNA-based models. The next logical step of this study is to 
knockdown BLG in cows and sheep. RNAi sequences could be either directly 
administered into the mammary gland, for example by teat injection of siRNAs, or 
used in fully modified animals that are generated by microinjection or produced 
via somatic cell nuclear transfer using genetically modified miRNA cells as 
donors. Currently work is in progress to evaluate the BLG knockdown efficiency 
of the tandem miRNA construct in cattle. Successful bBLG knockdown in cattle 
would possibly help us to study the functional implications of BLG on milk 
characteristics, allergenicity and overall protein secretion and lactation. Cow milk 
with reduced BLG will also tell us whether it is important for normal growth of 
calves.  
 
My results demonstrate the feasibility of RNAi for the knockdown of a milk 
protein and should also open avenues to apply the technique to reduce levels of 
other milk proteins, for example α-lactalbumin to reduce the amount of lactose, a 
milk sugar that cannot be converted by a substantial part of the human population 
or caseins which have been identified as some of the major milk allergens (187). 
Lactose-intolerant people do not have enough lactase enzyme to break down 
lactose to glucose and galactose and produce intestinal disorders (188). Lactose is 
synthesized by lactose synthetase complex which comprises α-lactalbumin gene. 
Complete disruption of the expression of α-lactalbumin gene resulted in lactose-
free milk, but milk became highly viscous and suckling pups were unable to get 
required nutrition from their mothers (50). In comparison to the gene knockout 
strategy, RNAi could be an alternative tool to reduce lactose level to an acceptable 
range in order to retain appropriate amounts of carbohydrate in milk without 
compromising other milk attributes (51). Although caseins supply essential amino 
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acids, carbohydrates and two essential inorganic nutrients, calcium and 
phosphorus for bone growth (189), bovine caseins have been identified as major 
milk allergens (187). Deletion of the κ-casein gene has been performed in mice 
and showed complete abolishment of milk production (190). Moreover, 
inactivation of α-casein has showed a significant decrease in other milk proteins 
that affects the normal growth of pups (191). In contrast, ß-casein has been found 
to be a non-essential component in milk proteins and showed little effect on milk 
production and pups body growth after disrupting its function in mice (183). 
Because the biological fuction of α and κ –casein is crucial for milk production, a 
complete knockout would not be desirable in farm animals. RNAi could be a 
useful tool to reduce the presence of α and κ –casein in order to make milk 
hypoallergenic particularly for those that are allergic to milk casein. There is 
another milk component in dairy milk such as milk fat that could be targeted by 
RNAi to improve milk quality. Dairy milk is high in saturated fats with very little 
unsaturated fatty acids. Too much saturated fat is one of the major risk factors for 
heart diseases. Reduction of milk fat may reduce the energy requirement of the 
cows that could reduce feed costs for the cows. As a consequence consumers 
could get low-fat milk with lower price (192). The major component of fatty acid 
metabolism in most of the living organisms is acetyl-coenzyme A carboxylases 
(ACC) and it has become an attractive target in drug discovery against a variety of 
human diseases (193). It has been reported that ACC can be reduced up to 70% by 
targeting its mRNA using sequence-specific catalytic RNA molecules (ribozymes) 
in cells. So far, nobody has reported on the reduction of ACC mRNA in order to 
reduce fat concentration in milk. Thus it would be interesting to utilize RNAi 
mechanism to reduce milk fat as this technology has progressed and has been 
validated in many mammals against various important targets.  
In summary, the results presented in this thesis have led to two major results. 
First, the efficiency of the specific miRNA reducing the expression of the BLG 
gene can be assessed in a transient assay in mammalian cells and resulted in the 
identification of effective miRNAs for the proof-of-principle experiment of BLG 
gene silencing experiments in vivo. Secondly, expression of an active miRNA can 
be directed to the mammary gland to efficiently (>95%) reduce the levels of the 
Chapter Six: General Discussion and Outlook 
 
140 
 
major allergenic milk protein BLG in vivo. My data on successful knockdown of 
bBLG and oBLG in mice are, to the best of my knowledge, the first demonstration 
of reducing this allergenic protein in the milk of animals and therefore validate the 
usefulness of the tandem miRNA construct as an effective tool to silence BLG 
expression in sheep and cattle. 
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Appendices 
 
Appendix 1: Screening of single miRNA constructs. 
 
 
 
 
 
 
 
 
 
 
A. A schematic representation of MscI restriction digest and position of the oligos GL 
725 and GL 726 to check integration and sequencing of GFP (green box) and single 
miRNA (red box). B. The gel electropherogram in this figure shows the image captured 
from the restriction digest of pGL 274-283 with MscI restriction enzyme and analysed on 
agarose gel. The analytical digest of ten miRNA constructs (lanes 1-10) shows the release 
of the expected 1.4 kb fragment after MscI digest on agarose gel indicated by an arrow. 
Arrows indicate the expected molecular weight. 
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Appendix 2: Restriction digestion strategy to chain-up 
miRNAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. A schematic representation of the restriction enzyme digestion of miRNA expression 
vectors to chain up miRNAs. B. The gel electropherogram in this figure shows the image 
captured from the restriction digest of the pGL 275, pGL 276, pGL 277 and pGL 279 
with SalI and BamHI restriction enzymes to open up the vectors and analysed on agarose 
gel (lanes 1-4). The miRNA inserts were excised from the same expression constructs 
using SalI and BglII restriction digest and analysed on agarose gel (lanes 5-8). Arrows 
indicate the expected molecular weight. 
 A 
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Appendix 3: Screening of tandem miRNA constructs. 
 
 
 
 
 
 
 
 
The analytical digest of the putative tandem miRNA clones (pGL 285-290) (lanes 1-6) 
with SalI and XhoI restriction enzymes released the expected 310 bp fragment for the 
tandem miRNA constructs. Arrows indicate the expected molecular weight. 
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Appendix 4: Restriction digest of pGL 152 and pGL 164 
expression constructs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A and B, schematic representation of the pGL 164 and pGL 152 expression vectors. C. 
The gel electropherogram shows the restriction digests of the pGL 152 and pGL 164 
expression vectors with the HindIII and BamHI restriction enzymes. The restriction digest 
of pGL 152 (lane 1) and pGL 164 (lane 2) excised the expected bands at 700 bp of bBLG 
cDNA and 4.6 kb linearized pGL 164 expression vector indicated by an arrow. Arrows 
indicate the expected molecular weight, CMV (purple box), MCS (blue box) and bBLG 
(green box). 
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Appendix 5: Analysis of putative pGL 297 expression clones. 
 
 
 
 
 
 
 
 
 
 
 
A. A schematic representation of the bBLG expression construct (pGL 297). The inserted 
bBLG cDNA is highlighted in green colour. B. Analytical digest of 3 clones from the 
bBLG cDNA ligation. Positive clones in lanes 1-3 release the expected 1.6 kb fragment 
(bBLG cDNA and the CMV promoter) indicated by an arrow, after BglII and XhoI 
restriction digest. Arrows indicate the expected molecular weight and CMV promoter 
(purple box). 
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Appendix 6: Generation of a TOPO-oBLG construct. 
 
 
 
 
 
 
 
 
 
 
 
A. A schematic representation of ligation of PCR product of oBLG cDNA (highlighted in 
yellow) in TOPO vector. B. A schematic representation of the TOPO-oBLG construct 
showing the position of the oligonucleotides GL 727and GL 728 for sequencing of the 
oBLG sequence. C. Analytical digest of 6 clones from the oBLG cDNA ligation. The 
positive clone 1 in lane 1 releases the expected 310 bp fragment (oBLG cDNA and lacZ), 
indicated by an arrow after BglI digest. Clones 2, 3, 5 and 6 respectively (lanes 2, 3, 5 and 
6, respectively) showed digested vectors and clone 4 (lane 4) remained linearized. Arrows 
indicate the expected molecular weight. 
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Appendix 7: Restriction digestion of pGL 164 and TOPO-
oBLG constructs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. and B. Schematic representation of the restriction digest of pGL 164 and TOPO-oBLG 
constructs. C. The gel electropherogram shows the restriction digests of the TOPO-oBLG 
vector and pGL 164 expression vectors with HindIII and NotI restriction enzymes. The 
restriction digest of TOPO-oBLG clone (lane 1) and pGL 164 expression vector (lane 2) 
excised the expected bands at 637 bp of oBLG cDNA and 5.34 kb linearized pGL 164 
expression vector indicated by an arrow. Arrows indicate the expected molecular weight, 
CMV promoter (purple box), MCS (blue box) and oBLG cDNA (yellow box). 
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Appendix 8: Analysis of putative pGL 448 clones. 
 
 
 
 
 
 
 
 
 
 
 
A. A schematic representation of the restriction digest of pGL 448 construct. B. 
Analytical digest of four clones of pGL 448. Positive clones in lanes 1-4 release the 
expected 650 bp fragment (oBLG cDNA) after HindIII and NotI restriction digest. 
Arrows indicate the expected molecular weight, CMV promoter (purple box) and oBLG 
cDNA (yellow box). 
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Appendix 9: A western blot detection of BLG on a SDS gel. 
 
 
 
 
 
 
Expression of bBLG and oBLG protein was determined by western blot assay after 
transfecting COS7 cells with pGL 297 and pGL 448. Equal amounts of total protein for 
transfected and non-transfected cells were loaded on a gel. The blot was immune-stained 
using an antibody directed against BLG (rabbit anti-BLG, 1:10,000 dilutions) and 
visualized using ECL detection reagent (GE Healthcare). WT, represents non-transfected 
cell as negative control, 1, indicates the expression of bBLG and 2, indicates the 
expression of oBLG as indicated by an arrow. 
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Appendix 10: Generation of a pGEM-T-bBLG construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. A schematic representation of ligation of PCR product of bBLG cDNA (highlighted in 
green) in pGEM-T vector. B. A schematic representation of the pGEM-T-bBLG construct 
showing the position of the oligos GL 732 and GL 733 for sequencing of the bBLG 
sequence. C. Analytical digest of the clone from the bBLG cDNA ligation. The positive 
clone in lane 1 releases the expected 600 bp fragment (bBLG cDNA), indicated by an 
arrow after XhoI digest. Arrow indicates the expected molecular weight. 
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Appendix 11: Analysis of putative pGL 449 clones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. and B. A schematic representation of the restriction digest of TOPO-bBLG and pGL 
293 constructs. C. The gel electropherogram shows the restriction digests of the TOPO-
bBLG vector and pGL 293 expression vectors with XhoI restriction enzyme. The 
restriction digest of pGL 449 expression vector excised the expected bands at 600 bp of 
bBLG cDNA indicated by an arrow. Numbers indicate gel lanes and arrow indicates the 
expected molecular weight and bBLG cDNA (green box). 
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Appendix 12: Identification of orientation of bBLG in pGL 
449 by restriction digestion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. and B. A schematic representation of the restriction digest of pGL 449 construct. C. 
The gel electropherogram shows the restriction digests of the clones of pGL 449 
construct. The restriction digest excised the expected band at 5.7 kb of bBLG cDNA with 
correct orientation (lanes 3 and 4) and 5.1 kb with incorrect orientation (lanes 1 and 2) as 
indicated by arrows. Numbers indicate gel lanes, C, represents pGL 293 vector (negative 
control), arrows indicate the expected molecular weight and bBLG cDNA (green box). 
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Appendix 13: Generation of a pGEM-WAP construct. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. A schematic representation of ligation of PCR product of pWAP (grey box) in pGEM-
T vector. B. A schematic representation of the pGEM-pWAP construct showing the 
position of the forward (F) and reverse (R) oligos for sequencing of the pWAP sequence. 
C. Analytical digest of the clones from the pWAP ligation. Except clone 4 (lane 4), all of 
the clones showed the expected 2.4 kb fragment (pWAP) indicated by an arrow after SpeI 
and EcoRV digest. Numbers indicate gel lanes and arrows indicate the expected 
molecular weight. 
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Appendix 14: Analytical digest of putative tissue specific 
pGL 298 clones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. A schematic representation of the restriction digest of pGEM-pWAP construct and 
CMV driven pGL 289 construct. B. A schematic representation of the restriction digest of 
pGL 298 construct. C. Analytical digest of the clones from the pWAP replacement. 
Clones 1 and 2 (lanes 1 and 2) showed the expected 2.8 kb fragment (pWAP) indicated 
by an arrow after SpeI and SacII digest. Numbers indicate gel lane, arrows indicate the 
expected molecular weight, WAP (grey box), CMV (purple box), GFP (green box) and 
miRNA (red box). 
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Appendix 15: Restriction digestion of tandem and single 
miRNA constructs. 
 
 
 
 
 
 
 
 
 
 
 
A. A Schematic representation of the pGL 298, pGL 277 and pGL 279 constructs 
restriction enzyme profile. B. This figure shows the image of the restriction digest of the 
pGL 298 (lane 1), pGL 277 (lane 2) and pGL 279 (lane 3) constructs with BamHI and 
SacII restriction enzymes. The restriction digest excised the expected band at 6.5 kb of 
vector backbone of pGL 298 and inserts of pGL 277 and pGL 279 constructs as indicated 
by arrows. Numbers indicate individual digests, arrows indicate the expected molecular 
weight, WAP (grey box), CMV (purple box), GFP (green box) and miRNA (red box). 
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Appendix 16: Analytical digest of putative clones of tissue 
specific pGL 446 and pGL 447. 
 
 
 
 
 
 
 
 
 
 
A. A Schematic representation of the tissue specific pGL 446 and pGL 447 constructs 
restriction enzyme profile. B. The figure shows the image captured from the restriction 
digest of pGL 446 construct with BamHI and SacII restriction enzymes. The restriction 
digest showed that clone 1 (lane 2) failed to swap with pWAP, however, clones 2-4 
showed integration of miRNA 4 (lanes 3-5). C. The figure shows the image captured 
from the restriction digest of pGL 447 construct with BamHI and SacII restriction 
enzymes. The restriction digest showed that clones 1-2 (lanes 2 and 3) showed integration 
of miRNA 6. However, clone 3 and 4 (lanes 4 and 5) failed to swap with pWAP. C, 
control pGL 298 digest and numbers indicate individual digests, arrows indicate the 
expected molecular weight, WAP (grey box) and miRNA (red box). 
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Appendix 17: Preparative gel of the pGL 449 fragment for 
pronuclear injection. 
 
 
 
 
 
 
 
 
 
 
A. A schematic diagram of the pGL 449 milk expression vector restriction enzyme 
profile. B. The linearised 16.3 kb NotI fragment (lane 1), harbouring chicken insulator 
(purple box), beta-casein promoter (red box) and bBLG cDNA (green box) with beta-
casein flanking sequences (blue box) was used for pronuclear injection. Number indicates 
individual digest and arrow indicates the expected molecular weight. 
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Appendix 18: Preparative gel of the miRNA fragment and the 
insulator for pronuclear injection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. A schematic diagram of the restriction enzyme profile of pGL 298, pGL 446, pGL 447 
and pBS 2 x insulator. B. SpeI and SacII restriction digestion excised a 2.8 kb fragment 
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harbouring WAP promoter and the tandem miRNA. C. SpeI and FspI restriction digestion 
of pGL 298, pGL 446 and pGL 447 constructs releasing a fragment of 3.15 kb fragment 
harbouring WAP promoter and the tandem miRNA with pA sequence and a 3.0 kb 
fragment encompassing WAP promoter and miRNA 4/6 sequence along with pA 
sequence. D. XhoI and NotI restriction digestion excised a 2.4 kb fragment harbouring 2 x 
chicken insulator. Number indicates individual digests, arrows indicate the expected 
molecular weight, pWAP (grey box), miRNA (red box), TK pA (roan box) and ß-globin 
insulator (purple box). 
 
Appendix 19: miRNA sequences + flanking vector sequences 
Yellow highlighting corresponds to the miRNA sequence. Lane 1 is the vector 
NTI sequence and Lane 2 is the sequence generated from sequencing. 
 
miRNA 1 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
 
Lane 1   1511   TGTATGCTGATATCCAGGCCCTTCATGGTCGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGATATCCAGGCCCTTCATGGTCGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACGACCATGAGGCCTGGATATCAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACGACCATGAGGCCTGGATATCAGGACACAAGGCCTGTT   159 
 
miRNA 2 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
 
Lane 1   1511   TGTATGCTGTTCTGCAGCAGGATCTCCAGGGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGTTCTGCAGCAGGATCTCCAGGGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACCCTGGAGACTGCTGCAGAACAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACCCTGGAGACTGCTGCAGAACAGGACACAAGGCCTGTT   159 
 
miRNA 3 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
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Lane 1   1511   TGTATGCTGAGCTCCTCCACATACACTCTCGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGAGCTCCTCCACATACACTCTCGTTTTGGCCACTG   117 
 
Lane 1   1553   CTGACGAGAGTGTGTGGAGGAGCTACAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    CTGACGAGAGTGTGTGGAGGAGCTACAGGACACAAGGCCTGTT   159 
 
 
miRNA 4 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
 
Lane 1   1511   TGTATGCTGTTTGTAGTCGGTGTCCAGCACGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGTTTGTAGTCGGTGTCCAGCACGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACGTGCTGGACCGACTACAAACAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACGTGCTGGACCGACTACAAACAGGACACAAGGCCTGTT   159 
 
miRNA 5 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
 
Lane 1   1511   TGTATGCTGAGATGTGGCACTGCTCCTCCAGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGAGATGTGGCACTGCTCCTCCAGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACTGGAGGAGGTGCCACATCTCAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACTGGAGGAGGTGCCACATCTCAGGACACAAGGCCTGTT   159 
 
miRNA 6 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
 
Lane 1   1511   TGTATGCTGCTTCTGAGCACACTCACCGTTGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGCTTCTGAGCACACTCACCGTTGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACAACGGTGAGTGCTCAGAAGCAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACAACGGTGAGTGCTCAGAAGCAGGACACAAGGCCTGTT   159 
 
miRNA 7 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
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Lane 1   1511   TGTATGCTGATCTTGAACACCGCAGGGATCGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGATCTTGAACACCGCAGGGATCGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACGATCCCTGGTGTTCAAGATCAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACGATCCCTGGTGTTCAAGATCAGGACACAAGGCCTGTT   159 
 
miRNA 8 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
 
Lane 1   1511   TGTATGCTGTTCAAGGCATCGATCTTGAACGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGTTCAAGGCATCGATCTTGAACGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACGTTCAAGAGATGCCTTGAACAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACGTTCAAGAGATGCCTTGAACAGGACACAAGGCCTGTT   159 
 
miRNA 9 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
 
Lane 1   1511   TGTATGCTGCCAGCACAAGGACTTTGTTCTGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGCCAGCACAAGGACTTTGTTCTGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACAGAACAAACCTTGTGCTGGCAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACAGAACAAACCTTGTGCTGGCAGGACACAAGGCCTGTT   159 
 
miRNA 10 + flanking sequences 
 
Lane 1   1469   AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   1510 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     AGGTAGTGAGTCGACCAGTGGATCCTGGAGGCTTGCTGAAGGC   75 
 
Lane 1   1511   TGTATGCTGTTTGCTCGGGCTCAGCACTGTGTTTTGGCCACTG   1552 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     TGTATGCTGTTTGCTCGGGCTCAGCACTGTGTTTTGGCCACTG   117 
 
Lane 1   1553   ACTGACACAGTGCTGCCCGAGCAAACAGGACACAAGGCCTGTT   1594 
                  ||||||||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    ACTGACACAGTGCTGCCCGAGCAAACAGGACACAAGGCCTGTT   159 
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Appendix 20: bBLG cDNA sequences + flanking vector 
sequences  
Yellow highlighting corresponds to the bBLG cDNA sequence. Lane 1 is the 
vector NTI sequence and Lane 2 is the sequence generated from sequencing. 
 
Lane 1   613    CTCGAGCTCAAGCTTCCTGCAGAGCTCAGAAGCGTGATCCCG   654 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   34     CTCGAGCTCAAGCTTCCTGCAGAGCTCAGAAGCGTGATCCCG   75 
 
Lane 1   655    GCTGCAGCCATGAAGTGCCTCCTGCTTGCCCTGGCCCTCACC   696 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   76     GCTGCAGCCATGAAGTGCCTCCTGCTTGCCCTGGCCCTCACC   117 
 
Lane 1   697    TGTGGCGCCCAGGCCCTCATCGTCACCCAGACCATGAAGGGC   738 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   118    TGTGGCGCCCAGGCCCTCATCGTCACCCAGACCATGAAGGGC   159 
 
Lane 1   739    CTGGATATCCAGAAGGTGGCGGGGACTTGGTACTCCTTGGCC   780 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   160    CTGGATATCCAGAAGGTGGCGGGGACTTGGTACTCCTTGGCC   201 
 
Lane 1   781    ATGGCGGCCAGCGACATCTCCCTGCTGGACGCCCAGAGTGCC   822 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   202    ATGGCGGCCAGCGACATCTCCCTGCTGGACGCCCAGAGTGCC   243 
 
Lane 1   823    CCCCTGAGAGTGTATGTGGAGGAGCTGAAGCCCACCCCTGAG   864 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   244    CCCCTGAGAGTGTATGTGGAGGAGCTGAAGCCCACCCCTGAG   285 
 
Lane 1   865    GGCGACCTGGAGATCCTGCTGCAGAAATGGGAGAATGATGAG   906 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   286    GGCGACCTGGAGATCCTGCTGCAGAAATGGGAGAATGATGAG   327 
 
Lane 1   907    TGTGCTCAGAAGAAGATCATTGCAGAAAAAACCAAGATCCCT   948 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   328    TGTGCTCAGAAGAAGATCATTGCAGAAAAAACCAAGATCCCT   369 
 
Lane 1   949    GCGGTGTTCAAGATCGATGCCTTGAACGAGAACAAAGTCCTT   990 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   370    GCGGTGTTCAAGATCGATGCCTTGAACGAGAACAAAGTCCTT   411 
 
Lane 1   991    GTGCTGGACACCGACTACAAAAAGTACCTGCTCTTCTGCATG   1032 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   412    GTGCTGGACACCGACTACAAAAAGTACCTGCTCTTCTGCATG   453 
 
Lane 1   1033   GAGAACAGTGCTGAGCCCGAGCAAAGCCTGGTCTGCCAGTGC   1074 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   454    GAGAACAGTGCTGAGCCCGAGCAAAGCCTGGTCTGCCAGTGC   495 
 
Lane 1   1075   CTGGTCAGGACCCCGGAGGTGGACGACGAGGCCCTGGAGAAA   1116 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   496    CTGGTCAGGACCCCGGAGGTGGACGACGAGGCCCTGGAGAAA   537 
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Lane 1   1117   TTCGACAAAGCCCTCAAGGCCCTGCCCATGCACATCCGGCTG   1158 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   538    TTCGACAAAGCCCTCAAGGCCCTGCCCATGCACATCCGGCTG   579 
 
Lane 1   1159   TCCTTCAACCCAACCCAGCTGGAGGAGCAGTGCCACATCTAG   1200 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   580    TCCTTCAACCCAACCCAGCTGGAGGAGCAGTGCCACATCTAG   621 
 
Appendix 21: oBLG cDNA sequences + flanking vector 
sequences  
Yellow highlighting corresponds to the oBLG cDNA sequence. Lane 1 is the 
sequence generated from sequencing and Lane 2 is the vector NTI sequence. 
 
Lane 1   52     AACGGCCGCCAGTGTGCTGGAATTCGCCCTTATGAAGTGCCT   93 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   264    AACGGCCGCCAGTGTGCTGGAATTCGCCCTTATGAAGTGCCT   305 
 
Lane 1   94     CCTGCTTGCCCTGGGCCTGGCCCTCGCCTGTGGCGTCCAGGC   135 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   306    CCTGCTTGCCCTGGGCCTGGCCCTCGCCTGTGGCGTCCAGGC   347 
 
Lane 1   136    CATCATCGTCACCCAGACCATGAAAGGCCTGGACATCCAGAA   177 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   348    CATCATCGTCACCCAGACCATGAAAGGCCTGGACATCCAGAA   389 
 
Lane 1   178    GGTGGCGGGGACTTGGCACTCCTTGGCTATGGCGGCCAGCGA   219 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   390    GGTGGCGGGGACTTGGCACTCCTTGGCTATGGCGGCCAGCGA   431 
 
Lane 1   220    CATCTCCCTGCTGGATGCCCAGAGTGCCCCCCTGAGAGTGTA   261 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   432    CATCTCCCTGCTGGATGCCCAGAGTGCCCCCCTGAGAGTGTA   473 
 
Lane 1   262    CGTGGAGGAGCTGAAGCCCACCCCCGAGGGCAACCTGGAGAT   303 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   474    CGTGGAGGAGCTGAAGCCCACCCCCGAGGGCAACCTGGAGAT   515 
 
Lane 1   304    CCTGCTGCAGAAATGGGAGAACGGCGAGTGTGCTCAGAAGAA   345 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   516    CCTGCTGCAGAAATGGGAGAACGGCGAGTGTGCTCAGAAGAA   557 
 
Lane 1   346    GATTATTGCAGAAAAAACCAAGATCCCTGCGGTGTTCAAGAT   387 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   558    GATTATTGCAGAAAAAACCAAGATCCCTGCGGTGTTCAAGAT   599 
 
Lane 1   388    CGATGCCTTGAATGAGGACAAAGTCCTTGTGCTGGACGCCGA   429 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   600    CGATGCCTTGAATGAGGACAAAGTCCTTGTGCTGGACGCCGA   641 
 
Lane 1   430    CTACAAAAAGTACCTGCTCTTCTGCATGGAAAACAGTGCTGA   471 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   642    CTACAAAAAGTACCTGCTCTTCTGCATGGAAAACAGTGCTGA   683 
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Lane 1   472    GCCCGAGCAAAGCCTGGCCTGCCAGTGCCTGGTCAGGACCCC   513 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   684    GCCCGAGCAAAGCCTGGCCTGCCAGTGCCTGGTCAGGACCCC   725 
 
Lane 1   514    GGAGGTGGACAACGAGGCCCTGGAGAAATTCGACAAAGCCCT   555 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   726    GGAGGTGGACAACGAGGCCCTGGAGAAATTCGACAAAGCCCT   767 
 
Lane 1   556    CAAGGCCCTGCCCATGCACATCCGGCTTGCCTTCAACCCGAC   597 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   768    CAAGGCCCTGCCCATGCACATCCGGCTTGCCTTCAACCCGAC   809 
 
Lane 1   598    CCAGCTGGAGGGGCAGTGCCACGTCTAGAAGGGCGAATTCTG   639 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   810    CCAGCTGGAGGGGCAGTGCCACGTCTAGAAGGGCGAATTCTG   853 
 
 
Appendix 22: WAP promoter sequences + flanking vector 
sequences  
Yellow highlighting corresponds to the WAP sequence. Lane 1 is the sequence 
generated from sequencing and Lane 2 is the vector NTI sequence. 
 
Lane 1   1      CAATTCTTTCACTGCTAAAACAGGGCGGGAGGAGTCCAGAGC   41 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1      CAATTCTTTCACTGCTAAAACAGGGCGGGAGGAGTCCAGAGC   41 
 
Lane 1   42     CCTGCCACTGGGTGCAGAACATGAAGACCCCTTGAGTGGAAA   83 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   42     CCTGCCACTGGGTGCAGAACATGAAGACCCCTTGAGTGGAAA   83 
 
Lane 1   84     GGGGTTATACAGCTGGACAGTGGTGGCGCACACCTTTAATCC   125 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   84     GGGGTTATACAGCTGGACAGTGGTGGCGCACACCTTTAATCC   125 
 
Lane 1   126    CAGCACTCGGGAGGCAGAGGCAGACGGATCTCTGAGTTCGAG   167 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   126    CAGCACTCGGGAGGCAGAGGCAGACGGATCTCTGAGTTCGAG   167 
 
Lane 1   168    GCCAGCCTGGTCTACAGAATGAGTTCCGGGACAGCCAGGGCC   209 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   168    GCCAGCCTGGTCTACAGAATGAGTTCCGGGACAGCCAGGGCC   209 
 
Lane 1   210    ACACAGAGAAACTCTTGTCTCGAAAAACCAAAAAAAAACAAA   251 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   210    ACACAGAGAAACTCTTGTCTCGAAAAACCAAAAAAAAACAAA   251 
 
Lane 1   252    AAAGGAAAGGGGTTACACAACAGAGACTCAGGTCACAGCTAC   293 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   252    AAAGGAAAGGGGTTACACAACAGAGACTCAGGTCACAGCTAC   293 
 
Lane 1   294    CCATCACACACAGGATACACATACAAAGGTGTTCACAGGCAG   335 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   294    CCATCACACACAGGATACACATACAAAGGTGTTCACAGGCAG   335 
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Lane 1   336    ATGAGGAACGAGGAGAAGGGGCTCAAGCAAGGGCCTAAAGTT   377 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   336    ATGAGGAACGAGGAGAAGGGGCTCAAGCAAGGGCCTAAAGTT   377 
 
Lane 1   598    TCTTTTTTTTTTTTTCTTCTTTTTTTTTTTCCCTGTGGCCTA   419 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   598    TCTTTTTTTTTTTTTCTTCTTTTTTTTTTTCCCTGTGGCCTA   419 
 
Lane 1   420    GAGTTTCAAGAGGCTGAGGACCTAGGCATGAACCAAGAGGGG   461 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   420    GAGTTTCAAGAGGCTGAGGACCTAGGCATGAACCAAGAGGGG   461 
 
Lane 1   462    CCAAACCACTTCAAGAAGCAGGGGGTAGCAGCAGAATCTCAC   503 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   462    CCAAACCACTTCAAGAAGCAGGGGGTAGCAGCAGAATCTCAC   503 
 
Lane 1   504    TATCAGCCTTGAGCACAGCTGGGAAGGAGATCCATGGAAACA   545 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   504    TATCAGCCTTGAGCACAGCTGGGAAGGAGATCCATGGAAACA   545 
 
Lane 1   546    ACCAAGAAAGAGCTGAAAGGGGCTGGAGAGATGGCTCAGCAG   587 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   546    ACCAAGAAAGAGCTGAAAGGGGCTGGAGAGATGGCTCAGCAG   587 
 
Lane 1   588    TTAAGAGCACTGAGTGCTCTTCCGAAGTCCTAGATTCAAATC   629 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   588    TTAAGAGCACTGAGTGCTCTTCCGAAGTCCTAGATTCAAATC   629 
 
Lane 1   630    CCAGCAACCATATGGTGGGTCACAACCATCTGTAATGAGATC   671 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   630    CCAGCAACCATATGGTGGGTCACAACCATCTGTAATGAGATC   671 
 
Lane 1   672    TGATGCCCTCTTCTGGTGTGTCTGAAGACAGCTACAGTGTAC   713 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   672    TGATGCCCTCTTCTGGTGTGTCTGAAGACAGCTACAGTGTAC   713 
 
Lane 1   714    TTATGTATAATAAATAAATAAATCTTTAGAAAGGGAGGGGGG   755 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   714    TTATGTATAATAAATAAATAAATCTTTAGAAAGGGAGGGGGG   755 
 
Lane 1   756    GAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA   797 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   756    GAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGA   797 
 
Lane 1   798    GAGAGAGAGAGAGAGCTGGAAGAGGGAGATCTGGGAAGTCTG   839 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   798    GAGAGAGAGAGAGAGCTGGAAGAGGGAGATCTGGGAAGTCTG   839 
 
Lane 1   840    CTGGCTTTATATGCTGACCATATATAGTCACCTGTGTTTACA   881 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   840    CTGGCTTTATATGCTGACCATATATAGTCACCTGTGTTTACA   881 
 
Lane 1   882    CACTGTGCTCATCACTTTGAAATCTCAGTGGTTTCTTCTTTG   923 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   882    CACTGTGCTCATCACTTTGAAATCTCAGTGGTTTCTTCTTTG   923 
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Lane 1   924    AGCCTGTGTCTGTAAGTTCACCAGGAGAGTGGTACATAGGCA   965 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   924    AGCCTGTGTCTGTAAGTTCACCAGGAGAGTGGTACATAGGCA   965 
 
Lane 1   966    AGAATAACAGCCAGTGGGCATAGGACACAGAGTGCATGGGCC   1007 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   966    AGAATAACAGCCAGTGGGCATAGGACACAGAGTGCATGGGCC   1007 
 
Lane 1   1008   CCAGCAAGACTGTAGAGAGAACAGAGCTCTGGCTCCTAAGAC   1049 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1008   CCAGCAAGACTGTAGAGAGAACAGAGCTCTGGCTCCTAAGAC   1049 
 
Lane 1   1050   ATAGGGCCTTCTGGGAAACTCAAGCAGCCAAGCAACCCTAGC   1091 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1050   ATAGGGCCTTCTGGGAAACTCAAGCAGCCAAGCAACCCTAGC   1091 
 
Lane 1   1092   CAGCCCTTTCCTGGTGGCCCTCCTTCTGTTCCAGCAAAGGCG   1133 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1092   CAGCCCTTTCCTGGTGGCCCTCCTTCTGTTCCAGCAAAGGCG   1133 
 
Lane 1   1134   GAAATGGGAACAGGGGTGGAAGCAGAGCATTGGCAGAGCATA   1175 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1134   GAAATGGGAACAGGGGTGGAAGCAGAGCATTGGCAGAGCATA   1175 
 
Lane 1   1176   GGTATGACTTAGTCTTGACTAACACAAGCATGGCAGTAGCCT   1217 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1176   GGTATGACTTAGTCTTGACTAACACAAGCATGGCAGTAGCCT   1217 
 
Lane 1   1218   GACAGTGGCCTAAATGTGGGGATGACTGCCTTAGATGGGGAT   1259 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1218   GACAGTGGCCTAAATGTGGGGATGACTGCCTTAGATGGGGAT   1259 
 
Lane 1   1260   GACTGCCTTAGATGGGCATGACTGCCTTAGATGGGGATGACT   1301 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1260   GACTGCCTTAGATGGGCATGACTGCCTTAGATGGGGATGACT   1301 
 
Lane 1   1302   GCCTTAGATGGGGATGACTGCCTTAGATGGAACAACAAACAT   1343 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1302   GCCTTAGATGGGGATGACTGCCTTAGATGGAACAACAAACAT   1343 
 
Lane 1   1344   CTATGGGCATGCTGTGGAACACTGGCCCACACACGGAACTGA   1385 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1344   CTATGGGCATGCTGTGGAACACTGGCCCACACACGGAACTGA   1385 
 
Lane 1   1386   AGGCACTGGCAATTTCCATAGGGCAGTTAAACCTAAAAGCAT   1427 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1386   AGGCACTGGCAATTTCCATAGGGCAGTTAAACCTAAAAGCAT   1427 
 
Lane 1   1428   GCTCACACTCAACAGGCTGCCGGAATCTCATGAGACACCTGG   1469 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1428   GCTCACACTCAACAGGCTGCCGGAATCTCATGAGACACCTGG   1469 
 
Lane 1   1470   AATAGACGAATGTAGAAACAGAGCAGAGAGTTGGTTGCCAAG   1511 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1470   AATAGACGAATGTAGAAACAGAGCAGAGAGTTGGTTGCCAAG   1511 
 
Lane 1   1512   GTCTGGGGGCTCAGAGGACAAGCAAGAGGCGCGGCTTTCCTT   1553 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1512   GTCTGGGGGCTCAGAGGACAAGCAAGAGGCGCGGCTTTCCTT   1553 
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Lane 1   1554   TGGGGCTGGCATGAAAGGAAATATCGAGGTTACAGCCTGAGA   1596 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1554   TGGGGCTGGCATGAAAGGAAATATCGAGGTTACAGCCTGAGA   1596 
 
Lane 1   1597   GGGCTTCCCCTGACACTTCGTATTCAAAGAGGCCATGGGCAC   1638 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1597   GGGCTTCCCCTGACACTTCGTATTCAAAGAGGCCATGGGCAC   1638 
 
Lane 1   1639   CAGTGAAGACAAAGGAGTATGGCCTGCACCACAGGCTGGCGC   1680 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1639   CAGTGAAGACAAAGGAGTATGGCCTGCACCACAGGCTGGCGC   1680 
 
Lane 1   1681   TGACAGTCAGTAAGCACACAGTCACTCTGGGTCATCCCATCC   1722 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1681   TGACAGTCAGTAAGCACACAGTCACTCTGGGTCATCCCATCC   1722 
 
Lane 1   1723   CCTTCCTTGCAAGAGAAATCAAGGAAATGTCCCGAGAACAAT   1764 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1723   CCTTCCTTGCAAGAGAAATCAAGGAAATGTCCCGAGAACAAT   1764 
 
Lane 1   1765   GGGGCACAGTGCCAGCAGGACATCTCTTCCTGCCCATGGCAC   1806 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1765   GGGGCACAGTGCCAGCAGGACATCTCTTCCTGCCCATGGCAC   1806 
 
Lane 1   1807   CCTTTGGCACGGTATGGGCCCTTCTGGGAAGGTGGCCTTCCA   1848 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1807   CCTTTGGCACGGTATGGGCCCTTCTGGGAAGGTGGCCTTCCA   1848 
 
Lane 1   1849   AATTGCTCTGCACAGGCAGCTCCTTTTCAATGTATGCCCGAC   1890 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1849   AATTGCTCTGCACAGGCAGCTCCTTTTCAATGTATGCCCGAC   1890 
 
Lane 1   1891   ACTCTCTACATGGAGCAAGCGCCTCCACACTCTTAGAAGAAT   1932 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1891   ACTCTCTACATGGAGCAAGCGCCTCCACACTCTTAGAAGAAT   1932 
 
Lane 1   1933   TTTAGAAAACTCCAGAAAAGCACCAGGAGAAGTCACCCTCAG   1974 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1933   TTTAGAAAACTCCAGAAAAGCACCAGGAGAAGTCACCCTCAG   1974 
 
Lane 1   1975   ATGTAGCCCGGACTCGAGCCTTGCTCAAAACCTCCTGTCTTG   2016 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   1975   ATGTAGCCCGGACTCGAGCCTTGCTCAAAACCTCCTGTCTTG   2016 
 
Lane 1   2017   TTTTCTATGTGACCTGTACAAATTTGGAGCTCAGAATTGCCT   2058 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2017   TTTTCTATGTGACCTGTACAAATTTGGAGCTCAGAATTGCCT   2058 
 
Lane 1   2059   TTGTCTGTGATGGGTTCCAACCCAACCACTCAAAGTGACACT   2100 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2059   TTGTCTGTGATGGGTTCCAACCCAACCACTCAAAGTGACACT   2100 
 
Lane 1   2101   TGTCACATTTGTCACTGATCCTATTTCTTCTTTTTCTGCTCC   2142 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2101   TGTCACATTTGTCACTGATCCTATTTCTTCTTTTTCTGCTCC   2142 
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Lane 1   2143   TTCATTTTCTCCGCTTTCATAATAAACAAGTATTACTTTTTA   2184 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2143   TTCATTTTCTCCGCTTTCATAATAAACAAGTATTACTTTTTA   2184 
 
Lane 1   2185   AGTGGGGGAAAAAATGACCACCCTTACAAAGGACTTTTTAAA   2226 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2185   AGTGGGGGAAAAAATGACCACCCTTACAAAGGACTTTTTAAA   2226 
 
Lane 1   2227   AATGGCCTCCATTGTGGCCCTTGTTCCTGGCAGCCTGGGCCT   2268 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2227   AATGGCCTCCATTGTGGCCCTTGTTCCTGGCAGCCTGGGCCT   2268 
 
Lane 1   2269   GCTCTCTCTGTGTGGCCAAGAAGGAAGTGTTGTAGCCCATCT   2310 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2269   GCTCTCTCTGTGTGGCCAAGAAGGAAGTGTTGTAGCCCATCT   2310 
 
Lane 1   2311   AGAGCTGTGCCAGCCTCTTCCCCCACCCCACCCCCAAAGTCT   2352 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2311   AGAGCTGTGCCAGCCTCTTCCCCCACCCCACCCCCAAAGTCT   2352 
 
Lane 1   2353   TCCTCCTGTGGGTCCTTTAAATGCATCCCAGACACTCAGACA   2394 
                |||||||||||||||||||||||||||||||||||||||||| 
Lane 2   2353   TCCTCCTGTGGGTCCTTTAAATGCATCCCAGACACTCAGACA   2394 
 
Lane 1   2395   GCCATCAGTCACTTGC   2410 
                |||||||||||||||| 
Lane 2   2395   GCCATCAGTCACTTGC   2410 
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Appendix 23: Comparison of secondary structures of bBLG 
and oBLG mRNA sequences.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The figure A and B show the secondary structure prediction from running the RNAfold 
version 2.0.0 on bBLG and oBLG mRNA sequences with accession numbers: 
NM_173929 and NM_001009366. The program calculates minimum free energy 
structure of an RNA sequence. The energy parameters are set as described by Mathews 
DH et al., ((194)). The bBLG and oBLG RNA sequences show -311.10 and -316.80 
kcal/mol of free energy, respectively. Both mRNA sequences are almost equally likely to 
occur since both are similar in minimum free energy values, but the structures are 
different. 
A 
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